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Abstract 
Superparamagnetic Iron Oxide Nanoparticles (SPIONs) have unique properties 
with potential application in targeted cancer treatment; including the ability to 
generate heat when placed in an external alternating magnetic field. However, 
challenges such as rapid circulatory clearance by the reticuloendothelial system 
(RES), the need for effective functionalisation with cancer-targeting agents and 
heterogeneity of SPIONs, remain to be overcome. The work in this thesis aims to 
develop SPIONs by addressing these challenges.  
Ferucarbotran (Resovist®), a clinically approved MRI contrast SPION with 
excellent heating potential was investigated. Three main hypotheses were tested; 
that RES uptake of SPIONs could be blocked in vitro and in vivo, that specific 
targeting could be achieved by functionalising SPIONs with non-immunoglobulin 
cancer-targeting proteins and that product heterogeneity could be addressed by 
physical separation.  
Studies included: (i) Interactions of SPIONs with different cell types (ii) Blocking 
cell uptake using polysaccharide derivatives (iii) Conjugation strategies to link 
SPIONs to near-infrared dyes to trace their blood levels (iv) Enhancing the 
circulatory retention of SPIONs via RES blocking (v) Site-specific conjugation 
methods to functionalise SPIONs with cancer targeting protein (vi) Cellular- and 
immuno-assays to test the binding of functionalised SPIONs to target antigen (vii) 
Size exclusion chromatography (SEC) to fractionate SPIONs.  
Results showed that Ferucarbotran was unspecifically internalised by all tested 
cell lines. A range of sulfated polysaccharides were shown to block this uptake in 
vitro and in vivo leading to prolonged circulatory times. Ferucarbotran was 
successfully functionalised with cancer-targeting protein and bound specifically to 
target antigen in ELISA. Cellular assays with a range of cell lines revealed the 
generalised altered behaviour of SPIONs upon surface modification with proteins. 
SEC successfully fractionated Ferucarbotran into more homogeneous products 
with improved heating properties. 
In conclusion, these results are consistent with the proposed hypotheses and form 
a platform for addressing the challenges of SPIONs-based cancer nanomedicine.  
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PBS/T   Phosphate Buffered Saline + 0.1 % Tween 20 
PDI   Polydispersity Index 
PEG   Poly ethylene glycol  
pgFe/cell  Picogram iron per cell 
PK   Pharmacokinetics 
PVDF   Polyvinylidene difluoride 
RAW 264.7   Murine monocytes/macrophages cell line  
RES   Reticuloendothelial system  
rh EGF  Recombinant human Epidermal Growth Factor 
rh bFGF   Recombinant human basic fibroblast growth factor 
RIPA   RadioImmunoPrecipitation Assay  
RT   Room temperature 
SAR   Specific absorption rate  
ScFv   Single chain fragment variable  
SDS   Sodium dodecyl sulfate  
SDS-PAGE  Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEC   Size Exclusion Chromatography 
SH   Thiol (sulfhydryl) group  
SPIONs  Superparamagnetic Iron Oxide Nanoparticles 
SupT1-NT  non-transduced human lymphoblastic leukaemia cell line  
SupT1-EGFR  SupT1 cells transduced with EGFR 
SupT1-EGFRvIII  SupT1 cells transduced with EGFR variant three 
T2   Transverse relaxation  
99mTc   Technetium-99m 
TEM   Transmission Electron Microscopy 
TEMED  Tetramethylethylenediamine  
µgFe/ml  Micrograms iron per millilitre 
U-251 MG  Human glioblastoma cell line 
U-87 MG  Human glioblastoma cell line  
v/v   Volume per volume  
w/v    Weight per volume 
WHO   World Health Organisation  
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1.1 Nanotechnology and Nanomedicine 
The term nano is derived from the Latin word nanus or Greek nanos meaning dwarf 
(Riehemann et al, 2009). The famous physicist Richard Feynman is considered the 
father of nanotechnology who was the first to highlight the concepts and ideas of 
nanoscience and nanotechnology in his talk “There’s Plenty of Room at the Bottom” 
given at the American Physical Society in Caltech on the 29th of December 1959. 
Feynman, although did not use the term nanotechnology, envisioned that scientists 
would be able to control and manipulate very small particles at the atomic and 
molecular levels (Feynman, 1960; Scheinberg et al, 2010; Toumey, 2009). It was 
not until a decade later that Professor Norio Taniguchi used the term 
nanotechnology. The modern nanotechnology era began with the development of 
the scanning tunnelling microscope in 1981 that enabled scientists to visualise 
individual atoms (Toumey, 2009).   
A range of definitions have been proposed for the term “Nanotechnology” in the 
literature but generally it is the science concerned with particles in the size range of 
0.1 to 100 nm; where 1 nm is a billionth (10-9) of a meter. The US National 
Nanotechnology Initiative (NNI) has defined it as:  
“Nanotechnology is concerned with materials and systems whose structures and 
components exhibit novel and significantly improved physical, chemical and 
biological properties, phenomena and processes due to their nanoscale size” 
(National Nanotechnology Initiative, 2000; Riehemann et al, 2009; Weissig et al, 
2014).  
Nevertheless, since 2000 this definition has been an area of controversy due to the 
100 nm limitation, which has no solid scientific basis, with many nanoparticles being 
developed above that “cut off” (Etheridge et al, 2013; Kreyling et al, 2010). A 
consensus about the definition of a “nanoparticle” or “nanomaterial” is still under 
debate, nevertheless a definition by the European commission has been proposed 
as follows (Bleeker et al, 2013; EU, 2011):  
“ ‘Nanomaterial’ means a natural, incidental or manufactured material containing 
particles, in an unbound state or as an aggregate or as an agglomerate and where, 
for 50% or more of the particles in the number size distribution, one or more external 
dimensions is in the size range 1 nm-100 nm.” 
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The European commission further defined ‘particles’, ‘agglomerates’ and 
‘aggregates’ as follows (EU, 2011):  
“ ’Particle’ means a minute piece of matter with defined physical boundaries; 
‘agglomerate’ means a collection of weakly bound particles or aggregates where the 
resulting external surface area is similar to the sum of the surface areas of the 
individual components; ‘aggregate’ means a particle comprising of strongly bound or 
fused particles.” 
Nanomedicine is a term, which describes the application of nanotechnology 
concepts to a range of medical applications. The unique physical and chemical 
characteristics of nanomedicine promise advantage over other conventional 
therapies in the ability to control and manipulate processes happening at the 
nanometre scale with great precision and in real time (Riehemann et al, 2009). 
Nanomedicine involves two distinct phenomena occurring at the nanoscale: 
transitions in the physicochemical properties of the nanoparticles and changes 
occurring due to their physiological interactions (Etheridge et al, 2013). 
Nanomedicine includes the development of nanoparticles and nanostructures to be 
used in a wide range of applications in both diagnosis and therapy (theranostics). In 
practice, nanomedicines can provide fast, convenient and inexpensive tools for 
molecular diagnostics, follow-up, imaging, treatments and much more (Riehemann 
et al, 2009).  
1.2 Evolution of nanomedicine  
The study of colloidal systems (i.e. systems containing nanosized components) was 
developed 50 years ago and the use of colloidal “nano” particles dates back to the 
late 1960s. For example anthracyclins were encapsulated in phospholipid vesicles 
(liposomes) in order to reduce their cardiotoxicity, nevertheless the term “nano” only 
appeared after the year 2000 in the liposomes literature (Weissig et al, 2014). Later 
in the 1980s the formulation of liposomes was further improved to increase the 
circulatory half-life by making them less visible to the reticuloendothelial system 
(RES) via “stealth” modifications (e.g. polyethylene glycol (PEG) coating) (Kamaly et 
al, 2012). The first approved nanodrug liposome came much later in 1995 with the 
approval of Doxil® by the US Food and Drug Administration (FDA) (Weissig et al, 
2014). The introduction of iron oxide nanoparticles later followed and they were 
mainly approved by the FDA as contrast agents in magnetic resonance imaging 
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(MRI) (e.g. Feridex® was approved in 1996) (Kamaly et al, 2012; Weissig et al, 
2014).  
The application of nanotechnology in medicine is expected to greatly influence the 
landscape of pharmaceutical and biotechnological industries (Kamaly et al, 2012). 
An extensive analysis of the current state of nanomedicine in 2012 by (Etheridge et 
al, 2013) has identified 67 commercially available nanodevices and 33 marketed 
nanotherapeutics. Furthermore, 122 therapeutics and 25 devices are currently in 
789 ongoing clinical trials (Etheridge et al, 2013; Weissig et al, 2014). It was found 
that almost two-thirds of nanotherapies are currently under investigation for cancer 
treatment while the rest are being developed or has been approved for infectious 
diseases, cardiac disorders, immune disorders, hormonal disorders, degenerative 
disorders, among others (Etheridge et al, 2013). A full list of all clinically approved 
nanopharmaceuticals are reviewed in (Weissig et al, 2014) and a list of 
nanopharmaceuticals under development are reviewed in (Weissig & Guzman-
Villanueva, 2015). 
1.3 Targeting nanomedicines to cancer cells 
Despite the recent advances in cancer diagnosis and therapy, Cancer Research UK 
has reported that 161,823 deaths from cancer has occurred in the UK in 2012 
(Cancer Research UK, 2012), while in the US, cancer is considered the second 
most common cause of mortality (American Cancer Society, 2013).  
Passive and active targeting strategies have been employed to develop 
nanomedicines for cancer diagnosis and therapy (Figure 1.1). A list of clinically 
approved anti-cancer nanoparticles is shown in Table 1.1. 
 25 
 
Figure 1.1: Targeting strategies for nanoparticles. 
Nanoparticles could be actively (via antibodies, ligands or nucleic acids) or passively (via 
EPR, RES or intratumoural delivery) targeted to tumour cells. EPR: enhanced permeability 
and retention effect, RES: reticuloendothelial system. Figure modified from (Parveen et al, 
2012). 
1.3.1 Passive targeting 
1.3.1.1 The Enhanced Permeability and Retention (EPR) effect  
EPR exploits one of the main hallmarks of cancer cells; the ability to induce 
angiogenesis (formation of new blood vessels) (Hanahan & Weinberg, 2000; 
Hanahan & Weinberg, 2011). Most tumours have immature, dense and leaky 
vasculature caused by their rapid development in response to tumour pro-
angiogenic signals (e.g. vascular endothelial growth factor (VEGF)) (Chauhan & 
Jain, 2013; Peer et al, 2007; Xu et al, 2015). Leaky junctions in tumour vasculature 
can allow entities from 100 to 500 nm to extravasate into tumours. On the contrary, 
normal vasculature has tight junctions between their endothelial cells that only allow 
particles less than 2 nm to cross (Xu et al, 2015) (Figure 1.2).   
The EPR effect is the ability of tumour blood vessels to retain large molecules due 
to 3 factors: (a) leaky properties of tumour vasculature, (b) poor clearance resulting 
Targeting of Nanoparticles  
Active  
Antibodies and antibody 
fragments 
Cognate receptor ligands 
 (e.g. carbohydrates, 
vitamins, proteins and 
peptides)  
Nucleic acids (Aptamers) 
Passive 
RES targetting 
EPR effect 
Localized delivery 
Via 
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from ineffective lymphatic drainage and (c) the minute size of the nanoparticles. This 
phenomenon provides a unique pharmacokinetic privilege to passively target 
nanomedicines to tumours thus reducing toxicity to normal tissues (Chauhan & Jain, 
2013; Peer et al, 2007; Xu et al, 2015). 
The EPR effect relies on increasing the circulatory time of drugs to increase tumour 
accumulation, which in most cases has been achieved by PEGylation (i.e. surface 
coating of nanoparticles with polyethylene glycol (PEG)) to reduce opsonisation (i.e. 
binding of plasma proteins) and rapid clearance by the reticuloendothelial system 
(RES) (e.g. Doxil®) (Chauhan & Jain, 2013; Peer et al, 2007). Furthermore, for the 
nanoparticles to effectively extravasate into tumours they should be smaller than 
400 nm with some studies showing that a diameter less than 200 nm is more 
effective (Peer et al, 2007).       
 
 
Figure 1.2: The Enhanced Permeability and Retention effect 
Nanoparticles (blue carriers) can passively localise to tumours by extravasation through the 
leaky tumour vasculature and get retained there due to the faulty lymphatic drainage. Figure 
adapted from (Peer et al, 2007). 
 
 
 
Nanoparticles   
Endothelial 
cells 
Blood flow 
Tumour cells 
Leaky tumour 
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 27 
1.3.1.2 The Reticuloendothelial System  
The monocytic-phagocytic system (MPS) or, as commonly known, the 
reticuloendothelial system (RES) comprises of the endothelial cells lining the blood 
vessels and the professional macrophages within tissues, for example (Iio & 
Wagner Jr, 1963; Lanza et al, 2004): 
• Kupffer cells in the liver 
• Free and fixed macrophages in the spleen and lymph nodes 
• Alveolar and intravascular macrophages in lungs 
• Histiocytes in connective tissues 
• Microglia in the nervous system 
• Osteoclasts in bone and bone marrow 
The liver is one of the main organs of the RES where Kupffer cells, the resident liver 
macrophages, constitute 80-90% of the total tissue macrophages (Bilzer et al, 
2006). Kupffer cells, situated alongside the endothelial cells in the lumen of liver 
sinusoids, play a vital role in host defence and are programed to internalize 
pathogens and other foreign substances (Bilzer et al, 2006) including nanoparticles 
(Shubayev et al, 2009). Consequently, typical biodistribution of nanoparticles 
following administration is 80-90% in the liver, 5-8% in the spleen and 1-2% in the 
bone marrow (Shubayev et al, 2009). 
The rapid clearance of nanoparticles by the RES has been clinically exploited to 
deliver therapies (e.g. liposomes and iron oxide nanoparticles) to RES organs. For 
instance some immunomodulatory anti-cancer drugs can be targeted to the RES in 
order to stimulate cell mediated or humoral immune responses against cancer cells 
(Allen & Martin, 2004). Examples of non-PEGylated liposomes who exploit this 
approach include Myocet® and Mepact™ (Allen & Martin, 2004; Kager et al, 2010). 
Another type of nanoparticles, which mainly rely on these professional phagocytes 
for their mode of action, are iron oxide nanoparticles. They are either used as iron 
supplements or MRI contrast agents (Akinc & Battaglia, 2013). Iron oxide 
nanoparticles are further discussed in section 1.6.3. 
1.3.1.3 Localised delivery  
Another approach to deliver nanoparticles to cancer cells is by direct injection into 
tumours. Nanoparticles can either act as carriers to deliver drugs to tumour cells or 
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they can be used to deliver heat therapy. Nanotherm® is an example of a 
nanoparticle directly injected into brain tumours to allow the delivery of localised 
heat therapy (Maier-Hauff et al, 2007; Maier-Hauff et al, 2011). Heat therapy is 
further discussed in section 1.6.4. Another example is DepoCyt®, a cytarabine 
liposomal injection, directly injected into the cerebrospinal fluid (CSF) for intrathecal 
treatment of lymphomatous meningitis (McClune et al, 2005). 
1.3.2 Active targeting  
Despite the efforts done to passively target nanoparticles to cancer cells via the 
EPR effect and PEGylation, the RES is still the main fate of most systemically 
administered nanoparticles (90% or more will be retained within the liver and 
spleen) (Xu et al, 2015). The functionalisation of nanoparticles with a targeting 
moiety that is able to bind to overexpressed cancer-specific biomarkers might 
provide better accumulation of nanoparticles within the tumour and reduce off-target 
side effects (Xu et al, 2015). This could be accomplished either via: (i) electrostatic 
adsorption of the targeting moiety to the surface of nanoparticles, (ii) covalent 
linkage via a chemical reaction or (iii) via an adapter molecule (e.g. biotin and 
streptavidin interaction) (Arruebo et al, 2009). Ideally cancer cells should have 104-
105 copies of the target surface marker (antigen or receptor) per cell. Binding of the 
nanoparticles might then induce receptor-mediated endocytosis and the release of 
the drug from nanocarriers (Peer et al, 2007). Alternatively, non-internalising 
receptors might encourage a bystander killing effect to neighbouring cancer cells 
(Peer et al, 2007).  
Targeting agents can be divided into antibodies and their fragments, nucleic acids 
(aptamers) or cognate receptor ligands (e.g. carbohydrates, vitamins and peptides) 
(Figure 1.1) (Parveen et al, 2012; Peer et al, 2007).  
Despite the promising findings seen in various pre-clinical studies with targeted 
nanoparticles (reviewed in (Kamaly et al, 2012)) with some ligand-targeted 
nanoparticles progressing to clinical trials (reviewed in (van der Meel et al, 2013)), 
the overall results of these studies remain inconclusive and unclear. This can be 
accounted to the lack of understanding of the interactions of nanoparticles with 
physiological proteins and the formation of protein coronas, which might mask the 
targeting moiety on the surface of the nanoparticles when administered in vivo (Xu 
et al, 2015). 
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Table 1.1: Clinically approved nanoparticles for cancer therapy 
Table modified from (Dawidczyk et al, 2014a; Dawidczyk et al, 2014b; Parveen et al, 2012; Weissig et al, 2014) 
D: diameter; MOA: mode of action; EPR: enhanced permeability and retention effect; FDA: US Food and Drug Administration; RES: reticuloendothelial system; PEG: 
polyethylene glycol; PK: pharmacokinetics; CSF: cerebrospinal fluid. 
*Classified as nanopharmaceuticals based on the presence of nanosized chambers within the drug (Weissig et al, 2014). 
Name Class Nanoparticle Drug Target cancer D nm 
Targeting 
approach 
Problem 
addressed/MOA 
Approval and 
additional 
references 
Doxil® 
 
Li
po
so
m
es
 
PEGylated 
“stealth” liposome 
Doxorubicin 
Ovarian 
cancer, multiple 
myeloma, 
Kaposi’s 
sarcoma 
100 
nm 
EPR, PEG coating 
help evade RES 
Reduce cardiotoxicity 
and adverse effects of 
the drug 
FDA 1995 
(Barenholz, 
2012) 
Myocet® 
(Caelyx®) 
Non-PEGylated 
liposome 
Metastatic 
breast cancer 
180 
nm RES 
Same as above+ drug 
depots in RES for slow 
release 
EU 2000 
(Leonard et al, 
2009) 
DaunoXome® 
 
Non-PEGylated 
liposome 
Daunorubicin 
citrate 
Kaposi’s 
sarcoma 
50 
nm 
EPR 
Reduce drug toxicity 
and side effects 
FDA 1996 
(Forssen & 
Ross, 1994) 
Marqibo® 
 
Vincristine 
sulfate 
Acute lymphoid 
leukemia 
100 
nm 
Improve PK of drug 
without increasing 
toxicity 
FDA 2012 
(Silverman & 
Deitcher, 2013) 
DepoCyt® 
 
Multivesicular 
liposomes Cytarabine 
Neoplastic 
meningitis 
20 
µm* Intrathecal injection 
Sustained release of 
the drug in the CSF for 
14 days 
 
FDA 1999/2007 
(Murry & 
Blaney, 2000) 
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Continuation of Table 1.1  
D: diameter; MOA: mode of action; n/a: not available; EPR: enhanced permeability and retention effect; FDA: US Food and Drug Administration; EU: Europe; PEG: 
polyethylene glycol; NAB: nanoparticles albumin bound; NSCLC: non-small cell lung cancer 
 
Name Class Nanoparticle Drug Target cancer D  Targeting approach Problem addressed/MOA 
Approval and 
additional 
references 
Mepact™ 
Li
po
so
m
es
 
Large multilamellar 
liposomes Mifamurtide 
Non-
metastasizing 
resectable 
osteaosarcoma 
n/a RES  Immunostimulant drug anchored in liposomal bilayer 
EU 2000 
(Kager et al, 
2010) 
Abraxane® 
(NAB-
paclitaxel) 
 P
ro
te
in
 
ca
rr
ie
r  Bovine serum 
albumin non-
specifically bound to 
the drug 
Paclitaxel 
 
NSCL and 
metastatic breast 
cancer 
130 
nm 
EPR 
 
Overcome the low solubility of 
the drug, therefore;  
 Eliminates the need for toxic 
solvent (Cremophor) 
 
Improve efficacy and decrease 
cytotoxicity 
FDA 2005 
(Green et al, 
2006) 
Opaxio® 
(Xyotax™) 
P
ol
ym
er
 
na
no
pa
rti
cl
es
 
Polyglutamate solid 
nanoparticles; drug 
released by 
enzymatic hydrolysis 
of nanoparticle 
Glioblastoma n/a 
FDA 2012 
(Shaffer et al, 
2007) 
Nanoxel 
M
ic
el
le
 
Nanoparticle delivery 
system for paclitaxel 
(amphiphilic micelles) 
Breast and 
ovarian cancer 80 nm 
India 
(Brahmachari et 
al, 2011) 
Genexol® 
Drug encapsulated in 
PEG-Poly (D, L-
lactide) micelles 
Metastatic breast 
and pancreatic 
cancer 
20-50 
nm 
Same as above+ sustained 
release of the drug 
South Korea 
2001 
(Kim et al, 
2004) 
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Continuation of Table 1.1  
D: diameter; MOA: mode of action; SPIONs: Superparamagnetic iron oxide nanoparticles; n/a: not available; FDA: US Food and Drug Administration; EU: Europe; 
PEG: polyethylene glycol; PLGH: poly-(D,L-lactide-co-glycolide); ALL: Acute Lymphoblastic Leukaemia; PK: pharmacokinetics, PD: pharmacodynamics, T1/2 : half-life; 
ALL: Acute Lymphoblastic Leukaemia; EPR: enhanced permeability and retention effect. 
Name Class Nanoparticle Drug Target cancer D  Targeting 
approach 
Problem 
addressed/MOA 
Approval and 
additional 
references 
Nanotherm® 
S
P
IO
N
s 
Aminosilane-
coated SPIONs n/a 
Glioblastoma, 
prostate and 
pancreatic 
cancer 
15 
nm 
Intratumoural 
injection 
Thermal ablation 
EU 2013 
(Thiesen & 
Jordan, 2008) 
Megace® ES 
N
an
oc
ry
st
al
s 
No carrier: the drug 
itself is formulated 
as nanocrystals 
Megestrol 
actetae Breast Cancer n/a 
Unknown but may 
interact with 
progesterone and 
glucocorticoid 
receptors 
 
Enhance the solubility 
and bioavailability of 
the drug. Reduce 
viscosity. 
FDA 2005 
(Junghanns & 
Müller, 2008; 
McNeil, 2009) 
Eligard® 
P
ol
ym
er
-b
as
ed
 PLGH polymer 
nanoparticles Leuprolide 
Advanced 
prostate cancer n/a None Sustained drug release 
FDA 2002 
(Sartor, 2003) 
Oncaspar® PEG polymer nanoparticles 
PEGylated L-
aspiraginase ALL n/a 
PEG increase half-
life of the drug 
Decrease allergic 
reaction to the drug 
and reduce frequency 
of administration 
FDA 1994 
(Dinndorf et al, 
2007; Lammers 
et al, 2008) 
Zinostatin 
stimalamer® 
C
on
ju
ga
te
 
pr
ot
ei
n Anti-tumour drug conjugated to 
styrene maleic acid 
copolymer 
Neocarzinostatin 
Primary 
hepatocellular 
carcinoma 
n/a EPR Improve drug PK and PD, prolong T1/2 
Japan 1994 
(Greish et al, 
2003). 
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Continuation of Table 1.1  
D: diameter; MOA: mode of action; n/a: not applicable; FDA: US Food and Drug Administration 
 
Name Class Nanoparticle Drug Target cancer D  Targeting approach 
Problem 
addressed/MOA 
Approval and 
additional 
references 
Ontak® 
C
on
ju
ga
te
 
pr
ot
ei
n Drug conjugated to 
interleukin-2 (IL-2) 
binding subunit 
Fragment A of 
Diphtheria toxin 
Primary 
cutaneous T-
cell lymphoma 
n/a 
Active targeting via 
IL-2 binding 
subunit 
Fusion protein target 
IL-2 receptor where 
toxin is released 
following internalisation 
FDA 1999 
(Foss, 2000) 
Gendicine® 
V
iro
so
m
es
 
Recombinant 
Adenovirus 
expressing wild type 
P53 
Gene therapy 
Head and neck 
squamous cell 
carcinoma 
n/a Adenoviral vector 
Adenovirus infects the 
target cells to insert 
P53 gene in the tumour 
cell genome 
China 2003 
(Pearson et al, 
2004) 
Rexin-G® Retroviral vector Cytocidal cyclin G1 construct 
All solid 
tumours 
100 
nm 
Retrovirus particle 
engineered with 
collagen binding 
motif 
Targets collagenous 
matrix proteins on 
tumours then the drug 
blocks endogenous 
cyclin-G1 causing cell 
cycle arrest 
 
Philippines 
2007 
(Gordon & Hall, 
2010) 
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1.4 Cellular interactions of nanoparticles  
The interaction of nanoparticles with cells and biological barriers is strongly 
influenced by nanoparticle characteristics such as surface chemistry, composition, 
size, shape and charge. These variables affect the way in which the nanoparticles 
are internalised by cells (Sahay et al, 2010a). For instance, if nanoparticles are 
conjugated to a ligand, the functionalised nanoparticles will interact with the 
corresponding receptor on the cell surface leading to receptor-mediated 
endocytosis. Otherwise, nanoparticles can be internalised via the various endocytic 
pathways utilised by the cell to transport extracellular cargos to the inside of the 
cells (Chou et al, 2011; Conner & Schmid, 2003).  
The plasma membrane lies at the interface of all cell-nanoparticle interactions. It 
consists of a phospholipid bilayer embedded with domains of lipids, carbohydrates 
and membrane proteins. Proteins embedded within the bilayer perform a range of 
functions including the transport of molecules and cell-cell recognitions. The 
membrane coordinates the entry and exit of biomolecules to and from the cell thus 
segregating the intracellular milieu (cytoplasm) from the extracellular environment 
(Cooper, 2000). The complexity of the plasma membrane can be accounted to: its 
flexibility, as it is a non-rigid structure that can deform, and its heterogeneity making 
the membrane different from one area to another (Nel et al, 2009). Furthermore, 
plasma membranes are not passive, they might secret ions, proteins or other 
molecules in reaction to the binding of the nanoparticles to the cell surface (Nel et 
al, 2009).  
In order to develop more efficient nanomedicines, our understanding of the 
interactions of nanoparticles at the cellular levels is crucial. Furthermore, in order to 
effectively deliver nanomedicines into the cells and the targeted organelles, it is of 
great importance to try and understand what happens at the plasma membrane 
interface (Nel et al, 2009). The interaction between individual nanoparticles as well 
as the solvent medium in a colloidal solution is governed by a number of attractive 
forces (e.g. Van Der Waals and depletion) and repulsive forces (e.g. electrostatic) 
added to that, other short-range forces including solvation and electrosteric forces. 
However, upon contact with a biological system the situation becomes far more 
complicated, as nanoparticles might interact with surface ligands, soluble proteins, 
excreted cellular products, hydrophobic as well as polar regions on the cell surface. 
All of which will change the way these nanoparticles behave in a biological setting 
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(Nel et al, 2009). Therefore, in order to effectively deliver nanoparticles inside the 
cells, they have to be able to transverse the plasma membrane utilising the various 
endocytic pathways (Sahay et al, 2010a).  
Endocytosis is the process by which macromolecules are carried into the cell in 
membrane-bound vesicles derived by the invagination and pinching-off of pieces of 
the plasma membrane. It can be broadly divided into 2 main types: phagocytosis 
(cell eating for large particles) and pinocytosis or fluid phase-endocytosis (cell 
drinking for small particles) (Conner & Schmid, 2003). The main characteristics of 
each type is summarised in Table 1.2 and Figure 1.3.  
Table 1.2: Summary of the different endocytic pathways.  
Information summarised from (Chou et al, 2011; Conner & Schmid, 2003; Verma & Stellacci, 
2010). 
Endocytosis 
Pinocytosis Phagocytosis 
D
ef
in
iti
on
 
Cell drinking of fluids and solutes, also known as fluid phase 
uptake. 
Pinocytosis can be subdivided into: 
Cell eating of 
large solid 
particles such 
as bacteria, 
yeast or 
remnants of 
dead cells.  
Mainly 
conducted by 
specialised 
cells including 
monocytes, 
macrophages 
and 
neutrophils. 
S
ub
ty
pe
s 
Macropinocytosis 
Caveolae-
mediated 
endocytosis 
Clathrin-
mediated 
endocytosis 
Clathrin- 
and 
caveolin-
independent 
endocytosis 
B
rie
f d
es
cr
ip
tio
n Large fluid 
pockets are 
trapped by 
formation of 
membrane 
protrusions 
Flask 
shaped 
invaginations 
Coated pits 
formed by 
assembly of 
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Figure 1.3: Mechanisms of endocytosis 
Endocytosis can be divided into phagocytosis (for large molecules) and pinocytosis (for 
small molecules). The illustration shows the different endocytic pathways by which 
molecules can enter the cells; each endocytic process is mechanistically distinct from the 
other. Phagocytosis and macropinocytosis are dependent on actin while clathrin and 
caveolae dependent endocytosis rely on dynamin to engulf molecules (Chou et al, 2011; 
Conner & Schmid, 2003).   
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1.4.1 Factors affecting cellular interactions of nanoparticles  
1.4.1.1 Size 
The size of the nanoparticles is a paramount factor determining cellular interactions 
and routes of endocytosis, although the polydispersity of most nanoparticle 
preparations makes it difficult to define exactly which pathways are responsible 
(Sahay et al, 2010a). Another important factor is protein opsonisation which can 
lead to particle aggregation and subsequent loss in size control (Akinc & Battaglia, 
2013). Whilst it is generally agreed that nanoparticles should have a minimum 
diameter of 40 to 60 nm to achieve cellular uptake, realistically it is more 
complicated as most internalisation processes occur by more than one pathway, 
some of which are size-independent (e.g. macropinocytosis) (Akinc & Battaglia, 
2013).  
Although phagocytosis is associated with uptake of large particles (> 1 µm), it has 
been reported that smaller nanoparticles can be internalised via this pathway 
specifically by professional phagocytic cells such as macrophages and monocytes 
(Akinc & Battaglia, 2013; Fischer et al, 2010; Lunov et al, 2011). Also, 
macropinocytosis can occur with relatively big nanoparticles (up to 1 µm). Whereas, 
clathrin mediated endocytosis can internalise particles in the size range of 10 to 300 
nm (Akinc & Battaglia, 2013). Generally, clathrin mediated endocytosis has been 
accounted for the uptake of nanoparticles by non-specialised mammalian cells 
(Blanco et al, 2015).  Although caveosomes are approximately 50-60 nm in diameter 
(Conner & Schmid, 2003), suggesting that they can only carry cargos of small 
nanoparticles, Wang et al showed that caveolae-mediated endocytosis facilitate the 
entry of nanoparticles in the 100 nm range (Wang et al, 2009).  
Size is also a crucial determinant of the fate of nanoparticles in vivo affecting 
extravasation, circulation times, immunogenicity, targeting, internalisation, 
intracellular trafficking, metabolism, degradation, clearance and uptake mechanisms 
as described in Figure 1.4 (Blanco et al, 2015; Mitragotri & Lahann, 2009). 
Therefore, depending on the intended biomedical application the size of the 
nanoparticles could be tailored (Blanco et al, 2015; Mitragotri & Lahann, 2009). 
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Figure 1.4: Effect of the size of nanoparticles on their uptake in the body 
NP: nanoparticles; D: hydrodynamic diameter; Figure modified from (Mitragotri & Lahann, 
2009). 
1.4.1.2 Charge 
Surface charge is another crucial factor in determining nanoparticle uptake. The cell 
membrane is negatively charged, suggesting that positively charged nanoparticles 
would be more efficiently taken up than neutral or anionic nanoparticles due to the 
electrostatic attractions between the particles and the negatively charged 
proteoglycans on the cell surface (Akinc & Battaglia, 2013; Albanese et al, 2012; 
Blanco et al, 2015; Sahay et al, 2010a). Furthermore, cationic nanoparticles are 
known to be cytotoxic while anionic and neutral ones are relatively safe (Akinc & 
Battaglia, 2013).  
The surface charge of nanoparticles is measured by the zeta potential which is the 
magnitude of the electrostatic potential at the electrical double layer surrounding a 
nanoparticle in solution (Clogston & Patri, 2011). When in contact with biological 
environments (e.g. serum), the surface charge of nanoparticles might be altered due 
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to the adsorption of proteins to the particle surface forming a corona (Albanese et al, 
2012; Sahay et al, 2010a). Since the type of protein corona formed around 
nanoparticles is dependent on the initial surface charge, studies comparing 
positively and negatively charged nanoparticles should be cautiously interpreted 
because they might be actually describing the effect of different corona 
compositions (Albanese et al, 2012). 
Most data available suggests that positively charged nanoparticles are mainly 
internalised via clathrin-mediated endocytosis with some utilising macropinocytosis, 
whereas strongly cationic nanoparticles may use caveolae-mediated endocytosis 
(Sahay et al, 2010a). Nonetheless, Perumal et al reported that cationic and neutral 
dendrimers were internalised via clathrin- and caveolin-independent endocytosis 
while, their anionic counterparts were internalised by caveolae mediated 
endocytosis (Perumal et al, 2008). Similarly, cellular entry of negatively charged 
nanoparticles (e.g. Doxil®) has been mainly attributed to caveolae-mediated 
endocytosis (Sahay et al, 2010b). While the mechanism of uptake of neutral 
nanoparticles is generally still unclear (Sahay et al, 2010a). It has been also shown 
that the extent of cellular internalisation of nanoparticles is dependent on the cell 
type. For instance Jordan et al have shown that fibroblasts tend to take up 
negatively charged nanoparticles more than positive ones while tumour cells tend to 
have opposite preferences with higher uptake of positive nanoparticles (Jordan et al, 
1999).     
1.4.1.3 Shape 
It has been shown that both the shape and the angle at which the nanoparticles 
encounter the cells can determine if the nanoparticles will be internalised. For 
instance, a nanoparticle in the shape of an elliptical disc will be internalised by 
macrophages if they are in contact with the pointed end of the disc but not with its 
flat region (Mitragotri & Lahann, 2009). This can be explained in terms of surface 
area because when macrophages are challenged with a large surface area they fail 
to internalise the particles and instead spread around them (Akinc & Battaglia, 
2013). While others showed that gold nanospheres with diameters of 14 nm and 74 
nm were 3 times preferentially internalised by HeLa cells than 14 X 74 nm cylindrical 
nanorods (Chithrani et al, 2006). Similar findings by Barua et al have revealed that 
even with targeting with an anti-HER2 antibody (Trastuzumab), cylindrical nanorods 
achieved higher specificity to HER2 expressing cell lines and less unspecific uptake 
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when compared to their spherical counterparts (nanospheres) and nanodiscs (Barua 
et al, 2013). 
Generally, it has been suggested that non-spherical nanoparticles could provide a 
good alternative for drug delivery as they might adhere better to the vasculature. 
Furthermore, they can align or tumble in the presence of blood flow rendering them 
less prone to rapid clearance and having longer half-lives (Blanco et al, 2015).     
1.4.1.4 Surface coating and design  
The choice of the surface chemistry of nanoparticles aims to maintain their 
dispersibility in biological solutions and keep the nanoparticles biocompatible so 
they do not induce toxic effects when administered in vivo (Akinc & Battaglia, 2013; 
Albanese et al, 2012). The evolution of nanoparticles coat design can be divided 
into 3 generations as seen in Figure 1.5 (Albanese et al, 2012). 
 
Figure 1.5: Evolution of nanoparticles design  
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The first generation nanoparticles were functionalised with basic non-stealth surface 
coatings that had poor colloidal stability leading to their aggregation in cell culture 
media and also their rapid removal from the circulation by the RES (Albanese et al, 
2012).   
The second generation nanoparticles involved optimisation of the surface coating to 
improve pharmacokinetics, reduce opsonisation and prolong circulation times 
(Albanese et al, 2012). Many approaches have been developed to sterically prevent 
both the hydrophobic and electrostatic interactions between nanoparticles and the 
various components of the blood (Fan et al, 2011; Gabizon, 2001; Gaur et al, 2000; 
Gupta & Gupta, 2005; Shubayev et al, 2009). This was achieved by surface coating 
of nanoparticles with brush-like structures to generate repulsive steric forces 
(Leckband & Israelachvili, 2001), reduce the protein corona (Li & Huang, 2010) and 
thus protect nanoparticles from recognition by macrophages (Moghimi & Szebeni, 
2003). In addition, these coatings also maintain inter-particle stability by reducing 
Van der Waals attractive forces between individual nanoparticles (Moghimi & 
Szebeni, 2003).  
The desired brush-like surface has been created by a number of soluble polymers, 
either non-ionic surfactants or zwitterions (Albanese et al, 2012; Alcantar et al, 
2000; Barrett et al, 2001; Huang et al, 2010; Ishihara et al, 1999; Kitano et al, 2010; 
Lemarchand et al, 2004; Zalipsky et al, 1996). Some examples are listed below: 
• Polyethylene glycol (PEG)  
• Polysaccharides (e.g. dextran, heparin, chitosan, etc.)  
• Poly N-vinyl pyrrolidone (PVP) 
• Poly vinyl alcohol (PVA) 
• Poly (2-methyl-2-oxazoline) (PMOXA)  
• Poly (2-ethyl-2-oxazoline) (PEOXA),  
• Poly (2-methacryloyloxyethyl phosphorylcholine) (PMPC)   
• Poly (sulfobetaine methacrylate) (PSBMA)  
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Coating of nanoparticles with brush-like dense polysaccharides layer (e.g. dextran, 
chitosan, heparin and starch) has resulted in sterically inhibiting the binding of 
proteins to the surface of nanoparticles (Lemarchand et al, 2004). For instance 
dextran and heparin coated PMMA (poly methyl methacrylate) nanoparticles 
showed a prolonged half-life when compared to naked ones (Passirani et al, 1998). 
On the contrary, studies done with dextran coated iron oxide nanoparticles showed 
that they are rapidly removed by the RES despite their dextran coating; 
nevertheless, their half-life was prolonged when the size of these nanoparticles was 
reduced to below 50 nm (Chouly et al, 1996). These findings highlight the 
complexity of nanoparticles interaction with biological systems which is dependent 
on a combination of factors rather than a single parameter (Lemarchand et al, 
2004).  
In summary, PEGylation of nanoparticles is widely considered to be the gold 
standard for biomedical applications since its introduction in the early 1990s as an 
alternative coating for liposomes (Li & Huang, 2010). Surface coating with PVP, 
PMPC and PMOXA are viewed as appropriate alternatives (Akinc & Battaglia, 
2013). Ideally stealth-coated nanoparticles should not be opsonised and thus should 
escape the RES to remain long enough in the circulation to penetrate the leaky 
tumour vasculature via the EPR effect. However, “stealthing” of nanoparticles is 
usually not fully effective, leading to loss of nanoparticles to the RES (Li & Huang, 
2010).  
Another approach to improve nanoparticle localisation into tumours is 
functionalisation with targeting moieties (see section 1.3.2). Nevertheless, the over 
reliance on the EPR effect as well as the lack of improved tumour accumulation 
following targeting has led to the development of the third generation nanoparticles 
(Shmeeda et al, 2009).  
Third generation nanoparticles includes “intelligent” particles that interact with 
biological cues such as low pH, hypoxia or matrix metalloproteinases in the tumour 
microenvironment. For example, Poon et al have developed nanoparticles with 
multi-layers; the first stealth PEG layer is deshielded in the low pH of the hypoxic 
tumour regions to reveal a positively charged poly-L-lysine layer readily taken up by 
tumour cells (Poon et al, 2011). While Sarkar et al coated liposomes with collagen-
mimetic peptides that are enzymatically cleaved by matrix metalloproteinase (MMP-
9) to release the liposomal cargo at the tumour site (Sarkar et al, 2007). Importantly, 
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since the cargo of the intelligent nanoparticles is released by the tumour, they 
remain protected from the RES organs and toxic side effects are reduced (Albanese 
et al, 2012). 
1.5 Biocompatibility of nanoparticles  
The Nanotechnology Characterisation Laboratory (NCL) and the National Cancer 
Institute (NCI) have assessed studies investigating more than 130 different types of 
nanoparticles (e.g. quantum dots, metal oxides, polymers, liposomes, dendrimers 
and gold colloids) and concluded that size, surface charge and hydrophobicity 
(dispersibility) of the nanoparticles are the three main parameters governing the 
biocompatibility of nanomaterials. The three parameters have been assessed 
independently for effect on biocompatibility and a colour coded phase diagram was 
used to represent the data (see Figure 3 in (McNeil, 2009)). Interpretation of the 
phase diagram has revealed that hydrophobic nanoparticles (with low dispersibility) 
can be considered relatively safe as the RES rapidly clears them from the circulation 
while hydrophilic particles should be made of biodegradable material to maintain 
their biocompatibility. Surface charge, independent of the other factors, can also 
affect the interaction of nanoparticles in vivo. Cationic nanoparticles were shown to 
be more cytotoxic (i.e. low biocompatibility) and can induce haemolysis and platelet 
aggregation when compared to anionic and neutral particles. Finally the size of the 
particles affects their clearance (see Figure 1.4), with small particles (<8 nm) mainly 
excreted via the kidney and larger ones (> 200 nm) mainly being trapped within the 
liver Kupffer cells. Intermediate size nanoparticles (~20-100nm) can penetrate the 
leaky tumour vasculature and get retained within the tumour (i.e. via the EPR effect) 
(Khandare et al, 2012; McNeil, 2009; Nel et al, 2009). 
In conclusion, even though many studies have attempted to define the rules 
affecting cellular uptake of nanoparticles, the exact mechanisms are still unclear and 
appear to vary from one nanoparticle to the other. When all the factors (e.g. size, 
charge, coatings, shape, protein corona composition etc.) are combined together an 
added level of complexity is observed, suggesting that a case-by-case examination 
for each nanoparticle will be the best approach. For instance minor modification to 
the particles’ size or surface chemistry can dramatically affect their physiological 
response (McNeil, 2009).    
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1.6 Superparamagnetic Iron Oxide Nanoparticles (SPIONs) 
SPIONs typically consist of an insoluble iron oxide magnetic core and a 
biocompatible hydrophilic surface coating to solubilize the core. The magnetic core 
is composed of magnetite (Fe3O4) and maghemite (Υ-Fe2O3) crystals. The coating 
can be made of synthetic or natural polymers, including dextran or its derivatives 
(carboxydextran, carboxymethylated dextran or starch), polyethylene glycol  (PEG), 
alginate and poly vinyl pyrrolidone (PVP) (Rosen et al, 2012; Weissleder et al, 
2014). 
SPIONs can be created with a wide range of hydrodynamic diameters depending on 
the intended use. Usually the term SPIONs refers to nanoparticles with a 
hydrodynamic diameter greater than 50 nm. Particles smaller than 50 nm are 
referred to as ultrasmall SPIONs (USPIONs) and particles of diameters less than 10 
nm are called very small SPIONs (VSPIONs) (Weissig et al, 2014). 
The miniaturisation of the iron oxide cores to the nanoscale (usually < 20 nm) leads 
to the development of unique magnetic properties, specifically superparamagnetism. 
This unique phenomenon occurs due to the reduction of the core sizes leading to 
each nanoparticle acting as a single magnetic domain that appears to retain no 
magnetisation upon the removal of a magnetic field (Karimi et al, 2013; Kievit & 
Zhang, 2011; Rosen et al, 2012).   
1.6.1 Clinical applications 
The superparamagnetic properties of SPIONs (Gupta et al, 2007) provide a versatile 
platform for different biomedical applications ranging from diagnosis to therapy 
(Krishnan, 2010). These applications include magnetic resonance imaging (MRI) 
(Bonnemain, 1998b; Hamm et al, 1994; Lawaczeck et al, 1997; Reimer & Balzer, 
2003; Sun et al, 2008), hyperthermia (Denardo & Denardo, 2008; Maier-Hauff et al, 
2007; Maier-Hauff et al, 2011; Plotkin et al, 2006; Vauthier et al, 2011; Wust et al, 
2002), drug delivery (De Jong & Borm, 2008; Dobson, 2006; Gupta & Gupta, 2005), 
stem cell labelling and tracking (Loebinger et al, 2009b; Mailänder et al, 2008; Park 
et al, 2008), tissue repair and cell separation (Gupta & Gupta, 2005).  
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1.6.2 Magnetic Resonance Imaging (MRI)  
The most well established clinical use of SPIONs is as MRI contrast agents. A range 
of SPIONs with different coatings and sizes have been clinically approved for this 
purpose (Rosen et al, 2012). For example AMI 121 (Lumirem® or Gastromark®), a 
300 nm silicon-coated SPION, is used orally for imaging the gastrointestinal tract 
(Bonnemain, 1998a). While Sinerem®, a dextran coated 30 nm SPION, was the first 
agent to be introduced for lymph node imaging which is an important tool in cancer 
staging (Bonnemain, 1998a). Endorem® (Feridex® in US) and Resovist® 
(Ferucarbotran) have been used in the detection of cancerous lesions in liver and 
spleen (Chachuat & Bonnemain, 1995; Reimer & Balzer, 2003). Both Endorem® and 
Resovist® have a dextran coating, and rely on their preferential uptake by healthy 
RES tissues with minimal uptake by tumour cells due to their impaired phagocytic 
system. Thus, when these organs are imaged with T2-weighted MRI, a signal loss 
(i.e. darkening) of the normal tissues is observed while cancerous lesions appear 
brighter facilitating their detection (Di Marco et al, 2007; Rosen et al, 2012).  
A list of clinically approved MRI contrast SPIONs is reviewed in (Weissig et al, 2014) 
while those undergoing testing in different clinical trials are reviewed in (Weissig & 
Guzman-Villanueva, 2015).  
1.6.3 SPIONs and the RES  
The rapid clearance of SPIONs from the circulation by the RES is dependent on 
many factors such as the hydrodynamic diameter, surface charge and coating 
(Chouly et al, 1996). The mechanism of uptake of dextran-coated SPIONs (e.g. 
Ferucarbotran, Feridex® (Endorem®)) by macrophages has been investigated in a 
number of studies and various mechanisms and receptors have been explored 
(Chao et al, 2012a; Lunov et al, 2010b; Raynal et al, 2004; Yang et al, 2011). Lunov 
et al have investigated a range of endocytic pathways including: macropinocytosis, 
pinocytosis, phagocytosis, clathrin- and caveolae-mediated endocytosis, and uptake 
by scavenger receptors (Lunov et al, 2010a). While Yang et al studied clathrin- and 
caveolae-mediated endocytosis, macropinocytosis among other pathways (Yang et 
al, 2011). Most studies indicated that scavenger receptors class A (Chao et al, 
2012a; Chao et al, 2012b; Lunov et al, 2010b; Raynal et al, 2004; Yang et al, 2011) 
and clathrin-mediated endocytosis (Lunov et al, 2010b; Yang et al, 2011) are 
responsible for the uptake of dextran-coated SPIONs by macrophages. While, Chao 
et al examined the role of carbohydrate recognition pathways and showed that 
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mannose receptors (Lectin-like receptors CD206) and SIGNR1 receptors are not 
involved in the uptake of dextran coated SPIONs although they mediate the uptake 
of bacterial polysaccharides such as dextrans (Chao et al, 2012a).  
1.6.3.1 Scavenger receptors  
Scavenger receptors (SR) were first identified in 1979 by Goldstein and Brown 
(Brown & Goldstein, 1979). There are 8 different classes of these receptors named 
class A to H mainly found on dendritic cells, macrophages, and some endothelial 
cells (Love & Jones, 2013). These receptors were first associated with the 
internalisation of oxidized low-density lipoproteins (oxLDL) which have been 
implicated in the pathogenesis of atherosclerosis (Canton et al, 2013). This 
superfamily of receptors is now sub-classed under the membrane-bound pattern 
recognition receptors (PRRs) and can recognise an extremely diverse and wide 
range of ligands (Canton et al, 2013).  SR play a critical role in multiple macrophage 
functions including phagocytosis, cell adhesion, host defence and production of 
reactive oxygen species (Kelley et al, 2014). SR have also been implicated in the 
pathophysiology of a number of diseases, for instance: atherosclerosis, diabetes 
type II and Alzheimer’s disease (Canton et al, 2013; Love & Jones, 2013). An 
extensive review of ligands and tissue distribution of scavenger receptors is 
discussed in (Canton et al, 2013).  
Class A scavenger receptors  
The class A scavenger receptor subfamily is of particular interest as they have been 
shown to be responsible for the uptake of dextran-coated SPIONs by macrophages 
(Chao et al, 2012a; Chao et al, 2012b; Lunov et al, 2010b; Raynal et al, 2004; Yang 
et al, 2011). These receptors are homo trimeric transmembrane proteins with long 
extracellular C-terminus and a short cytoplasmic tail (Kelley et al, 2014). As with 
other members of this superfamily, class A scavenger receptors play a critical role in 
both the innate immunity and host defence as well as in the pathogenesis pathways 
of many diseases (e.g. atherosclerosis, endotoxemia, stroke, inflammation and 
coronary artery disease) (Kelley et al, 2014).    
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 The class A scavenger receptors can be subdivided into 5 subtypes (Kelley et al, 
2014; Love & Jones, 2013): 
• SR-AI/II: expressed by most macrophages 
• Macrophage receptor with a collagenous structure (MARCO): limited to 
macrophages of the spleen marginal zone 
• Cellular response protein (CSR): increased expression seen in cells in 
response to oxidative stimuli  
• Scavenger receptor with C-type lectin (SRCL): mainly on endothelial cells 
and is not expressed by macrophages 
• Scavenger receptor A5 (SCARA5): found on epithelia and not expressed on 
macrophages.     
 Scavenger receptor class A is a multi-functional receptor that can bind to a variety 
of ligands such as: polyanionic macromolecules (e.g. dextran sulfate, heparin, 
polyinosinic acid and fucoidan), modified lipoproteins, bacteria and apoptotic cells 
(Kelley et al, 2014; Platt & Gordon, 2001; Raynal et al, 2004). Dextran sulfate is 
known to be an efficient blocker of this receptor (Patel et al, 1983; Yoshinobu et al, 
1994).  
1.6.4 Magnetic hyperthermia  
A property with potential use in cancer therapy is the ability of SPIONs to produce 
heat when put in an external alternating magnetic field. This phenomenon results 
from the conversion of electromagnetic energy into thermal energy (Cherukuri et al, 
2010). The heat generated by SPIONs can cause not only the direct death of cancer 
cells but also sensitise them to the effect of chemotherapy and radiotherapy 
(Thiesen & Jordan, 2008; Wust et al, 2002).  
The use of heat to treat illnesses is not a new concept. In fact it has been exploited 
since the time of Hippocrates (460370 BC) who believed that any illness could be 
treated by heating the patient’s body (Ito et al, 2005). Many approaches have been 
developed to deliver heat to cancerous tissues, for example local hyperthermia, 
interstitial and endocavitary hyperthermia, regional hyperthermia and part-body 
hyperthermia, whole-body hyperthermia and hyperthermic isolated limb perfusion 
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(reviewed in (Wust et al, 2002)). Furthermore, a wide number of clinical trials 
utilising hyperthermia therapy in combination with radiotherapy and/or 
chemotherapy have been conducted for the treatment of breast, CNS, 
gynaecological, head and neck and skin cancers (reviewed in (Mallory et al, 2015; 
Wust et al, 2002)). Despite the presence of effectiveness in some of these trials, 
local and systemic side effects persist (Wust et al, 2002). Two main drawbacks 
arise: (a) the difficulty of heating the tumours to the intended temperatures without 
causing damage to the nearby normal tissues (Ito et al, 2005) and (b) the need to 
develop non-invasive real-time temperature monitoring systems (Mallory et al, 
2015). The first drawback can be overcome by localised hyperthermic treatments 
exploiting the unique magnetic properties of SPIONs while the second problem is 
still to be overcome. Moreover, SPIONs provide an exciting alternative for 
hyperthermia owing to their unique properties of being injectable, nontoxic and 
biocompatible (Ito et al, 2005). 
Gordon et al were the first to introduce the use of magnetic nanoparticles to deliver 
inducible localised hyperthermia in 1979 by injecting dextran magnetite directly into 
mammary carcinomas in Sprague Dawley rats (Gordon et al, 1979; Ito et al, 2005). 
Since then many pre-clinical studies have tested the use of magnetic nanoparticles 
for hyperthermia. Some of which rely on direct injection of nanoparticles near or 
inside the tumours (Thiesen & Jordan, 2008) while others target the nanoparticles 
using monoclonal antibodies towards antigens expressed on cancer cells (Denardo 
& Denardo, 2008).  
1.7 Resovist® 
The main SPION investigated in this thesis is Ferucarbotran, the active ingredient of 
Resovist®. Resovist® was clinically approved as a T2 MRI contrast agent to detect 
focal liver cancerous lesions (Reimer & Balzer, 2003). Resovist® has an average 
hydrodynamic diameter of 60 nm and consists of a mixture of magnetite-Fe3O4 and 
maghemite-γFe2O3 crystals embedded in a carboxydextran shell to provide stability 
and biocompatibility of the nanoparticles both in solution and in vivo (Gupta et al, 
2007; Reimer & Balzer, 2003) (see Figure 1.6). 
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Figure 1.6: Schematic presentation of Resovist® 
The nanoparticles are made up of Magnetite–Fe3O4 and Maghemite–γFe2O3 core 
surrounded by a watery carboxydextran coat made up of multiple carboxylated glucose units 
(inset). The particles have an average hydrodynamic diameter of 60 nm with core size of 4.2 
nm.  
Resovist® has been tested both in vitro and in vivo and showed promising heating 
ability. Temperatures as high as 72.40C and 450C-59.90C were achieved in vitro and 
in vivo respectively (Hao-Yu et al, 2007; Takamatsu et al, 2008; Tseng et al, 2009). 
In vivo experiments performed on CT-26 colon carcinoma xenografts in mice 
showed effective tumour shrinkage (Hao-Yu et al, 2007; Tseng et al, 2009) when 
heated to 460C (Tseng et al, 2009). In these studies temperatures up to 550C were 
achieved within the tumours (Tseng et al, 2009). In another study rabbits with renal 
VX2 carcinoma implanted in their kidneys were used. Here, intra-arterial selective 
hyperthermia was achieved using transcatheter arterial embolization (TAE) with 
Ferucarbotran (Takamatsu et al, 2008). Tumours were heated to 450C for 20 
minutes leading to increased apoptosis when compared to control tumours 
(Takamatsu et al, 2008).  
Therefore, Resovist® is considered an excellent candidate for clinical development 
in hyperthermia due to its well documented safety profile with few reported side 
effects in pre-clinical studies (Lawaczeck et al, 1997) and in patients (Balzer T, 
1996; Hamm et al, 1994; Kehagias et al, 2001; Reimer & Balzer, 2003; Reimer et al, 
1995; Shamsi et al, 1998). 
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1.7.1 Resovist® Pharmacokinetics 
Resovist® has a distribution half-life of 3.9 to 5.8 minutes and an elimination half-life 
of 2.4-3.6 hours. Approximately 80% of the injected dose of Resovist® rapidly 
accumulates in the liver within minutes following its injection (Reimer & Balzer, 
2003). Furthermore, after 6 hours of intravenous administration the nanoparticles 
are exclusively taken up by liver Kupffer cells (Reimer & Balzer, 2003). The rapid 
clearance of Resovist® and other dextran coated SPIONs by the RES (Chouly et al, 
1996) represent a pharmacokinetic challenge that limits the use of these SPIONs for 
non-imaging applications.  
1.8 Hyperthermia for glioblastoma 
One of the most developed areas of SPIONs-based hyperthermia therapy in cancer 
is for the treatment of glioblastoma. Glioblastoma multiform (GBM) (WHO Grade IV) 
is one of the deadliest and most aggressive types of brain tumours; it is also the 
most common type of glial tumours, accounting for 60% of gliomas (Hoelzinger et al, 
2007). The standard of care for GBM is surgical resection followed by radiotherapy 
with concurrent chemotherapy with temozolomide (TMZ, Temodar®) and a further 6 
months of maintenance temozolomide (Stupp et al, 2005). Despite decades of 
research, the median survival of glioblastoma sufferers is only 14.6 months with no 
standard treatment for recurrent/relapsed patients resulting in very poor prognosis 
and high morbidity and mortality rates (Silva et al, 2011). These clinical outcomes 
highlight the urgent need for novel treatment approaches for GBM and magnetic 
hyperthermia represents a promising budding field. 
Clinical studies have shown that hyperthermia could promote GBM cell death, 
reduce tumour mass and increase survival (Silva et al, 2011). MagForce®, a 
German nanomedicine company, was the first to introduce the clinical use of 15 nm 
positively charged aminosilane coated iron oxide nanoparticles (NanoTherm™) for 
cancer hyperthermia. Preclinical studies on glioma cell lines and cerebral cortical 
neurons have revealed preferential uptake of NanoTherm™ by tumour cells (Jordan 
et al, 1999). While in vivo animal studies performed on a rat glioma intracranial 
model comparing Resovist® with NanoTherm™ revealed prolonged survival with 
NanoTherm™. The researchers concluded that this could be explained by the rapid 
diffusion of Resovist® to the surrounding tissues and thus the dissipation of the 
generated heat. However, histological studies done on rat brains did not investigate 
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the cell types containing SPIONs (e.g. tumour cells, microglia, neurons, etc.) 
(Jordan et al, 2006).  
The promising preclinical results, mentioned above, have led to phase I and II 
clinical trials involving the direct intratumoural injection of Nanotherm™ into brain 
tumour lesions. The therapy proved to be safe and well tolerated by GBM patients 
(Maier-Hauff et al, 2011; Plotkin et al, 2006) and clinical trials in glioblastoma, 
prostate, oesophageal and pancreatic cancers are ongoing (MagForce, 2015). 
Interestingly, post-mortem studies performed on treated patients with glioblastoma 
revealed the presence of nanoparticles aggregates mainly in brain macrophages 
with minor localisation into tumour cells (van Landeghem et al, 2009). These 
findings highlight the importance of studying the interaction of SPIONs with 
components of the tumour microenvironment.  
Similar to other tumours, the tumour microenvironment of glioblastoma includes a 
wide range of cells (e.g. vascular cells, neural progenitor cells, microglia and 
immune cells) (Charles et al, 2011). Of particular interest are microglial cells, which 
constitute 30% of the brain tumour mass (Charles et al, 2011) and the tumour 
associated macrophages (the resident macrophages of the tumour) which promote 
tumorigenesis, invasion and metastasis, tumour survival and proliferation (Garris & 
Pittet, 2013). In addition, glioblastoma cells were reported to communicate with 
nearby normal brain parenchyma (astrocytes, oligodendrocytes and neurons) via 
secreted molecules that can facilitate tumour invasion and malignant progression 
(Hoelzinger et al, 2007). Therefore, even with intratumoural injection of SPIONs into 
GBM tumours, SPIONs are faced with an array of cells that might internalise them 
and thus deprive the main tumour core from the heating effect of the activated 
SPIONs. Consequently, in vitro and in vivo assays investigating the uptake of 
SPIONs by tumour cells and components of the microenvironment become crucial.  
1.9 Targeting SPIONs to cancer cells  
Mainly SPIONs have been passively targeted to the RES for imaging purposes (see 
sections 1.3.1.2, 1.6.2 and 1.6.3). However, active targeting has been achieved by 
covalently linking SPIONs to various targeting moieties to facilitate specific uptake 
by cancer cells. Targeting agents include small molecules (such as folate, 
arginylglycylaspartic acid (RGD) and transferrin), monoclonal antibodies, antibody 
fragments and aptamers. A comprehensive list of all targeting strategies for SPIONs 
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is reviewed in (Kamaly et al, 2012; Rosen et al, 2012) and some examples are 
discussed below.  
1.9.1 Small molecules  
Folate receptors (FR) are cysteine rich cell surface glycoproteins that bind to folates, 
there are 3 types of folate receptors: α, β and γ (Chen et al, 2013). Folate is a 
generic term that describes folic acid (vitamin B9) and structurally related 
compounds. Folates play an important role in DNA synthesis, DNA repair, DNA 
methylation and cell division (Kelemen, 2006). Folate receptors are exciting targets 
for the development of cancer specific therapies for two main reasons: (a) the 
preferential overexpression of folate receptors (mainly FR α) on cancer cells (e.g. 
ovarian, epithelial, cervical, lung, kidney and brain tumours) and their limited 
expression in normal tissues (Kelemen, 2006); (b) folic acid is a cheap and a 
structurally stable small peptide (441 Da) that can be conjugated to drugs, 
nanoparticles or diagnostic markers while maintaining its binding ability to the 
receptor (Zwicke et al, 2012). Folate ligands (e.g. antibodies or folates) have been 
conjugated to different types of SPIONs (Rosen et al, 2012) and were shown to bind 
specifically in vitro and in vivo (Chen et al, 2008; Choi et al, 2004; Fan et al, 2011; 
Kalber et al, 2011; Sonvico et al, 2005; Sun et al, 2006).  
Transferrin receptors are another example of potential therapeutic targets for cancer 
nanomedicines. Transferrin receptor (TfR or CD71) is a membrane bound 
glycoprotein that mediates the uptake of iron by cells via transferrin (Daniels et al, 
2012; Ponka & Lok, 1999). Transferrin is a small peptide (80 KDa) that has iron 
chelating properties and regulates the transport, storage and utilisation of iron by 
cells (Ponka & Lok, 1999). Similar to folate receptors, TfR are overexpressed by 
many cancers (e.g. squamous cell carcinomas, liver, breast and pancreatic cancers) 
with low levels in normal tissues (Daniels et al, 2006a; Daniels et al, 2006b). 
SPIONs labelled with transferrin were used for MR imaging and were found to 
specifically localise to TfR positive tumours (Högemann-Savellano et al, 2003). 
While Kresse et al functionalised USPIO with human transferrin that were shown to 
localise to mammary carcinomas overexpressing TfR in vivo as detected with MRI 
(Kresse et al, 1998).    
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1.9.2 Aptamers 
Aptamers are a class of nucleic acid molecules formed of short single strands of 
DNA or RNA oligonucleotides that fold to form secondary and tertiary 3-D 
structures. Aptamers are synthesised to bind targets with high affinity and specificity 
and can be considered as the nucleic acid equivalents of antibodies (Ni et al, 2011).  
Aptamers can also be engineered to have effective functional groups to facilitate 
conjugation to nanoparticles (Jayasena, 1999; Rosen et al, 2012) and aptamer-
SPION conjugates have been developed to target cancer cells. For instance Wang 
et al synthesised SPIONs functionalised with aptamers targeting prostate-specific 
membrane antigen (PSMA). The functionalised SPIONs were specifically 
internalised by prostate cancer cells suggesting their potential use for prostate 
cancer imaging and therapy (Wang et al, 2008). While in a study done by Herr et al 
aptamer-SPION conjugates were used for leukemic cancer cell extraction from 
blood samples using magnetic cell separation techniques (Herr et al, 2006). 
Similarly, Bamrungsap et al used aptamer-conjugated magnetic nanoparticles for 
very sensitive selective cancer cell detection in a variety of biological fluids (e.g. 
foetal bovine serum (FBS), human plasma and whole blood) (Bamrungsap et al, 
2012). 
1.9.3 Antibodies and antibody fragments  
Antibodies (immunoglobulins) are the most established targeting agents currently 
available.  As seen in Figure 1.7, a basic IgG 1 antibody (~ 150 KDa) is a Y-shaped 
molecule consisting of four polypeptide chains: 2 identical heavy chains (H) (~50 
KDa) and 2 identical light chains (L) (~ 25 KDa) held together by covalent disulphide 
bonds and non-covalent bonds. The heavy chain is made up of 4 distinct regions 
(domains) while the light chain has two domains. Three out of the four domains of 
the heavy chain and two out of the three domains of light chains were found to be 
constant among antibody chains of the same isotype, consequently named constant 
domains (C) (Janeway et al, 2001). On the contrary, the terminal domain of each 
chain was found to vary greatly between different antibodies, thus named variable 
domains (V). The paired VH and VL terminal domains of the antibody determine its 
specificity and renders two antigen binding sites on each antibody (Janeway et al, 
2001).  
Whole Y-shaped antibodies could be fragmented by proteolytic digestion into 
different moieties: (i) the two arms; named fragment antigen binding (Fab) 
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containing the variable fragments (Fv) and (ii) the trunk; named the fragment 
crystallizable (Fc) region (Nelson & Reichert, 2009). The Fc region was observed to 
readily crystallize, hence the nomenclature (Janeway et al, 2001; Nelson & Reichert, 
2009). The Fc fragment lacks antigen binding activity but plays an important role in 
the biological effector function of the antibody by inducing antibody-dependent 
cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) (Sathish 
et al, 2013).  
The rapid development in recombinant antibody technology has led to the 
generation of different varieties of antibody fragments (examples are shown in 
Figure 1.7). Each antibody fragment has unique physicochemical properties (e.g. 
molecular weight, affinity, half-life, etc.) that determine its pharmacokinetic and 
pharmacodynamic behaviour and could be tailored according to the intended use 
(Nelson, 2010).    
 
Figure 1.7: Structure of a whole IgG 1 antibody and examples of some antibody 
fragments 
C= Constant domain; V= Variable domain; H= Heavy chain; L= Light chain; S-S= Disulfide 
bond; Fc= fragment crystallizable; Fab= fragment antigen binding region; Fv= variable 
fragment and ScFv=single chain fragment variable. 
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Since a number of antibodies have been approved for clinical use as anticancer 
therapies (reviewed in (Scott et al, 2012)), antibodies provide exciting targeting 
moieties for the development of SPION-based targeted therapies for both imaging 
and treatment of cancers. Examples of FDA-approved antibodies used in targeting 
studies involving nanoparticles include: anti-epidermal growth factor receptor 2 
(HER2) antibody (Trastuzumab, Herceptin®) (Chen et al, 2009; Cirstoiu-Hapca et al, 
2007), anti-epidermal growth factor receptor 1 (EGFR) antibody (Cetuximab, 
Erbitux®) (Bouras et al, 2015; Kaluzova et al, 2015; Liu et al, 2011; Suwa et al, 
1998) and anti-CD20 antibody (Rituximab, Mabthera®) (Cirstoiu-Hapca et al, 2007). 
Other studies have used antibodies developed for research against vascular 
endothelial growth factor (VEGF) (Abakumov et al, 2015; Hsieh et al, 2012), 
prostate-specific membrane antigen (PSMA) (Bates et al, 2014; Mukherjee et al, 
2014; Tse et al, 2015), chemokine receptor 4 (CXCR4) (He et al, 2012), glypican-3 
(GPC3) (Li et al, 2012) and mucin-1 (MUC1) (Shahbazi-Gahrouei & Abdolahi, 2013; 
Shanehsazzadeh et al, 2014). 
Similar to whole antibodies a number of antibody fragments, specifically antigen 
binding fragments (Fab), have been FDA approved for use in the clinic (e.g. 
Cimzia®, ReoPro® and Lucentis®) (Herrington-Symes et al, 2013; Nelson, 2010).  
Fab and single chain variable fragments (scFv) are the most commonly investigated 
fragments for the functionalisation and targeting of nanoparticles (Byrne et al, 2008). 
The small size of these fragments makes them more beneficial than whole antibody 
molecules as it allows the conjugation of multiple fragments per nanoparticle thus 
improving the multivalent targeting potential (Bazak et al, 2014). Examples of 
studies that used this approach include work by Huang et al using Docetaxel loaded 
iron oxide nanoparticles targeted with a scFv to Endoglin (Huang et al, 2014), while 
Vigor et al conjugated an anti-carcinoembryonic antigen (CEA) scFv to SPIONs and 
were able to achieve a specific MRI signal in CEA positive cancer cells (Vigor et al, 
2010). Yang et al conjugated an anti-EGFR scFv to SPIONs and could show 
specific internalisation by EGFR expressing cells (Yang et al, 2009). SPIONs have 
also been functionalised by Fab fragments, for instance Ndong et al used Fab 
fragment derived from the anti-folate receptor alpha antibody Farletuzumab; their 
results showed specific uptake of the conjugate by receptor-positive cancer cells 
both in vitro and in vivo (Ndong et al, 2015). Similarly, Quatra et al targeted folate 
receptors by functionalising iron oxide nanocrystals with a Fab fragment derived 
from anti-folate receptor alpha antibody (MOV19) (Quarta et al, 2015). Some studies 
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also used the bivalent F(ab’)2 fragment to target iron oxide nanoparticles to E-
selectin (Kang et al, 2002; Leung, 2004). Targeting with Fab fragments has also 
been employed with several liposomal preparations carrying chemotherapeutic 
cargos (Bazak et al, 2014).  
1.9.4 Designed Ankyrin Repeat Proteins (DARPins) 
The work presented in this thesis explores a novel targeting approach using 
Designed Ankyrin Repeat Proteins (DARPins). DARPins are small high affinity non-
immunoglobulin protein scaffolds derived from naturally occurring ankyrin proteins, 
that can be readily generated to bind specific targets (Tamaskovic et al, 2012).  
Ankyrin repeat (AR) proteins occur naturally in all species, including humans, and 
are implicated in a number of diverse biological processes. AR proteins are involved 
in many protein-protein interactions and were found intracellularly, extracellularly 
and even membrane bound. This versatility indicates that they can adapt to various 
environmental conditions (Binz et al, 2003). Furthermore more than 2000 AR 
proteins were identified highlighting their importance in nature (Letunic et al, 2002).  
A typical AR consists of 33 amino acids that form a β-turn followed by two anti-
parallel α-helices and a loop that reaches the β-turn of the next repeat (see Figure 2 
in (Binz et al, 2003)). Usually four to six repeats constitutes an AR protein 
(Tamaskovic et al, 2012). An assembled AR protein was mimicked to a “cupped 
hand” where the fingers are the β-hairpins and α-helices represent the palm (see 
Figure 1 in (Sedgwick & Smerdon, 1999)). Interactions with targets occur via the 
protruding β-turns and the first α-helix (Binz et al, 2003; Sedgwick & Smerdon, 
1999). The high versatility and modularity of the ankyrin repeat domains enable 
surface evolution by duplications, deletions or shuffling of the repeats (Kobe & 
Kajava, 2000). Hence, DARPins provide a versatile scaffold for the evolutionary 
generation of protein domains displaying specific binding surfaces. 
DARPins have been generated from AR via consensus design approach (Binz et al, 
2004), which has been applied for the design of other classes of repeat proteins 
(e.g. zinc finger peptides) (Kajander et al, 2006). Briefly, consensus design involves 
amino acid sequence alignments of many structurally related proteins to identify 
conserved residues. The hypothesis is that residues that occur with high frequency 
would maintain protein folding and stability while specific target interaction residues 
will not be conserved (Kajander et al, 2006). Using the consensus design strategy, a 
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library of designed AR proteins was generated with fixed framework residues and 
randomised potential interaction residues, then high affinity binders were selected 
against the specified target (Binz et al, 2004). DARPins are made up of a C-terminal 
and N-terminal capping repeats on either side of the protein enclosing a number of 
randomized designed ankyrin repeats module (Figure 1.8); they can be engineered 
to bind to specific targets with exceptionally high affinities (Binz et al, 2003; Stumpp 
et al, 2008) as well as being remarkably stable (Wetzel et al, 2010; Wetzel et al, 
2008).  
DARPins provide a wide range of possible applications; they can be used alone or 
genetically/chemically linked to other moieties (e.g. other DARPins, drugs, toxins, 
PEG (to increase their half-life), peptides, proteins or antibody Fc domains) (Stumpp 
et al, 2008).  
DARPins are advantageous over antibodies in many aspects for instance (Binz et 
al, 2005; Stumpp et al, 2008): (a) their small size provides better tumour 
penetration; (b) antibodies are large and difficult to engineer site specific 
attachments to them; (c) DARPins are much more stable than antibodies and 
therefore will provide a better option for hyperthermia therapy when conjugated to 
SPIONs; (d) the production of whole antibodies is laborious and expensive.  
 
 
Figure 1.8: Basic structure of DARPins 
A DARPin is made up of an N-terminal (blue) and a C-terminal (black) cap that encloses a 
variable number of ankyrin repeats.  
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1.10 Summary and research aims 
SPIONs possess unique magnetic properties that could be exploited to develop 
effective anti-cancer therapies such as magnetic hyperthermia. Yet, many 
challenges lie ahead before this can be achieved. The aim of this project was to 
investigate means to address three major challenges encountered in the 
development of SPIONs for targeted cancer treatment (i) uptake by non-cancer 
cells, particularly the RES, leading to rapid clearance and potential for healthy tissue 
damage, (ii) lack of specificity for cancer cells and (iii) SPIONs heterogeneity. 
Resovist® (Ferucarbotran) was used as the major SPION for the study due to its 
clinical safety profile and heating potential. 
First, the interaction of SPIONs with different cell types was characterised and the 
effects of scavenger receptor blockers measured (Chapter 3). It was hypothesised 
that SPIONs circulation time could be prolonged by blocking RES with 
polysaccharide derivatives. This hypothesis was tested in chapter 4.  
Second, it was hypothesised that specific targeting of SPIONs could be achieved by 
functionalising with cancer-targeting proteins such as DARPins. This hypothesis 
was tested in Chapter 5.  
Third, it was hypothesised that SPIONs heterogeneity could be addressed by 
physical separation to achieve more uniform preparations. This hypothesis was 
tested in Chapter 6.  
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2.1 Materials  
All materials were purchased from Sigma Aldrich (Dorset, UK) unless otherwise 
specified. 
2.1.1 General buffers 
Table 2.1: Formulation of PBS buffers 
Solution Formula 
Phosphate 
buffered Saline 
(PBS) 
Dissolve 1 bottle (96 g) of Dulbecco’s Phosphate Buffered Saline 
(Modified, without calcium chloride and magnesium chloride) in 10 L 
distilled water (dH2O)  
PBS/Tween 
(PBS/T) 
Add 10 ml of Tween-20 to 10 L of PBS solution  
2.1.2 Cell culture  
Table 2.2: List of cell lines investigated 
Cell line* Cell type Supplier 
RAW 264.7 Murine monocytes/macrophages 
American Type Culture 
Collection (ATCC®, TIB-71™) 
U-87 MG Human glioblastoma ATCC®, HTB-14™ 
U-251 MG Human glioblastoma Health Protection Agency (HPA) Culture Collection 
Neural stem cells 
(NSCs) Murine NSCs 
Dr Paolo Salomoni (UCL Cancer 
Institute) 
A375 Human melanoma Health Protection Agency (HPA) Culture Collection 
LS174T Human colorectal carcinoma Health Protection Agency (HPA) Culture Collection 
293T and 293T-
EGFR 
Human Embryonic Kidney 
(HEK) cells 
Dr Martin Pule (UCL Cancer 
Institute) 
SupT1, SupT1-
EGFR and 
SupT1-EGFRvIII 
Human lymphoblastic 
leukaemia 
Dr Martin Pule (UCL Cancer 
Institute) 
*All investigated cell lines were cultured as adherent cells except SupT1 cells were cultured 
as suspension cells.  
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Table 2.3: Cell culture media  
Cell lines Media Formula 
RAW 264.7 and 
A375 
Dulbecco’s modified Eagle’s medium (DMEM) (Gibco®, Thermo 
Fisher Scientific, Cheshire, UK) supplemented with 10% foetal 
bovine serum (FBS) (Gibco®), 100 U/ml of penicillin, 0.1 U/ml 
streptomycin and 1% L-glutamine  
LS174T, U-87 MG 
and U-251 MG 
DMEM supplemented with 10% FBS (Gibco®), 100 U/ml of 
penicillin, 0.1 U/ml streptomycin, 1% L-glutamine and 1% of non-
essential amino acids (PAA Laboratories GmbH, Pasching, Austria) 
293T DMEM supplemented with 10% FBS (Gibco
®) and 1% L-glutamine 
(PAA Laboratories GmbH, Pasching, Austria) 
SupT1 RPMI-1640 supplied with L-glutamine and supplemented with 10% FBS (Gibco®)  
Neural stem cells 
(undifferentiated) 
NeuroCult™ Proliferation Kit (Mouse) (STEMCELL™ Technologies, 
Grenoble, France) media supplied with recombinant human 
epidermal growth factor (rh EGF), recombinant human basic 
fibroblast growth factor (rh bFGF) (STEMCELL™ Technologies) 
and 100 U/ml of penicillin and 0.1 U/ml streptomycin. 5 µl of 0.1 
µg/µl of rh bFGF and 50 µl of 10 µg/ml rh EGF were added per 50 
ml of the media 
 
Table 2.4: Cell culture solutions 
Solution Formula 
Trypsin  1x Trypsin (0.05%) with EDTA (PAA Laboratories GmbH, Pasching, 
Austria) 
Accutase®  1x Accutase solution  
Laminin  Prepare 10 µg/ml solution; dilute Laminin stock solution 1:100 in sterile PBS  
PBS 1x Sterile PBS solution (Gibco®) 
Freezing media 
for NSCs 
Full media (as stated above in Table 2.3) supplied with 10% DMSO 
Freezing media 
for SupT1 Cryoprotective Freezing Medium (Lonza, Basel, Switzerland)  
Freezing media 
for all other cell 
lines 
10% DMSO in FBS; 9 ml FBS + 1 ml DMSO  
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2.1.3 Iron quantification assays 
Table 2.5: Solutions for ferrozine assay 
Solution Formula 
50 mM NaOH 0.2 g of sodium hydroxide (NaOH) in 100 ml distilled water (dH2O) 
4 M HCl 250 ml of dH2O + 125 ml 37% (12 M) hydrochloric acid (HCl) stock solution  
Iron releasing 
buffer 
0.45 g of potassium permanganate (KMnO4) in 10 ml dH2O + 3.5 ml 
4 M HCl + 6.5 ml dH2O 
Iron detection 
buffer 
In 5 ml dH2O dissolve 0.015 g neocuproine, 0.015 g ferrozine, 0.99 
g ascorbic acid, 0.96 g ammonium acetate. 
Table 2.6: Solutions for Prussian blue staining 
Solution Formula 
Cell fixation 
solution 2% formalin and 2.5% glutaraldehyde in PBS 
Staining solution 4 g potassium hexacyanoferrate (II) trihydrate dissolved in 20 ml dH2O + 20 ml 2% HCl 
2.1.4 Immunofluorescence staining 
Table 2.7: Solutions for immunofluorescence staining 
Solution Formula 
Fixation solution 4% formaldehyde (methanol-free ampoules) containing 20 mM HEPES buffer, pH 7.4 
Permeabilisation 
solution 0.1% Triton-X in PBS  
Blocking solution 5% goat serum in PBS/Tween (PBS/T) 
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2.1.5 Transmission Electron Microscopy (TEM) 
Reagents kindly prepared by the Electron Microscopy Unit at UCL Medical School, 
Royal Free Campus. 
Table 2.8: Solutions for TEM  
Solution Formula 
Fixation solution 20 ml 20% paraformaldehyde (Analar BDH) + 16 ml 25% glutaraldehyde (TAAB) + 59 ml PBS (Oxoid) 
Osmium tetroxide 1% osmium tetroxide (Analar BDH) + 1.5% potassium ferricyanide (BDH) in PBS (Oxoid) 
Toluidine blue 
stain 
1% Toluidine Blue (Raymond Lamb) with 0.2% Pyronin (Raymond 
Lamb) in 1% sodium tetraborate (Analar BDH) 
Reynold’s lead 
citrate 
Dissolve 1.33 g lead nitrate (BDH) in 15 ml dH2O and 1.76 g 
sodium citrate (BDH) in 15 ml dH2O, mix solutions together (30 ml) 
and dissolve the resulting precipitate with 8 ml of 1 M NaOH (BDH), 
make up to final volume of 50 ml 
Lemix epoxy resin 
(TAAB) 
Lemix A (25 ml) + Lemix B (55 ml) + Lemix D (20ml). Pour into 
plastic resin bottle, mix and add 2 ml of benzyldimethylamin 
(BDMA), then mix well. 
 
2.1.6 Superparamagnetic iron oxide nanoparticles (SPIONs) 
Table 2.9: List of SPIONs investigated 
SPIONs Supplier Size Range Coating 
Functional 
group 
Iron 
concentration 
Ferucarbotran 
(FC) 
Meito 
Sangyo 
Co. LTD., 
Tokyo, 
Japan 
45-65 
nm Carboxydextran 
OH, COOH 
(Hydroxyl 
and 
carboxylic) 
55.6-58.6 
mgFe/ml 
Nanomag®-D-
spio-amine 
(NM) 
Micromod 
Partikelte-
chnologie 
GmbH, 
Germany 
50-120 
nm Dextran 
NH2 
(amine) 2.4 mgFe/ml 
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2.1.7 Chemical conjugation of Ferucarbotran 
Table 2.10: Solutions used in SPIONs modification 
Solution Formula 
50 mM borate 
buffer (pH=8.5) 
Dissolve 4.77 g sodium tetraborate decahydrate in 250 ml dH2O; 
adjust to pH 8.5 with 4 M HCl 
0.1 M MES buffer Dissolve 1.95 g 2-(4-morpholino) ethanesulphonic HCl into 100 ml dH2O. Adjust to pH 6 with 5 M NaOH 
230 mM sulfo-
NHS 
Add 40 µl of 0.1 M MES buffer to 1 vial of sulfo-NHS (N-
hydroxysulfosuccinimide) (no weigh format, Thermo Fisher 
Scientific, Cheshire, UK) 
EDC/NHS 
activation buffer 
1.21 mg of EDC (1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide-
hydrochloride) and 8.8 µl of 230 mM sulfo-NHS (Thermo Fisher 
Scientific) in 200 µl of 0.1 M MES buffer  (pH=6) 
25 mM glycine Dissolve 0.18 g glycine into 100 ml PBS 
100 mM cysteine  Dissolve 1.2 g cysteine into 10 ml PBS 
 
Table 2.11: List of near infrared (NIR) dyes used 
Product Supplier Functional group Reactivity 
DyLight® 
800 NHS 
ester 
Thermo Scientific, 
Pierce Biotechnology 
NHS ester  
(N-Hydroxysuccinimide) 
Amine 
IRDye® 800 
CW azide 
LI-COR Biosciences, 
Lincoln, Nebraska, 
USA 
Azide 
Copper free click 
reaction with 
dibenzocyclooctyne 
(DBCO) 
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2.1.8 RES blockers 
Table 2.12: List of RES blockers investigated 
Name Product Supplier 
Average 
MW 
(Daltons) 
Concentration 
for in vitro 
experiments 
Doses for in 
vivo 
experiments 
D-70 Dextran 70 
Pharmacosmos 
ALS, Holbaek, 
Denmark 
70,000 Da 32 mg/ml Not tested 
D-40 Dextran 40 Meito Sangyo Co. LTD. 40,000 Da 32 mg/ml Not tested 
DSO4 8 Dextran sulfate sodium salt 8 Sigma Aldrich 
• 6,500-
10,000 Da 
(Average 
~8,000 
Da) 
1 mg/ml Not tested 
DSO4 
500 
Dextran sulfate 
sodium salt 500 Sigma Aldrich 
500,000 
Da 30 µg/ml 
 3, 7.5, 15 
and 30 mg/kg 
J-18 
Dextran sulfate 
sodium sulphur 
18 (for oral 
administration) 
Meito Sangyo 
Co. LTD. 1600 Da 1 mg/ml 30 mg/kg 
J-5 
Dextran sulfate 
sodium sulphur 
5 (for i.v. 
administration) 
Meito Sangyo 
Co. LTD. 1600 Da 1 mg/ml Not tested 
Fucoidan 
Fucoidan from 
Fucus 
vesiculosus 
Sigma Aldrich 
20000 - 
200000 
Da 
30, 50 and100 
µg/ml 15 mg/kg 
MW: molecular weight, Da: Daltons  
2.1.9 Reagents for protein characterisation 
Table 2.13: Recipe for SDS-PAGE gels 
Reagent Formula 
7.5% resolving 
gel 
3.85 ml dH2O, 2 ml 30% Acrylamide (Protogel), 2 ml 1.5M Tris-HCl 
pH 8.8, 80 µl 10% sodium dodecyl sulfate (SDS), 80 µl 10% 
ammonium persulfate (APS), 8 µl tetramethylethylenediamine 
(TEMED) 
10% resolving gel 3.2 ml dH2O, 2.67 ml 30% Acrylamide, 2 ml 1.5 M Tris-HCl pH 8.8, 80 µl 10% SDS, 80 µl 10% APS, 8 µl TEMED 
16% resolving gel 1.6 ml dH2O, 4.27 ml 30% Acrylamide, 2 ml 1.5 M Tris-HCl pH 8.8, 80 µl 10% SDS, 80 µl 10% APS, 8 µl TEMED 
4% stacking gel 3.6 ml dH2O; 0.67 ml 30% Acrylamide, 0.625 ml 1 M Tris-HCl pH 6.8, 50 µl 10% SDS, 50 µl 10% APS, 5 µl TEMED 
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Table 2.14 Reagents for protein analysis 
Reagent Formula 
1x SDS-PAGE running buffer 25 mM Tris-HCl, 192 mM Glycine, 0.1% (w/v) SDS 
4x Reducing buffer 
1.25 mM Tris-HCl solution in dH2O (pH 6.8), 20% w/v 
glycerol, 4% w/v β-mercaptoethanol, 0.1% w/v 
bromophenol blue and 0.1% w/v SDS 
4x Non-reducing buffer 1.25 mM Tris-HCl solution in dH2O (pH 6.8), 20% w/v glycerol, 0.1% w/v bromophenol blue and 0.1% w/v SDS  
Coomassie gel staining 
solution  
0.1 g Coomassie blue R-250 in 100 ml methanol, 20 ml 
glacial acetic acid and 80 ml dH2O 
Coomassie gel de-staining 
solution 
1.25 L methanol, 1 L dH2O and 250 ml glacial acetic 
acid 
 
Table 2.15 Reagents for western blotting  
Reagent Formula 
RadioImmunoPrecipitation 
Assay (RIPA) buffer 
50 mM Tris HCl pH 8 + 150 mM NaCl + 1% Nonidet P-
40 + 0.5% sodium deoxycholate + 0.1% SDS (solution 
was stored at 40C) 
Cell lysis buffer 
20 ml of RIPA buffer + 1 tablet of cOmplete ULTRA 
Tablets  (protease inhibitors) (Roche). Aliquoted and 
stored at -200C  
Transfer Buffer Stock (10x) 30 g Trizma
® base, 144.2 g glycine and 10 g SDS in 1 L 
dH2O 
Transfer Buffer (1x) 100 ml of 10x transfer buffer stock, 700 ml dH2O and 200 ml methanol 
5% Milk 2.5 g semi-skimmed Marvel milk (Marvel, UK) in 50 ml PBS/T 
1% Milk 0.5 g semi-skimmed Marvel milk in 50 ml PBS 
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2.1.10 Molecular weight markers  
SeeBlue® Plus2 pre-stained protein standard was obtained from Invitrogen Ltd 
(Paisley, UK) and PageRuler™ Unstained Protein Ladder was obtained from 
Thermo Scientific.  
 
Figure 2.1: Pre-stained molecular weight markers used in SDS-PAGE 
(A) SeeBlue® Plus2 and (B) PageRuler™ Unstained Protein Ladder (Pictures taken from 
Invitrogen Ltd and Thermo Scientific catalogues, respectively). 
2.2 Methods 
2.2.1 Cell culture 
All cells were maintained in culture media previously stated in Table 2.3 at 370C in a 
humidified incubator containing 5% CO2. All cell culture procedures were performed 
in a class II Hood and incubations were done inside the incubator at 370C (unless 
otherwise specified). 
All cells were purchased as frozen aliquots and stored either in liquid nitrogen or in a 
-800C freezer. To bring cells into culture, cells were thawed in a water bath at 370C 
then resuspended in 6 ml of full media and centrifuged at 280 x g for 5 minutes. The 
supernatant was aspirated using vacuum pump and the pellet was resuspended in 
10 ml media and transferred into T25 flasks (Corning®, Tewksbury, MA, USA).   
For all adherent cell lines (except RAW 264.7 and NSCs) once they became 
confluent, the cells were washed once with 10 ml PBS and then detached from the 
flask by incubation with 7 ml Trypsin/EDTA (Table 2.4) for 5 minutes inside the 
incubator at 370C. Next the cells were neutralised with an equal volume of media 
Example
The apparent molecular weights of the protein bands in SeeBlue® Plus2
Pre-Stained Standard in several buffer systems is shown below. The pro-
tein bands have different mobilities in various SDS-PAGE buffer systems.
For more information on this phenomenon, contact technical service (see
previous page) or visit our Web site at www.invitrogen.com.
Protein Approximate Molecular Weights (kDa)
Myosin
BSA
Glutamic
Dehydrogenase
Alcohol Dehydrogenase
Carbonic Anhydrase
Myoglobin Red
Lysozyme
Aprotinin
Insulin, B Chain
NuPAGE® Novex
Bis-Tris 4-12% Gel
98 78 62 64 71
64 55 49 51 55
50 45 38 39 41
36 34 28 28 n/a
22 17 17 19 n/a
16 16 14 14 n/a
6 7 6 n/a n/a
4 4 3 n/a n/a
250 210 188 191 210
Tris- NuPAGE® NuPAGE® NuPAGE®
Glycine Tricine MES MOPS Tris-Acetate
©1999-2002 Invitrogen Corporation. All rights reserved.
IM-1008F 072602
Phosphorylase 148 105 98 97 111
250 
36 
50 
64 
98 
148 
22 
 16 
 
6 
 
4 
 
A B 
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and then centrifuged at 280 x g for 5 minutes. Finally the media was aspirated using 
a vacuum pump and the cell pellets were resuspended in full media and split 
accordingly into a fresh flask containing full media. 
For RAW 264.7 cells, once the cells became confluent they were washed once with 
10 ml PBS and then 10 ml of fresh full media was added to the flask. Cells were 
then detached from the flask using Corning® cell scrapers and split accordingly into 
fresh flasks.  
For suspension cell lines (SupT1), cells were maintained in 15 ml of full media in 
T125 flasks (Corning®) kept upright. Once the cells became confluent, 14 ml of 
media was aspirated using vacuum pump and replaced with 15 ml of fresh media.     
For cryogenic storage, once cells were confluent they were detached from the flasks 
as explained above and centrifuged at 280 x g. The pellets were resuspended in 10 
ml of freezing media (see Table 2.4) and then 1 ml were aliquoted into Nunc™ 
CryoTube® vials (Thermo Scientific) and stored at -800C in Mr. Frosty™ Freezing 
Container (Thermo Scientific) filled with isopropanol for at least 48 hours before 
being transferred to liquid nitrogen storage. 
2.2.2 Cell uptake and blocking experiments 
Generally cells were seeded at 2X105 cells/well in 24-well plates (Corning®) and left 
to attach overnight. Next day the cells were treated with Ferucarbotran at three 
different concentrations (0.1, 0.5, 1 mgFe/ml) for 4 hours. Cells were then washed 3 
times with cold PBS to remove excess unbound SPIONs and treated according to 
one of the protocols described below.  
In blocking experiments, cells were pre-treated with the blockers for 15 minutes 
before being challenged with Ferucarbotran. Dextran sulfates (DSO4 500 and DSO4 
8) were tested at an initial concentration of 30 µg/ml, while fucoidan was tested at 
30, 50 and 100 µg/ml.  For low molecular weight dextran sulfates: DSO4 8, J-18 and 
J-5 dose escalation studies were done until a blocking effect was observed at 1 
mg/ml. Unsulfated dextrans (D-70 and D-40) did not show any blocking effect even 
at concentrations as high as 32 mg/ml. Results shown in chapter 3 were performed 
at the concentrations stated in Table 2.12.  
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2.2.2.1 Ferrozine assay 
After the cells were treated and washed as described in section 2.2.2, the number of 
cells in 3 control wells was counted and averaged to be used in Equation 2.1. Next, 
the cells were lysed with 200 µl of 50 mM NaOH and the intracellular iron content 
was determined using the colorimetric ferrozine assay developed by (Riemer et al, 
2004) and then compared to a standard curve of Ferucarbotran samples of known 
iron concentrations. 100 µl of each cell lysate was aliquoted into an Eppendorf tube 
then 100 µl of dH2O (solvent of Ferucarbotran) was added. 100 µl aliquots of serial 
dilutions of Ferucarbotran at 0.15, 0.3, 0.6, 1.25, 2.5, 5, 10, 15, 20, 25 and 50 
µgFe/ml were prepared from the stock solution and then 100 µl of 50 mM NaOH 
was added to each tube. Next, to each tube of cell lysates and Ferucarbotran, 100 
µl of iron releasing buffer (Table 2.5) was added and then the tubes were vortexed 
and incubated at 600C in a water bath for 2 hours. Next the tubes were left to cool 
down for 10 minutes before 30 µl of iron detection buffer (Table 2.5) was added to 
each tube. The tubes were then incubated for 30 minutes to allow for maximum 
colour development. 100 µl of each tube was then aliquoted into a 96-well plate 
(Corning®) and the absorbance was measured at 550 nm on Varioskan™ Flash 
Multimode reader (Thermo Scientific). The amount of iron per cell (pgFe/cell) was 
calculated as follows: 
pgFe / cell = Concentration (µgFe /ml)number of cells / ml X 10
6
     Equation 2.1 
2.2.2.2 Perl’s Prussian blue staining 
Cells were treated in accordance to the protocol described above (section 2.2.2), 
washed thoroughly with cold PBS and then fixed using fixation solution (Table 2.6) 
for 10 minutes at room temperature (RT). Next, the cells were washed with PBS and 
stained with a freshly prepared Prussian blue staining solution (Table 2.6) for 10 
minutes and counterstained with eosin, mounted with DPX and imaged with 100x oil 
immersion lens using Carl Zeiss Axioskop MOT 2 microscope (Carl Zeiss, 
Germany). 
2.2.3 Confocal Laser Scanning Microscopy (CLSM) 
2X105 cells/well were seeded on coverslips (VWR International, Leicestershire, UK) 
in 24-well plates then allowed to attach overnight. Next day, cells were incubated for 
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4 hours with 0.1 mgFe/ml Ferucarbotran labelled with Alexa Fluor® 633 hydrazide 
(Invitrogen) using the periodate oxidation chemistry as described in (Abdollah et al, 
2014; Vigor et al, 2010). Afterwards, cells were washed with cold PBS then treated 
with CellMask™ Orange plasma membrane stain (2.5 µg/ml) (Invitrogen) for 5 
minutes at 370C. After washing with PBS, cells were fixed with 4% formaldehyde/20 
mM HEPES buffer pH 7.4 at 370C for 10 minutes. Finally, nuclei were 
counterstained with Hoeschst 33342 (Invitrogen) (1/5000) for 30 minutes at RT in 
the dark on a rocker before the coverslips were mounted with ProLong® gold 
antifade (Invitrogen) and imaged using a Zeiss LSM 510 meta confocal microscope 
(Carl Zeiss). Images were processed using Zeiss LSM Image Browser (Carl Zeiss) 
and Image J software (U.S. National Institutes of Health, Bethesda, Maryland, USA).  
2.2.4 Transmission Electron Microscopy (TEM) and X-ray microanalysis  
Cells were seeded at 2X105 cells/well in 6-well plates (Corning®) and allowed to 
attach overnight. Next day the cells were treated with 0.5 mgFe/ml Ferucarbotran for 
4 hours before being washed 3 times with cold PBS. Then the cells were fixed in 
1.5% glutaraldehyde/1% paraformaldehyde/PBS pH 7.4, for a minimum of 2 hours, 
and stored at 4°C until processing for TEM. 
TEM protocol (described below) was kindly provided and done by the Electron 
Microscopy Unit at UCL Medical School, Royal Free Campus. 
Fixed cells were centrifuged to form a pellet in a 0.5 ml Eppendorf. The cells were 
then washed with two changes of phosphate buffer (Oxoid) and post-fixed with 
osmium tetroxide. The cells were resuspended during each change of solution and 
allowed to stand for 10 minutes, before removal of the supernatant and addition of 
the next processing solution. They were then washed using several changes of 
distilled water to remove the osmium tetroxide and dehydrated using increasing 
alcohol concentrations of 30%, 50%, 70%, 90% and 100%. The samples were left in 
50% alcohol / 50% Lemix (TAAB) epoxy resin mixture on a mixer overnight to 
infiltrate with resin. They were then placed in 100% Lemix resin for a minimum of 4 
hours, embedded in fresh Lemix Resin and polymerised at 700C overnight. 
Semi-thin (1µm) sections were cut using glass knives on a Reichert-Jung Ultracut 
microtome, collected on glass microscope slides and stained using 1% Toluidine 
Blue. Ultrathin sections were cut using a diamond knife (Diatome) and collected on 
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300HS, 3.05 mm copper grids (Gilder). The ultrathin sections were stained using 
saturated alcoholic uranyl acetate (UA) (TAAB) for 5 minutes followed by Reynold’s 
lead citrate, also for 5 minutes. Sections examined with EDAX were not stained with 
UA or Lead. 
The sections were viewed and photographed using a Philips CM120 transmission 
electron microscope fitted with EDAX DX-4 microanalytical system for X-ray 
microanalysis of the samples.    
2.2.5 Neuronal stem cells culture 
Protocols for maintenance, differentiation and staining of mouse neuronal stem cells 
(NSCs) were kindly provided by Dr Paolo Salomoni (UCL Cancer Institute). Prior to 
culturing the cells, T25 flasks (Greiner), 24-well plates (Corning®) or cover slips 
(VWR) were coated with 10 µg/ml of laminin in sterile PBS for 2 hours at RT on a 
rocker. Then the laminin was aspirated and the cells were maintained in media 
described in Table 2.3. 
2.2.5.1 Differentiation protocol 
When cells reached 80-90% confluency, they were detached from the flasks using 
Accutase® then centrifuged at 240 x g before being resuspended in fresh media 
supplemented with rh bFGF and rh EGF, counted and seeded at 2 X105 cells/well in 
24-well plates pre-coated with laminin. Next day the media was removed and the 
cells were washed with sterile PBS before adding media supplemented with rh 
bFGF only (i.e. rh EGF was removed). The cells were left for 3 days then on the 
fourth day the cells were again washed with sterile PBS and incubated with media 
containing no growth factors and then left for 5 days. At the end of the 8-day period 
the cells were differentiated into a mixed culture of neurons, oligodendrocytes and 
astrocytes before being treated with SPIONs.  
2.2.5.2 Immunofluorescence staining for CLSM  
Coverslips were placed in 24-well plates and coated with laminin for 2 hours. Then 
2X105 cells were seeded on each coverslip and allowed to attach overnight. Next 
day the cells were differentiated according to the protocol described above (section 
2.2.5.1). Then cells were fixed using 4% formaldehyde/20 mM HEPES buffer pH 7.4 
at 370C for 10 minutes. Cells were permeabilised using 0.1% triton in PBS for 5 
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minutes at RT before being incubated with a blocking solution of 5% goat serum in 
PBS/T for 1 hour at RT.  
To confirm differentiation; undifferentiated and differentiated cells were prepared as 
described above then stained for the neuronal markers using a mouse anti-neuronal 
βIII tubulin (Promega, 1/2000) for neurons, rabbit anti-GFAP (Dako, 1/3000) for 
astrocytes and rabbit anti-OLIG2 (Millipore, 1/1000) for oligodendrocytes. Cells were 
incubated with the primary antibodies overnight at 40C. Next day, Alexa Fluor® 488 
goat anti-mouse IgG  (Life Technologies, 1/1000) and Alexa Fluor® 488 goat anti-
rabbit IgG (Molecular Probes, 1/1000) prepared in 5% goat serum were added to 
the cells for 1 hour at RT in the dark. Nuclei were counterstained with Hoechst 
33342 (Invitrogen, 1/5000) for 30 minutes at RT in the dark. Finally the cells were 
washed 3 times with PBS and the coverslips were mounted with ProLong® gold 
antifade (Invitrogen) and left overnight to dry at RT. Slides were imaged using a 63x 
oil immersion lens on Zeiss LSM 510 meta confocal microscope. Images were 
processed using Image J software and Zeiss LSM Image Browser (Carl Zeiss).  
For uptake experiments, differentiated cells were incubated with 0.5 mgFe/ml 
Ferucarbotran for 4 hours before being washed 3 times with sterile cold PBS, fixed 
and treated as described above. Ferucarbotran was detected in the cells using 
mouse anti-dextran antibody (STEMCELL™, 1/100) followed by Alexa Fluor® 488 
goat anti-mouse IgG  (Life Technologies, 1/500). Neurons were detected with rabbit 
anti-neuronal βIII tubulin (Covance, 1/1000), while OLIG2 and GFAP were stained 
using the same primary antibodies as above then Alexa Fluor® 546 goat anti-rabbit 
IgG (Molecular Probes, 1/1000) was used to detect the neuronal markers.  
2.2.5.3 Uptake and blocking experiments 
2X105 cells/well of NSCs were seeded in 24-well plates or coverslips (for Prussian 
blue staining) pre-coated with laminin. Next the cells were differentiated following 
the protocol described above (section 2.2.5.1). After the differentiation cells were 
pre-treated with the blockers at the concentrations stated in Table 2.12 for 15 
minutes before adding Ferucarbotran at concentrations of 0.1, 0.5 and 1 mgFe/ml 
for 4 hours. The cells were then either lysed with 50 mM NaOH and the intracellular 
iron content determined using the ferrozine assay (as described in 2.2.2.1) or 
stained with Prussian blue (as described in 2.2.2.2). 
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2.2.6 PrestoBlue™  cell viability assay   
PrestoBlue™(Invitrogen) is used to quantitatively measure the proliferation of cells 
by being reduced in viable cells to a highly florescent compound (Invitrogen product 
data sheet). Cells were seeded in 96-well plates at 20,000 cells/well then allowed to 
attach overnight. Next day they were incubated with 1:2 serial dilutions of 
Ferucarbotran (10 to 0.02 mgFe/ml), DSO4 500 (300 to 0.59 µg/ml) and J-18 (10 to 
0.02 mg/ml) for 4 hours followed by incubation with PrestoBlue™ (10 µl/ml) for 1 
hour. The fluorescence was measured at 560/600 nm and percentage cell viability 
was calculated in reference to untreated controls. Each concentration was 
performed in triplicate and the experiment was repeated 3 times. Percentage cell 
viability was calculated using the equation below: 
% Cell viability!=Rs-Rm
Rc-Rm
 X 100           Equation 2.2
    
Where Rs = fluorescence reading of sample, Rm = fluorescence reading of media 
(without cells) and Rc = fluorescence reading of control (untreated control).  
To ensure that the brown colour of Ferucarbotran did not interfere with the assay; 
fluorescence readings of wells containing Ferucarbotran only were compared to 
fluorescence reading of media (without cells). No difference was detected between 
the two readings.       
2.2.7 Conjugation of Nanomag®-D-spio-NH2 to DyLight® 800 NHS ester dye  
The particles were purchased as a suspension in water, which is incompatible with 
the labelling protocol. Consequently, water was exchanged with 50 mM sodium 
borate buffer (pH 8.5) using a PD-10 desalting column (GE Healthcare, UK). 
500 µl of 50 mM sodium borate buffer was added to 50 µg of the lyophilized dye. 
The resultant dye solution was subsequently added to 1 ml of SPIONs solution (2.4 
mgFe). The reaction was allowed to proceed for 1 hour at RT on a roto-torque. The 
solution was purified by applying the sample on a PD-10 column equilibrated with 
PBS. 
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2.2.8 Conjugation of Ferucarbotran to IRdye® 800CW azide 
Ferucarbotran (88.6 µl, 5 mg Fe) was buffer exchanged into 0.1 M MES buffer using 
a PD-10 column. Next the solution was incubated with 200 µl of EDC/sulfo-NHS 
activation buffer (Table 2.10). The reaction was allowed to proceed for 20 minutes at 
RT (on a rotator) and was terminated by application to a PD-10 column equilibrated 
with PBS (pH=7.4). Next, 200 µg of dibenzocyclooctyne-amine (DBCO-NH2) linker 
in 1 ml PBS was sonicated to promote dissolution then added to the reaction 
mixture and incubated for 2 hours at RT followed by the addition of 100 µl/ml of 25 
mM glycine for 30 minutes to block the remaining reactive sites. The sample (FC-
NH-DBCO conjugate) was buffer exchanged using a PBS-equilibrated PD-10 
column to remove excess unreacted linker. Finally, 2.5 µl of 20 mg/ml (~50 µg) of 
IRDye® 800 CW azide was incubated with the FC-NH-DBCO conjugate for 3 hours 
at 370C in a water bath. The resultant NIR-conjugated SPIONs were extensively 
purified by passing, at least thrice, through PD-10 columns equilibrated with PBS to 
remove any dye that was non-specifically attached to the dextran coat of 
Ferucarbotran.  
Following all SPIONs conjugations, the integrated signal intensity of a serial dilution 
of known iron concentrations of the conjugates was measured at 800 nm on an 
Odyssey® infrared scanner (LI-COR Biosciences, Lincoln, Nebraska, USA) to plot a 
standard curve. Integrated signal intensity (also known as pixel volume) is defined 
by the Odyssey® infrared scanner software as the sum of the intensity values for all 
pixels enclosed by a shape, multiplied by the area of the shape (counts mm2).   
2.2.9 Characterisation of SPIONs following conjugation   
2.2.9.1 Dynamic Light Scattering (DLS) 
SPIONs were characterised before and after functionalisation using a Zetasizer 
Nano ZS90 (Malvern, Worcestershire, UK) to identify their hydrodynamic diameter 
and polydispersity index (PDI). SPIONs solutions were prepared in sterile-filtered 5 
mM NaCl.  
2.2.9.2 Transmission Electron Microscopy (TEM) 
TEM characterisation of SPIONs was kindly done by Dr Joseph Bear. SPIONs 
samples were diluted in distilled water and visualised with a Jeol 2100 HRTEM with 
a LaB6 source operating at an acceleration voltage of 200 kV with an Oxford 
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Instrument UTW EDX detector running AZTEC software. Micrographs were taken in 
a Gatan-Orius charge coupled device (CCD). Core sizes were measured from high-
resolution TEM images using ImageJ software.  
2.2.10 Uptake of FC-IRDye 800 on RAW 264.7 cells 
2X105 cells/well were seeded in 24-well plates and allowed to attach overnight. Next 
day the cells were pre-treated with DSO4 500 or J-18 for 15 minutes before being 
incubated with 0.1 mgFe/ml of FC-IRDye 800 for 4 hours. The cells were then 
washed 3 times with cold PBS and the NIR signal measured on the Odyssey® 
infrared scanner (LI-COR). Finally the cells were lysed using 50 mM NaOH and the 
intracellular iron measured using ferrozine assay as described in section 2.2.2.1.  
2.2.11 In vivo blocking of the uptake of SPIONs by the RES  
All in vivo experiments were performed using mouse models in compliance with 
licenses issued under the U.K. Animals (Scientific Procedures) Act 1986 after local 
ethical committee review. All mice were 6-8 week old female BALB/c (Charles River 
Laboratories, UK). The mice had an average weight of 20 g at the start of the 
experiments. All NIR-labelled SPIONs were injected at a dose of 10 µmolFe/kg. 
SPIONs and blockers were prepared in PBS and sterile filtered (using 0.22 µm 
syringe filter) under a cell culture hood prior to injections to minimise bacterial 
contamination. All injections were administered intravenously through tail veins.  
For Nanomag-D-spio-DyLight 800 (NM-DyLight 800), DSO4 500 was first tested (2 
mice per group) at 4 different concentrations: 0 (unblocked), 3, 7.5, 15 and 30 mg/kg 
and then a period of 24 hours was given to allow for sufficient blocking of the liver 
then NM-DyLight 800 was injected.  
For the remainder of the blocking experiments, DSO4 500 and J-18 were evaluated 
at 30 mg/kg while fucoidan was tested at 15 mg/kg.  
In the next set of experiments DSO4 500 was tested in 4 independent experiments 
(n=8). 24 hours following the administration of DSO4 500, NM-DyLight 800 or FC-
IRDye 800 were injected. Blocked mice were compared to unblocked control (n=8) 
injected with NM-DyLight 800 or FC-IRDye 800 only.     
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Next, DSO4 500 was further evaluated at 3 different blocking times: either DSO4 
500 and FC-IRDye 800 were given simultaneously (0 hours, n=3), or the blocker 
was given either 2 hours (n=3) or 24 hours (n=3) before the administration of FC-
IRDye 800. In the experiments testing J-18 as a blocker; it was injected 0, 30 and 
120 minutes prior to the administration of FC-IRDye 800, each group had 2 mice 
similar to the unblocked control. Next, fucoidan (n=3) was evaluated in comparison 
with DSO4 500 (n=3); blockers were administered 24 hours prior to FC-IRDye 800 
and compared to unblocked control (n=1). Finally fucoidan (n=2) and DSO4 500 
(n=2) were tested when given directly before FC-IRDye 800 and evaluated against 
the unblocked control (n=2).  
One hour following the injection of the NIR-labelled SPIONs, the mice were 
anaesthetized using a 1% isoflurane (Ivax Pharmaceuticals, UK) oxygen mixture. 
Blood was collected by cardiac puncture in EDTA-coated tubes (Teklab or BD 
Vacutainer®) and the mice were sacrificed by cervical dislocation. For SPIONs 
quantification, a 100 µl aliquot of each blood sample was transferred into a 96-well 
plate (Corning®) and then the integrated signal intensity was measured at 800 nm 
on an Odyssey® infrared scanner. 
2.2.12 Radiolabelling of Ferucarbotran with Technetium-99m (99mTc) for 
SPECT/CT imaging  
The work described below was done by Dr Rafael Torres Martin de Rosales (King's 
College London) as part of a collaboration with UCL. Radiolabelling and SPECT 
imaging were done at the Division of Imaging Sciences and Biomedical Engineering, 
King's College London, Lambeth Wing, St. Thomas’ Hospital. 
Technetium-99m-dipicolylamine-alendronate (99mTc-DPA-ale) linker was 
synthesized as previously described in (De Rosales et al, 2009; de Rosales et al, 
2011). The linker was purified using a C18 Sep-Pak® light column, yielding 200 µl of 
460 MBq of 99mTc-DPA-ale in dH2O. Then 3 µl of pure Ferucarbotran (0.174 mgFe) 
was added and the mixture was incubated at 400C for 30 minutes while shaking. 
The vial was then cooled down to RT and the contents transferred to an Amicon® 
Ultra 0.5 ml centrifugal filter with a 10 KDa cut off that had been previously washed 
with 3 × 500 µl of dH2O. The filter was centrifuged at 11000 x g for 3 minutes. The 
remaining retained solution contained 50 µl of radiolabelled nanoparticles to which 
300 µl of saline was added and the mixture was sonicated for 1 minute and 
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centrifuged as described before. This process was repeated 5 times until no more 
unbound 99Tc-DPA-ale was detected in the filtrates. The total radioactivity in the 
filtrates and SPIONs solution was measured to determine the radiolabelling yield 
(36%). The final 99Tc-DPA-ale-Ferucarbotran conjugate was diluted to 500 µl using 
saline ready to be injected into mice (100 µl/mouse).  
Prior to injections and imaging, female BALB/c mice (6-8 weeks) were anesthetized 
with isoflurane and oxygen mixture and kept under its influence for the duration of 
the experiment (maximum 4 hours) and culled by cervical dislocation at the end of 
the imaging session. All injections were done intravenously through the tail vein 
using 0.3 ml insulin syringes. Six mice were used in total (3 pre-treated with 
fucoidan and 3 unblocked). In the blocked group, mice were injected with 100 µl of 
fucoidan solution at a dose of 15 mg/kg followed by 100 µl of the 99Tc-DPA-ale-
Ferucarbotran conjugate (15-30 MBq of 99mTc) 2-10 minutes after the blocker. While 
the unblocked group was treated with 100 µl of radiolabelled Ferucarbotran only. 
Immediately after the injections the mice were imaged with SPECT/CT.   
SPECT/CT images were obtained with a NanoSPECT/CT PLUS preclinical animal 
scanner (Mediso, Hungary) equipped with four heads, each with nine 1 mm pinhole 
collimators, in helical scanning mode in 20 projections over 20 minutes. The CT 
images were obtained with a 45 kV X-ray source, 1000 ms exposure time in 180 
projections over 10 minutes. Images were reconstructed in a 256 × 256 matrix using 
the HiSPECT (Scivis GmbH) reconstruction software package, and fused using 
InVivoScope (IVS) software (Bioscan, France).  
After the mice were culled, selected organs were harvested, washed and weighed. 
The retained radioactivity in each organ was measured with a CRC-25R dose 
calibrator (Capintec, USA) or a 1282 COMPUGAMMA gamma counter (LKB Wallac, 
Finland) and the percentage-injected dose per gram of tissue (%ID/g) was 
calculated.   
2.2.13 Statistical analysis 
2.2.13.1 In vitro cell experiments 
All in vitro experiments were repeated at least 4 times with 3 triplicates per 
treatment. Representative data is shown unless otherwise specified, values 
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represent means and error bars are for standard deviations. p values were 
calculated using Student’s unpaired 2 tailed t test.  
2.2.13.2 In vivo experiments 
Statistical analysis was kindly done by Mr Ankur Ravinarayana Chakravarthy, MSc 
(UCL Cancer Institute).  
For NM-DyLight 800 and FC-IRDye 800 in vivo experiments, the effect of DSO4 500 
blocking was assessed using a total of 8 mice per group in 4 independent 
experiments (2-mice/group for NM-DyLight 800 and 1-3 mice/group for FC-IRDye 
800). An ANOVA test was used to assess variance associated with the different 
experiments, and statistical significance between groups (blocked versus 
unblocked) was assessed using a Tukey HSD test on the fitted model. For FC-
IRDye 800 final experiment with DSO4 500 (Figure 4.15), Shapiro-Wilk test 
confirmed that the data was normally distributed, and therefore a Student’s unpaired 
2 tailed t test was used to assess statistical significance of the data. p values less 
than 0.05 were considered statistically significant. 
2.2.14 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) 
Gel casting was done using Mini-PROTEAN® Tetra Handcast Systems (Bio-Rad, 
Hemel Hempstead, Hertfordshire, UK). Gels were prepared using the recipes 
mentioned in Table 2.13. The resolving gel was first prepared and then poured into 
the casting glass and allowed to dry before adding the 4% stacking gel and the 
comb. After gels were completely dried they were placed in the electrophoresis 
chamber containing 1x SDS-PAGE running buffer (Table 2.14) and the combs were 
removed before the samples were loaded. The electrophoresis chamber was then 
connected to PowerPac™ 3000 electrophoresis power supply set at 150 V and 
allowed to run for 60 minutes. The gels were either subjected to western blotting 
(section 2.2.15) or stained using Coomassie blue stain by incubating the gels with 
Coomassie blue staining solution (Table 2.14) for 30 minutes followed by de-
staining solution (Table 2.14) for 1 hour.    
2.2.15 Western blotting  
Following gel electrophoresis (see section 2.2.14) proteins were transferred from 
SDS-PAGE gels into polyvinylidene difluoride (PVDF) membrane (Bio-Rad). The gel 
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was sandwiched between PVDF membrane (pre-activated in methanol for 5 
minutes) and pre-wetted layers of chromatography filter paper (Whatmen, 
Maidstone, UK) and sponges, before being placed in the gel holding cassette (Bio-
Rad). The cassette was then submerged in Mini Trans-Blot® electrophoretic transfer 
cell (Bio-Rad) containing 1x transfer buffer (Table 2.15). Finally the cell was 
connected to PowerPac™ 3000 power supply set at 100 V and allowed to run for 70 
minutes.  
Next the membrane was removed from the cassette and washed once with PBS 
before being blocked in 5% milk (Table 2.15) at 40C overnight on platform shaker. 
Next day, the membrane was incubated with the appropriate dilution of the primary 
antibody prepared in 1% milk for 1 hour at RT on platform shaker. The membrane 
was then washed in PBS/T for 30 minutes with 3 buffer changes while shaking. Next 
the membrane was incubated with the solution of horseradish peroxidase (HRP) 
conjugated secondary antibody prepared in 1% milk for 1 hour at RT on shaking 
platform before being washed in PBS/T for 30 minutes with 3 buffer changes (List of 
antibodies used is shown in Table 2.16). Finally the membrane was incubated with 1 
ml of Luminata™ Classico Western HRP substrate (Merck Millipore Ltd., Cork, 
Ireland) for 2 minutes and the chemiluminescent signal was developed using 
Amersham Hyperfilm ECL (GE Healthcare, UK). 
Table 2.16: Antibodies used in western blotting 
Target 
protein Primary antibody Dilution 
Secondary 
antibody Dilution 
EGFR 1 Rabbit Anti-EGFR 1 (Cell Signalling Technology, Inc.) 1:1000 
Anti-Rabbit 
HRP  1:500 
HER2 Rabbit Anti-HER2 (Cell Signalling Technology, Inc.) 1:2000 
Anti-Rabbit 
HRP 1:2000 
β-Tubulin Mouse Anti β-Tubulin (Sigma) 1:20,000 Anti-mouse HRP 1:1000 
E69 
Polyclonal mice serum immunised with 
E69 (provided by Dr Berend Tolner, 
UCL Cancer Institute) 
1:500 
Anti-Mouse 
HRP 
1:1000 
G3 Polyclonal mice serum immunised with G3 (provided by Dr Berend Tolner) 1:500 
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2.2.16 Conjugation of Ferucarbotran to DARPins  
DARPins (anti-EGFR E69 and anti-HER2 G3) were kindly provided by Dr Berend 
Tolner (UCL Cancer Institute). DARPins were stored under reducing conditions in 
PBS/5 mM dithiothreitol (DTT) to keep the proteins as monomers. However, DTT 
interferes with the reaction; therefore it was removed immediately before use by a 
PD-10 column equilibrated with PBS and protein concentrations were determined 
spectrophotometrically at 280 nm using Equation 2.3.    
A280 = ε280 x C x L             Equation 2.3
         
Where A280 = absorbance at 280 nm, ε280 = molar extinction coefficient (0.1%, 280 
nm, 1 cm path length), C= protein concentration (g/L) and L= path length of the 
cuvette (cm).   
A280 was measured on NanoDrop® (ND-1000) spectrophotometer (Thermo 
Scientific). ε280 was calculated based on the protein primary amino acid sequence 
using ExPASy ProtParam tool (http://web.expasy.org/protparam/). Amino acid 
sequences of E69 and G3 were kindly provided by Dr Berend Tolner and are shown 
in Figure 2.2. For E69, ε280 = 0.859 and for G3, ε280 = 0.208. 
 
Figure 2.2: Amino acid sequence of E69 and G3 DARPins 
E69 sequence: 
G3 sequence: 
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Ferucarbotran is dissolved in water, which was exchanged with 0.1 M MES buffer 
(pH=6) by running 1.42 ml of Ferucarbotran stock solution (58.6 mgFe/ml) on a PD-
10 column equilibrated with 0.1 M MES buffer. Next the samples were incubated 
with 1.6 ml of EDC/sulfo-NHS activation buffer (19.2 mg of EDC and 140.8 µl of 230 
nM sulfo-NHS (Table 2.10)) for 20 minutes at RT (on a rotator). The reaction was 
terminated by application of the sample to a PD-10 column equilibrated with PBS 
(pH=7.4). Next, 71.2 mg of BMPH linker (N-beta-maleimidopropionic acid hydrazide-
TFA, Thermo Scientific) in 1.6 ml PBS was added to the reaction mixture and 
incubated for 2 hours at RT followed by 100 µl/ml of 25 mM glycine for 30 minutes to 
block the remaining reactive sites. The sample (FC-NH-BMPH conjugate) was 
purified using a PBS-equilibrated PD-10 column to remove excess unreacted linker. 
Next, FC-NH-BMPH conjugate solution was divided into two equal volumes. To 
each tube either 2 mg of E69 or 1.2 mg of G3 (molar equivalent to E69) in PBS was 
added to the reaction mixture and incubated overnight at RT on the rotator. Next 
day, 100 µl/ml of 0.1 M cysteine was added for 30 minutes to block the unreacted 
active sites. The samples were then concentrated using Centriprep® centrifugal 
filters (cut off 30 KDa) (Merck Millipore) by spinning them for 10 minutes at 1500 x g. 
Finally the samples were purified using SEC on a column packed with Superdex 75. 
To detect proteins in the purified conjugates, 30 µl of selected fractions were mixed 
with 10 µl of 4x reducing buffer and boiled for 15 minutes at 990C. Samples were 
run on 16% SDS-PAGE gels then stained with Coomassie blue to visualise the 
proteins (as previously described in section 2.2.14).   
2.2.17 Characterisation of Ferucarbotran-DARPins conjugates 
Conjugates were characterised with DLS and western blotting. DLS and zeta 
potential measurements were performed on Zetasizer Nano ZS90 (Malvern) as 
previously described in section 2.2.9.1. For western blots, 30 µl of 300 µgFe/ml of 
Ferucarbotran (FC) or its conjugates (FC-E69 and FC-G3) were added to 10 µl of 
either 4x reducing or non-reducing buffers (Table 2.14). Control samples of the 
corresponding DARPin at 1 µg/ml and Ferucarbotran at 1 mgFe/ml were also 
prepared. Under reducing conditions the samples and controls were boiled for 15 
minutes at 990C to ensure the dissociation of the bond between the linker and the 
DARPins. Next, 20 µl of each sample was loaded into a 16% SDS-PAGE gel and 
run as previously described in section 2.2.14 and 2.2.15. The membranes were then 
probed with either anti-E69 or anti-G3 polyclonal mouse sera before being 
incubated with anti-mouse HRP secondary antibody (as described in Table 2.16).  
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2.2.18 Testing binding of Ferucarbotran-E69 conjugates to EGFR using ELISA 
Layouts of the ELISA plates and the raw experimental results are shown in 
Appendix 1. 
2.2.18.1 Indirect ELISA  
Nunc MaxiSorp 96-well plate (Thermo Scientific) was washed once with PBS and 
then either coated with PBS or 4.7 µg/ml of EGFR (Sino Biologicals Inc., Beijing, 
China) overnight at 40C. Next day the plate was washed 3 times with PBS/T and 3 
times with PBS before adding 300 µl/ well of the blocking solution PBS/TB (PBS 
containing 0.1% Tween and 1% BSA). The plate was incubated for 1 hour at RT on 
a shaker. Next the wells were treated (according to the diagram in Appendix 1) with 
80 µl (in PBS) of either 500 µgFe/ml of Ferucarbotran (FC) or its conjugates (FC-
E69 and FC-G3); 1 µM of DARPins (E69 =21.6 µg/ml and G3=14.35 µg/ml); 5 µg/ml 
of Cetuximab or PBS. The samples were left on the plate for 1 hour at RT on the 
shaker before being washed with PBS/T (3x) and PBS (3x). 80 µl/well of the primary 
antibodies (prepared in PBS/TB) were then added: anti-E69 (1:500) in half of the 
plate and anti-dextran (1:100) in the other half for 1 hour at RT on the shaker. The 
plate was again washed in PBS/T (3x) and PBS (3x) before adding 80 µl/well of the 
secondary antibodies (prepared in PBS/TB) to the wells. Anti-mouse IRDye 800 CW 
(1:5000) was used to detect bound anti-E69 and anti-dextran while Cetuximab was 
detected with anti-human DyLight 649 (2 µg/ml). The plates were incubated for 1 
hour at RT in the dark on the shaker and then washed as described above. The 
signal of the bound secondary antibodies was measured on Odyssey® infrared 
scanner at 800 nm and 700 nm for anti-mouse IRDye 800 CW and anti-human 
DyLight 649, respectively.   
2.2.18.2 Immobilizer plates 
Nunc™ Amino™ Immobilizer polysorp plates (Thermo Scientific) were used to 
covalently link EGFR via its sulfhydryl groups at pH 7.5 to the nucleophilic groups 
present on the surface of the plate. The plate was washed once with PBS before 
coating the wells with 4.7 µg/ml of EGFR in PBS (pH=7.5) for 1 hour at RT on the 
shaker. The plate was then washed 3 times with PBS/T and 3 times with PBS. An 
extra blocking step was employed to block the reactive sites on the plate using 300 
µl/well of 10 mM cysteine. The plate was incubated for another hour before being 
treated with 300 µl/well of PBS/TB for 1 hour at RT on the shaker. Next the plate 
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was washed as explained previously and incubated with 80 µl (in PBS) of either 500 
µgFe/ml of Ferucarbotran or its conjugates (FC-E69 and FC-G3); 1 µM of DARPins 
(E69 and G3); 5 µg/ml of Cetuximab or PBS (according to the diagram in Appendix 
1). The samples were left on the plates for 1 hour at RT on the shaker before being 
washed with PBS/T (3x) and PBS (3x). 80 µl/well of the primary antibodies 
(prepared in PBS/TB) were then added to the corresponding wells: anti-E69 (1:500); 
anti-G3 (1:500) and anti-dextran (1:100) were added to E69, G3 and Ferucarbotran 
(or its conjugates) coated wells, respectively, and incubated for 1 hour at RT on the 
shaker. The plates were washed as described previously and then incubated with 
80 µl/well of secondary antibodies prepared in PBS/TB. Anti-mouse IRDye 800 CW 
(1:5000) was used to detect bound anti-E69, anti-G3 and anti-dextran while 
Cetuximab was detected with anti-human DyLight 649 (2 µg/ml). The plates were 
incubated in the dark on the shaker for 1 hour and then washed as described above. 
The signal of the bound secondary antibodies was measured on Odyssey® infrared 
scanner at 800 nm and 700 nm for anti-mouse IRDye 800 CW and anti-human 
DyLight 649, respectively.    
2.2.18.3 Sandwich ELISA 
Nunc MaxiSorp 96-well plate (Thermo Scientific) was washed once with PBS and 
then coated with 80 µl (in PBS) of either 500 µgFe/ml of Ferucarbotran or its 
conjugates (FC-E69 and FC-G3); 1 µM of DARPins (E69 and G3); or PBS 
(according to the diagram in Appendix 1) for 1 hour at RT on the shaker. The wells 
were then blocked with 300 µl/well of PBS/TB for 1 hour on the shaker before being 
washed 3 times with PBS/T and 3 times with PBS. The wells were then incubated 
with 80 µl/well of 4.7 µg/ml of EGFR in PBS for another hour on the shaker and then 
washed as described previously. Bound EGFR was detected by adding 80 µl/well of 
5 µg/ml Cetuximab solution in PBS and incubated for an hour on the shaker. Finally 
the plates were washed and incubated with anti-human DyLight 649 (2 µg/ml) for 1 
hour on the shaker in the dark and then washed. The signal of the bound secondary 
antibodies was measured on Odyssey® infrared scanner at 700 nm.  
2.2.19 Detecting EGFR and HER2 expression on cells using western blotting  
2X106 cells were centrifuged at 280 x g and washed once with cold PBS and re-
pelleted. The cell pellet was resuspended in 100 µl cell lysis buffer (Table 2.15) and 
incubated on ice for 30 minutes. Next the samples were centrifuged at 280 x g for 
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10 minutes at 40C and the supernatants were transferred to fresh tubes and placed 
on ice. Total protein concentration was measured using Bio-Rad protein assay 
(Bradford assay) and compared to 1:2 serial dilutions of bovine serum albumin 
(BSA) starting from 5 mg/ml. 5 µl of each sample was placed in a 96-well plate then 
25 µl of Bio-Rad reagent A and 200 µl of Bio-Rad reagent B were added to each 
well and incubated for 15 minutes. The absorbance was measured at 630 nm on 
Varioskan™ Flash Multimode reader (Thermo Scientific) and the total protein 
concentrations of each cell lysate was calculated from the standard curve. Next, 
each cell lysate was prepared in 4x reducing buffer (Table 2.14) and dH2O to a final 
total protein concentration of 1 µg/ml. The samples were then denatured at 990C for 
5 minutes then stored at -200C until processing.  
Gels were prepared as described in section 2.2.14 then 20 µl of each sample was 
loaded into the gels and run as described in section 2.2.15. The membranes were 
then probed with either anti-EGFR, anti-HER2 or anti β-Tubulin before being 
incubated with the corresponding HRP conjugated secondary antibodies (as 
described in Table 2.16).  
2.2.20 Testing binding of E69 DARPin on EGFR expressing cell lines using 
flow cytometry 
In these experiments all incubations, washings and centrifugations were done on ice 
or at 40C to minimise internalisation. All data analysis was done using FlowJo 
software (Treestar Inc., San Carlos, CA, USA). 
2.2.20.1 U-251 glioma cell line 
When cells reached 70-80% confluency, they were detached from the flasks using 
trypsin. The cells were centrifuged and the pellet was washed with cold PBS before 
being centrifuged again and resuspended in cold PBS at the concentration of 106 
cells/ml. 500 µl of the cell suspension was placed into each FACS tube (BD 
Falcon™, Beford, USA). Cells were then treated according to Table 2.17. Cells were 
incubated with the samples for 1 hour then centrifuged at 280 x g for 5 minutes and 
the pellet was resuspended in cold PBS supplemented with 0.5% bovine serum 
albumin (BSA) (PBS/BSA) and gently vortexed. The primary antibodies were added 
and further incubated for 1 hour. The washing step was repeated before the 
secondary antibodies were added for 20 minutes in the dark. After the final washing 
step, the cells were resuspended in 300 µl of cold PBS/BSA and kept on ice until 
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analysed using BD LSRFortessa™ X-20 cell analyser (BD Biosciences, San Jose, 
California, USA). Cells treated with anti-DARPins and secondary antibodies (anti-
DARPins control) were used as negative control.  
Table 2.17: Treatments added for Flow cytometry analysis on U251 MG cells. 
Name Sample added Primary antibody Secondary antibody 
Untreated n/a n/a n/a 
Cetuximab 
100 nM 
Cetuximab (15 
µg/ml) 
n/a 
Anti-human DyLight 647 
(1:2000, Thermo 
Scientific) 
Herceptin 100 nM Herceptin (15 µg/ml) n/a 
Anti-human DyLight 647 
(1:2000) 
E69 100 nM E69 (2.16 µg/ml) 
Polyclonal anti-E69 
mouse serum (1:1000) 
Anti-mouse DyLight 647 
(1:2000, Thermo 
Scientific) 
G3 100 nM G3 (1.435 µg/ml) 
Polyclonal anti-G3 mouse 
serum (1:1000) 
Anti-mouse DyLight 647 
(1:2000) 
Anti-
DARPins 
control 
n/a 
Polyclonal anti-E69 or 
anti-G3 mouse serum 
(1:1000) 
Anti-mouse DyLight 647 
(1:2000) 
n/a: not applicable  
2.2.20.2 293T cells 
Once confluent, the media was aspirated and the cells were washed with cold PBS. 
Cells were detached from the flask with 0.1% EDTA in PBS, centrifuged and 
resuspended in cold PBS before being counted and resuspended at a concentration 
of 106 cells/ml. 0.5 ml of the cell suspension was placed into each FACS tube. The 
cell suspensions were then ready to be treated according to Table 2.18. Cells were 
incubated with the samples for 1 hour then centrifuged at 300 x g for 5 minutes and 
the supernatant decanted, the pellet was resuspended in cold PBS, gently vortexed 
and centrifuged again before being resuspended in 500 µl of cold PBS and the 
primary antibodies were added and further incubated for 1 hour. The washing step 
was repeated before the secondary antibodies were added for another hour in the 
dark. After the final washing step, the cells were resuspended in 500 µl of cold PBS 
and kept on ice until analysed using CyAn™ ADP Flow Cytometer (Beckman 
Coulter) to detect fluorescence in the Alexa Fluor 488 channel. Untreated cells and 
cells treated with secondary antibodies only were used as negative controls. 
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Table 2.18: Treatments added for Flow cytometry analysis of E69 binding to 293T 
cells. 
Name Sample added Primary antibody Secondary antibody 
Untreated n/a n/a n/a 
Cetuximab 
100 nM 
Cetuximab (15 
µg/ml) 
n/a Anti-human Alexa Fluor 488 (1:1000, Molecular probes) 
E69 100 nM E69 (2.16 
µg/ml) 
Polyclonal anti-E69 
mouse serum 
(1:500) 
Anti-mouse Alexa Fluor 488 
(1:1000, Molecular probes) 
G3 100 nM G3 (1.435 
µg/ml) 
Polyclonal anti-G3 
mouse serum 
(1:500) 
Anti-mouse Alexa Fluor 488 
(1:1000, Molecular probes) 
n/a: not applicable  
2.2.20.3 SupT1 cells  
Three types of SupT1 cells were used: SupT1-NT, SupT1-EGFR and SupT1-
EGFRvIII, all were treated in a similar manner as will be described below. Cells 
were centrifuged at 280 x g and then the media was removed before the cells were 
washed with cold PBS once and resuspended in PBS. Cells were counted and 
resuspended at a concentration of 106 cells/ml. 1 ml of the cell suspension was 
placed into each FACS tube. The cell suspensions were then ready to be treated 
with samples, primary and secondary antibodies according to Table 2.19 and in a 
similar fashion to 293T cells (see 2.2.20.2).  
To investigate whether foetal bovine serum (FBS) present in the full cell culture 
media affects the binding of E69 to EGFR, cells were resuspended in cell culture 
media (RPMI) containing 0, 0.1%, 1%, 5% and 10% FBS instead of cold PBS and 
treated similar to above.  
Cells were analysed using BD Accuri™ C6 flow cytometer (BD Biosciences). 
Untreated cells and cells treated with secondary antibodies only were used as 
negative controls. 
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Table 2.19: Treatments added for Flow cytometry analysis of E69 binding to SupT1 
cells. 
Name Sample added Primary antibody Secondary antibody 
Untreated n/a n/a n/a 
Cetuximab 100 nM Cetuximab (15 
µg/ml) n/a 
Anti-human DyLight 649 (2 
µg/ml, Thermo Scientific) 
MR 1.1 MR 1.1 2 µg/ml  n/a 
Anti-human DyLight 649 (2 
µg/ml, Thermo Scientific)  
E69 100 nM E69 (2.16 
µg/ml) 
Polyclonal anti-
E69 mouse 
serum (1:500) Anti-mouse APC (1:1000, 
Molecular probes)  
G3 100 nM G3 (1.435 
µg/ml) 
Polyclonal anti-
G3 mouse 
serum (1:500) 
n/a: not applicable 
2.2.21 Testing binding of Ferucarbotran-DARPins conjugates on EGFR 
expressing cell lines 
2.2.21.1 Gliomas 
U-251 MG cells were seeded at 2X105 cells/well in 24-well plates (Corning®) and left 
to attach overnight. Next day they were pre-treated with 30 µg/ml of DSO4 500 for 
15 minutes followed by challenging the cells with Ferucarbotran, FC-E69 or FC-G3 
at 0.5 mgFe/ml for 4 hours. Cells were then washed 3 times with PBS to remove 
excess unbound SPIONs and intracellular iron content determined using ferrozine 
assay (see section 2.2.2.1).  
2.2.21.2 SupT1  
3X105 cells/well were added to a V-bottom sterile 96-well plates (Corning®). Cells 
were pre-treated with 30 µg/ml of DSO4 500 for 15 minutes before adding 
Ferucarbotran, FC-E69 or FC-G3 at 0.3 mgFe/ml for 4 hours. The plates were then 
centrifuged at 300 x g and the supernatant was decanted. 200 µl of cold PBS was 
added per well then the cells were centrifuged again. The washing was repeated for 
3 times to remove excess unbound SPIONs. Finally the cells were centrifuged and 
the pellet resuspended in 200 µl 50 mM NaOH and the intracellular iron content 
determined using ferrozine assay (see section 2.2.2.1).     
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2.2.22 Magnetic separation of Ferucarbotran using MACS® LS column 
MACS® LS columns (Miltenyi Biotec GmbH, Germany) were inserted into a 
QuadroMACS™ Separator (Miltenyi Biotec GmbH) then they were rinsed with 3 ml 
of degassed and sterile filtered buffer (PBS, 0.5% BSA and 2 mM EDTA). 
Ferucarbotran solutions were prepared in 500 µl of the same buffer to the final 
amount of either 50 µg or 20 µg iron. Ferucarbotran solutions were applied to the 
column and the flow through was collected. The column was washed 3 times using 
3 ml of buffer each time. The eluents were collected and denoted (wash 1, 2 or 3). 
The LS column was then removed from the separator and placed on a new 
collection tube. Finally 5 ml of buffer was applied into the LS column and the 
magnetic fraction was immediately eluted by firmly applying the plunger supplied. 
The iron content of the collected samples was measured using ferrozine assay (see 
section 2.2.2.1).  
2.2.23 Column packing for Size Exclusion Chromatography (SEC)  
All solutions were sterile filtered and degassed using 0.22 µm Corning® bottle top 
vacuum filters prior to use. ÄKTA prime plus FPLC system (Amersham Biosciences) 
was used for all size exclusion chromatography studies. All SEC media were 
purchased from GE-Healthcare (Amersham, UK). All columns appeared to be 
uniformly packed and elution profiles of the gel filtration standard (Bio-Rad) are 
shown in Appendix 2.  
2.2.23.1 Sephadex G-100 
This media is made up of soft beads that require swelling prior to packing the 
column. 17.33 g of dry Sephadex G-100 coarse was incubated in 260 ml of PBS for 
at least 72 hours at RT. After incubation, the slurry was poured slowly and in one 
portion into an XK16/100 column fitted with a packaging reservoir and held at an 
angle to avoid the formation of air bubbles. The column was connected to the FPLC 
system and run at 0.5 ml/min with maximum pressure of 0.05 MPa.   
To check the packing efficiency, a gel filtration standard (Bio-Rad) was applied on 
the column. The lyophilised powder was dissolved in 0.5 ml PBS and injected into 
the column. The sample was run at flow rates between 0.2 and 0.4 ml/min with 
maximum pressure of 0.05 MPa, which was eventually increased to 0.2 MPa.  
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2.2.23.2 Superdex 75 Prep Grade  
This media is made up of hard beads that do not require swelling; it is supplied by 
the manufacturer as a solution in 20% ethanol. To remove the storage solution, the 
media was left at RT until all the media settled then the upper solution was decanted 
and the media re-suspended in dH2O. This was repeated at least 2 times to remove 
all traces of ethanol.  
The slurry was then poured into an XK16/60 column fitted with a packing reservoir. 
The column was packed in 3 steps according to the manufacturer’s instructions: 
step 1 at flow rate of 3 ml/min and maximum pressure of 0.45 MPa for 90 minutes. 
Step 2: at 2.5 ml/min and maximum pressure of 0.45 MPa for 30 minutes. Step 3: 
the packing reservoir was removed and the top adapter of the column attached and 
the packing process was continued at 3 ml/min for another 20 minutes. After all the 
media settled the top adapter was adjusted and the column was ready for use.      
To check the packing efficiency, 300 µl of gel filtration standard was injected into the 
column and run at 1 ml/min with maximum pressure of 0.45 MPa. 
2.2.23.3 Superdex 200 
This column was purchased as a pre-packed XK 16/60 column. 
2.2.23.4 Superose 6 and 12 Prep Grade 
This media is made up of hard beads similar to Superdex 75. The slurry preparation 
was similar to that explained for Superdex 75 (see section 2.2.23.2). 
The slurry was then poured into an XK16/60 column fitted with a packing reservoir. 
The column was packed following the manufacturer’s protocol at a flow rate of 2 
ml/min until all media had settled. Then it was increased to 3 ml/min and 4 ml/min 
for Superose 6 and 12 respectively, for 60 minutes. The packing reservoir was 
disconnected and replaced with the top adapter that was adjusted to the top of the 
media bed. Then the flow rate was increased to reach maximum pressure of 0.4 
MPa and 0.5 MPa for Superose 6 and 12, respectively, for another 5-6 minutes. 
Finally the top adapter was re-adjusted on top of the media bed and the column was 
ready for use.  
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To check the packing efficiency, 500 µl of gel filtration standard was injected into the 
columns and run at 1 ml/min with maximum pressure of 0.3 MPa and 0.5 MPa for 
Superose 6 and 12, respectively.  
2.2.24 Fractionation of Ferucarbotran with SEC 
All fractionation experiments were done on columns equilibrated with PBS. 80 µl of 
Ferucarbotran stock solution (56.3 mgFe/ml) was diluted in 1 ml PBS and injected 
into the columns. The samples were run at 1 ml/min except on Sephadex G-100 
where the samples were run at 0.1-0.5 ml/min.   
2.2.25 Measuring the heating ability of fractionated Ferucarbotran 
Magnetic hyperthermia experiments were kindly done by Dr Paul Southern at the   
UCL Healthcare and Biomagnetics Laboratory, The Royal Institution of Great 
Britain. Magnetic hyperthermia heating ability was characterised by the intrinsic loss 
parameter (ILP) using the Magnetic Alternating Current Hyperthermia (MACH) 
system using a 6 turn coil, inner diameter 20 mm and length 35 mm with an AC field 
of 13500 A/m at a frequency of 905 kHz. The temperature was measured using 
fluoroptic temperature probes to minimize non-specific radiofrequency heating of the 
probes. The temperature profile was fitted using the corrected slope analysis as 
described by Wildeboer et al to determine the ILP (Wildeboer et al, 2014). 
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3.1 Introduction 
The aim of the work presented in chapter 3 is to investigate means to address the 
rapid clearance of SPIONs by the RES. This is an important challenge in the 
development of SPIONs because a short circulatory half-life severely limits 
availability and potential for non-RES targeted applications. The SPION investigated 
in this chapter is Ferucarbotran, which in its pharmaceutical formulation (Resovist®) 
was clinically developed as an MRI contrast agent targeting the RES (Reimer & 
Balzer, 2003).  
The uptake of Ferucarbotran is mediated by macrophages as described in many 
published reports, which have concluded that this internalisation is mediated by 
scavenger receptor class A (SR A) (see introduction section 1.6.3) (Chao et al, 
2012a; Chao et al, 2012b; Lunov et al, 2010b; Raynal et al, 2004; Yang et al, 2011). 
Ferucarbotran is coated with dextran (Reimer & Balzer, 2003); a branched 
polysaccharides derived from a bacterium called Leuconostoc mesenteroides 
(Jeanes et al, 1954; Pleuvry, 2004; Quon, 1988). Dextran is made up of repeated 
units of D-glucose linked mainly by alpha glycosidic 1,6 linkages with occasional 
alpha 1,3 branching (Figure 3.1, left) (Jeanes et al, 1954; Quon, 1988). Since some 
of the ligands of SR A are sulfated polysaccharides (e.g. dextran sulfate and 
fucoidan) (Chao et al, 2012b; Segers et al, 2013; Sonia et al, 2009); it was 
hypothesised that the RES uptake of SPIONs could be competitively blocked using 
polysaccharide derivatives. To test this hypothesis a range of polysaccharides were 
evaluated for their ability to block Ferucarbotran uptake at a cellular level.  
3.1.1 Polysaccharides investigated as RES blockers 
Seven different polysaccharides were chosen for investigation in this study. The 
polysaccharides investigated are listed in Table 3.1, along with their clinical 
applications. Their characteristics are described below. The RES blockers were 
divided into blockers of scavenger receptors and pharmaceutical agents.   
3.1.1.1 Scavenger receptor blockers  
Dextran sulfate 500 (DSO4 500): is a synthetic dextran derivative prepared by the 
esterification of bacterially derived dextran with sulphuric acid to replace some of the 
hydroxyl (OH) groups with sulfate (SO4) groups (Figure 3.1, right) (Ricketts, 1952). 
The DSO4 500 chosen for investigation in this thesis contained 17% sulfur content, 
which corresponds to approximately 2.3 sulfate groups per glucosyl residue (Sigma 
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product information sheet). DSO4 500 is a known inhibitor of scavenger receptors in 
vitro especially on macrophages and has been used before in many inhibitory 
studies (Sonia et al, 2009). DSO4 500 is also known to block liver Kupffer cells and 
has been studied extensively in vivo (Bradfield et al, 1974; Das et al, 1987; Fujiwara 
et al, 1996; Illum et al, 1986; Jansen et al, 1991; Liu et al, 1992; Patel et al, 1983; 
Sands & Jones, 1987; Yoshinobu et al, 1994).  
Fucoidan: Another known ligand of scavenger receptor A is fucoidan (Thelen et al, 
2010), which has also been used in some inhibitory studies on macrophages 
(Segers et al, 2013). Fucoidan is a polysaccharide mainly made up of fucose and 
sulfate ester groups (Cumashi et al, 2007; Li et al, 2008) (see Figure 3.1, right). 
Fucoidan is extracted from different species of brown seaweed (e.g. Fucus 
vesiculosus, Undaria pinnatifida and Macrocystis pyrifera) and some marine 
invertebrates (e.g. sea urchins and sea cucumbers) (Li et al, 2008). It is 
commercially available in many food supplements (Fitton, 2011) and has been 
subjected to intense research for the past decade due to its versatile biological 
applications (Cumashi et al, 2007; Li et al, 2008). These biological functions include 
antioxidant, antiviral, anticoagulant, anti-inflammatory and reduction of blood lipids 
among other applications (Cumashi et al, 2007; Li et al, 2008; Lira et al, 2011). 
Fucoidan has also been reported to have an anti-cancer effect (Kwak, 2014) and 
has been investigated in osteoarthritis, stem cell modulation, kidney disease and 
liver disease (Fitton, 2011). 
3.1.1.2 Pharmaceutical agents 
Pharmaceutical agents might have potential as RES blockers and could provide a 
safer and clinically approved alternative to DSO4 500.  
A number of dextrans are available as pharmaceutical products and were shown to 
be safe and well tolerated by patients. For instance dextran 40 and 70 have been 
mainly used as plasma expanders in patients suffering from trauma, burns, 
hypovolemia and hypotension (Wade et al, 1997).  
Two low molecular weight dextran sulfates were provided by Meito Sangyo Co. 
Japan. Dextran sulfate sodium salt sulfur 18 (J-18) (also known as MDS KOWA) 
(RAD-AR Council, 2015) is approved in Japan as an anti-hyperlipidemic and anti-
arteriosclerotic agent (Fujishima et al, 1986); it has also been tested for the 
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treatment of diabetic retinopathy (Mimura et al, 1983) and acute cerebral thrombotic 
infarction (Fujishima et al, 1986).  
 
Figure 3.1: Chemical structure of polysaccharides investigated 
Dextran is made up of repeated glucose units linked together with α-(1,6) linkages with few 
α-(1,3) branchings. In dextran sulfate, some of the hydroxyl groups are replaced with sulfate 
groups. While fucoidan is a fucose rich sulfated polysaccharide derived from seaweed. 
Table 3.1: Clinical applications of the blockers used 
Name Product Clinical application References 
D-70 Dextran 70 Plasma expander 
(Wade et al, 
1997). 
D-40 Dextran 40 Plasma expander 
DSO4 8 Dextran sulfate sodium salt 8 Dextran sulfates were tested 
as anti-coagulants and  
anti-HIV but not used 
clinically 
(Flexner et al, 
1991) DSO4 
500 Dextran sulfate sodium salt 500 
J-18 Dextran sulfate sodium sulphur 18 (for oral administration) Oral anti-hyperlipidemic (RAD-AR 
Council, 2015). 
J-5 Dextran sulfate sodium sulphur 5 (for I.V administration) 
Parenteral anti-
hyperlipidemic 
Fucoidan Fucoidan extracted from brown seaweed Fucus vesiculosus Food supplement (Fitton, 2011). 
n/a: not available  
O
H
HO
H
HO
H
O
OHH
H
O
O
H
HO
O
HO
H
O
OHH
H
O
H
HO
H
HO
H
O
OHH
H
O
H
HO
H
HO
H
O
OHH
H
O
H
HO
H
HO
H
H
OHH
OH
α-(1,3) 
α-(1,6) 
α-(1,6) 
α-(1,6) 
O
O
H
Na3oso
H
HO
H
O
H
H
O
H
Na3oso
H
HO
H
O
oso3Na
H
H
oso3Na
Dextran 
Dextran Sulfate  
Fucoidan 
OH
O
O
OH
CH3
O
CH3
OSO3
OSO3
OSO3
  
94 
3.1.2 Experimental approach  
The effect of the polysaccharides investigated was first evaluated on a murine 
monocyte/macrophage cell line; RAW 264.7 originally developed by Raschke et al 
(Raschke et al, 1978). This cell line has been used extensively in the study of the 
interactions of nanoparticles, and specifically SPIONs, with macrophages (Chao et 
al, 2012a; Lunov et al, 2010a; Lunov et al, 2010b; Yang et al, 2011). Once the 
experimental conditions were established on macrophages, the research was 
further expanded to include tumour cell lines.    
Having established the effect of the blockers on macrophages and tumour cell lines, 
the next step was to investigate the same blockers on other cell types that would 
occur within the tumour microenvironment (see introduction section 1.8). For this, 
with a focus on glioblastoma, differentiated neural stem cells (NSCs) were used.  
Neural stem cells (NSCs) provide a good model for investigating the uptake of 
Ferucarbotran by normal brain cells. In adult human brains, NSCs were isolated 
from various regions (e.g. the subventricular zone (SVZ), the dentate gyrus, the 
lining of the lateral ventricles, the hippocampus and the subcortical white matter) 
(Sanai et al, 2005). NSCs are multipotent and self-renewing cells that can give rise 
to the neuronal and glial progenitors cells. Neuronal progenitor cells then 
differentiate into neurons while glial progenitor cells can give rise to astrocytes and 
oligodendrocytes (Sanai et al, 2005). Neurons are responsible for conducting the 
electrical signals throughout the nervous system while astrocytes and 
oligodendrocytes provide insulation, structural support and nutrition for the neurons 
(Rinholm & Bergersen, 2012; Sanai et al, 2005). In vitro isolated murine neural stem 
cells could be stimulated to differentiate into neurons, astrocytes and 
oligodendrocytes (Regad et al, 2009). Studying the interaction with these cells could 
elucidate the non-target specific uptake of Ferucarbotran by cells within the tumour 
microenvironment and will not only detract the SPIONs from reaching the desired 
target but it might induce toxic side effects if taken up by normal cells. 
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3.1.3 Research Aims and Objectives  
Aim: To develop a system to investigate the effect of polysaccharide derivatives on 
the cellular interactions of Ferucarbotran with different types of cells.   
Objectives: 
• Establish assays to evaluate the uptake, internalisation and blocking of 
Ferucarbotran by RAW 264.7 macrophage cell line via quantitative and 
qualitative iron assays that can be applicable to other cells. 
• Test the effect of seven different polysaccharides as potential RES blockers 
on macrophages.   
• Investigate the cellular interactions of Ferucarbotran and polysaccharide 
blockers with different tumour cell lines. These include gliomas (U-87 MG 
and U-251 MG), melanoma (A375) and colorectal carcinoma (LS174T) cell 
lines.  
• Evaluate the uptake of Ferucarbotran by components of glioblastoma 
microenvironment using differentiated neural stem cells as a model for 
normal brain cells.  
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3.2 Results  
3.2.1 Uptake of Ferucarbotran by macrophages  
Two different methods were established to measure internalisation of 
Ferucarbotran: (1) A quantitative colorimetric iron assay (ferrozine assay) originally 
developed by Riemer et al to measure intracellular iron (Riemer et al, 2004) and (2) 
Prussian blue staining to visualise Ferucarbotran inside the cells. The latter method 
gives visually striking dense blue aggregates due to the reaction of the reagent with 
the iron, it has been used extensively to stain SPIONs in cells and tissues (Branca 
et al, 2010; Kalber et al, 2005; Lee et al, 2009; Schöpf et al, 2005; Smith et al, 
2007). The assays were developed on RAW 264.7 cells, a murine 
monocyte/macrophage cell line (Campa et al, 2005).  
First, serial dilutions of known iron concentrations of Ferucarbotran were used to 
establish the linear range of the ferrozine assay and create a standard curve (Figure 
3.2).  
 
Figure 3.2: Standard curve of serial dilution of Ferucarbotran measured with ferrozine 
assay.  
Left: Iron concentrations above 20 µgFe/ml were in the non-linear range of the assay. 
Right: A linear increase (R2 = 0.996) was observed in the absorbance of Ferucarbotran 
samples with concentrations between 0.3 - 20 µgFe/ml.  
The ferrozine assay was then applied to measure iron levels in lysates from cells 
that had been incubated with different concentrations of Ferucarbotran. Absorbance 
values of the different samples were extrapolated from the standard curve to 
measure the iron concentrations, which were then converted to pgFe/cell values 
according to Equation 2.1 as described in materials and methods section 2.2.2.1.  
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Results (Figure 3.3 A) showed that the intracellular iron levels of macrophages 
increased, in a dose dependent manner, as the concentration of Ferucarbotran 
applied on cells increased. 
Prussian blue staining showed the presence of blue aggregates, apparently inside 
the cells treated with Ferucarbotran, indicating that Ferucarbotran had been 
internalised (Figure 3.3 B). 
 
Figure 3.3: Uptake of Ferucarbotran by RAW 264.7 cells 
A: Ferrozine assay was used to measure the uptake of Ferucarbotran by macrophages. 
Cells were treated with 3 different concentrations of Ferucarbotran 0.1, 0.5 and 1 mgFe/ml 
as the concentration of Ferucarbotran increased the intracellular iron increased while the 
untreated control showed no detectable iron levels. B: Prussian blue staining showed the 
presence of Ferucarbotran as blue aggregates inside the cells compared to none visible in 
the untreated control. Bars represent the average of readings of 3 wells/treatment and error 
bars are for standard deviations.      
3.2.2 Internalisation of Ferucarbotran by macrophages  
Further studies using TEM and CLSM were used to confirm that Ferucarbotran is 
being internalised by the cells rather than adhering extracellularly.  
For CLSM, Ferucarbotran was chemically conjugated to Alexa Fluor® 633-hydrazide 
dye (shown in green) in order to visualize it inside the cells; the cell membrane was 
labelled using CellMask® orange (red) to define the cell boundaries. The nuclei were 
counterstained with Hoechst 33342 (blue). CLSM images of RAW 264.7 cells 
(Figure 3.4) showed the presence of aggregates of Ferucarbotran in the cytoplasm 
of the cells with none localising in the nucleus. CellMask® orange is slowly 
internalised by the cells (Invitrogen product data sheet) and showed some 
cytoplasmic staining in addition to membrane staining; nevertheless it clearly 
showed the cell boundaries. Z–series stacks were performed to confirm the 
presence of Ferucarbotran within the cells (Figure 3.5).  
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Figure 3.4: Internalisation of Ferucarbotran as seen with CLSM 
RAW 264.7 cells were incubated with Ferucarbotran fluorescently labelled with Alexa Fluor® 
633-hydrazide (shown in green) for 4 hour. The cell membrane was then stained with 
CellMask® orange (red) before the cells were fixed and the nuclei counterstained with 
Hoechst 33342 (blue). CLSM showed internalisation of Ferucarbotran by the macrophages. 
No unspecific background signal was detected in control cells treated with secondary 
antibodies only (not shown). 
 
 
Figure 3.5: Orthogonal views of a Z-series confocal micrograph of RAW 264.7 cells 
treated with Ferucarbotran. 
Ferucarbotran (green) appears to be internalised by the cells (white arrows) as shown in two 
orthogonal views across the Z-series. Nuclei were counterstained with Hoechst 33342 
(blue). 
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Internalisation of Ferucarbotran was further studied using TEM; this method is well 
suited to SPIONs analysis as the electron dense iron content of SPIONs facilitates 
the visualisation of their cores (Figure 3.6). Furthermore X-ray microanalysis on 
TEM sections can confirm the elemental content of the electron dense aggregates 
seen inside the cells (Figure 3.8). 
TEM showed that Ferucarbotran was indeed internalised by macrophages and 
appeared as aggregates rather than as single entities. All intracellular nanoparticles 
detected were in cytoplasmic vesicles and none seen in the nucleus. Low 
magnification TEM images of macrophages (Figure 3.7) showed nanoparticles in 
the process of being phagocytosed; invagination of the cell membrane was seen as 
the cells were engulfing Ferucarbotran aggregates. Some particles were also seen 
attaching to the extracellular membrane. X-ray microanalysis of unstained TEM 
slides (Figure 3.8) confirmed the presence of iron in the electron dense aggregates 
detected inside the macrophages and also differentiated the SPIONs from other 
electron dense structures seen inside the cells.  
 
Figure 3.6: TEM images of macrophages (RAW 264.7) 
Ferucarbotran was seen inside macrophages as electron dense vesicles in the cytoplasm. 
No particles were detected in the nucleus (N) or the untreated control.   
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Figure 3.7: TEM micrograph 
of RAW 264.7 showing 
phagocytosis 
Low magnification TEM image 
(6000x) showed some 
nanoparticles being phagocy-
tosed by macrophages (black 
arrow) while other particles 
appear on the surface of the 
cells attached to the outer 
membrane (black arrow 
heads). Other particles were 
internalised and appeared as 
clusters inside the cells (white 
arrow heads). Vesicles 
containing Ferucarbotran were 
mainly seen in the cytoplasm 
with none detected in the nu-
cleus (N). 
 
Figure 3.8: X-ray microanalysis on TEM sections of RAW 264.7 cells  
To confirm the presence of iron in the aggregates observed inside the macrophages; X-ray 
microanalysis was used. An iron peak (red arrow, up) was observed in the vesicles 
containing the rod shaped aggregates compared to no iron peak (red arrow, down) in the 
other uniformly shaped electron dense vesicles inside the cells that are suspected to be 
glycogen or lipid storage.     
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3.2.3 Blocking the uptake of Ferucarbotran by macrophages 
Having established the quantitative and qualitative iron assays for SPIONs 
internalisation, the next step was to investigate the effect of different 
polysaccharides as potential blockers of Ferucarbotran uptake by cells.   
As shown in Figure 3.9, compared to unblocked cells, DSO4 500 followed by DSO4 
8 showed the most efficient blocking ability causing 94% (±15) and 89% (±2.55) 
reduction in the uptake of Ferucarbotran, respectively. J-18 showed a moderate 
blocking ability with 56% (± 13.2) reduction and finally J-5 caused a slight reduction 
of 20% (± 12.7) in the iron uptake of cells. On contrast both unsulfated dextrans, D-
40 and D-70, surprisingly showed an increase in the uptake of Ferucarbotran by 
cells.  
Results obtained with Prussian blue staining were consistent with the quantitative 
findings of the ferrozine assay. Ferucarbotran appeared as blue aggregates inside 
the unblocked cells but no staining was visible in the DSO4 500 treated cells. DSO4 
8 and J-18 showed a reduction in the blue aggregates while D-70 appeared similar 
to the unblocked cells (Figure 3.10).  
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Figure 3.9: Blocking the uptake of Ferucarbotran by RAW 264.7 cells as measured 
with ferrozine assay 
Cells pre-treated with DSO4 500 showed the lowest iron uptake followed by DSO4 8. Both J-
18 and J-5 showed small but significant decrease in the uptake of Ferucarbotran by cells. 
Unsulfated dextrans (D-40 and D-70) caused an unexpected increase in Ferucarbotran 
uptake. Bars represent the average of readings of 4 wells/treatment and error bars are for 
standard deviations. All results of blocked compared to unblocked cells were statistically 
significant (p<0.05) as measured by Student’s two-tailed unpaired t test. 
 
Figure 3.10: Prussian blue staining of RAW 264.7 cell 
DSO4 500 caused a marked reduction in the uptake of Ferucarbotran (blue aggregates) by 
macrophages (top right) while the lower molecular weight dextran sulfates were less 
effective (bottom left and bottom middle). D-70 (bottom right) did not show any blocking 
ability, as the uptake of Ferucarbotran was similar to unblocked cells (top middle). Cells were 
imaged using a 100x oil immersion lens, scale bar=20 µm. 
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DSO4 500 and J-18 were further investigated at different iron concentrations (Figure 
3.11). Macrophages were pre-treated with the blockers before being challenged with 
3 different concentrations of Ferucarbotran. Results showed that DSO4 500 caused 
a dramatic decrease in the uptake of Ferucarbotran by cells at all the tested iron 
concentrations. While J-18 blocked the uptake to a much lesser extent with the most 
efficient blocking seen at Ferucarbotran concentration of 0.1 mgFe/ml as a 43.6 % 
(± 1.7) reduction was observed at this iron concentration compared to 38.6% (±1.3) 
and 30.2% (±3.7) reduction at 0.5 and 1 mgFe/ml respectively.   
 
 
Figure 3.11: Uptake and blocking of 3 different concentrations of Ferucarbotran with 
DSO4 500 and J-18 on RAW 264.7 cells. 
Blue bars represent unblocked cells treated with 3 different concentrations of Ferucarbotran: 
0.1, 0.5 and 1 mgFe/ml. An increase in the intracellular iron was observed as the 
concentration of Ferucarbotran increased as measured with ferrozine assay. On the contrary 
cells pre-treated with DSO4 500 (red bars) and J-18 (green bars) showed a marked 
reduction in Ferucarbotran uptake (at all tested concentrations) with DSO4 500 being a more 
efficient blocker. Bars represent the means of readings of 3 wells/treatment and error bars 
are for standard deviations. p<0.001 of blocked cells compared to unblocked controls. 
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3.2.4 Uptake of Ferucarbotran by tumour cell lines  
Next the interaction of Ferucarbotran with four different tumour cell lines was 
investigated on: two glioma cell lines (U-87 MG and U-251 MG), a melanoma 
(A375) and a colorectal carcinoma (LS174T) cell lines.  
Following the initial experiments performed on macrophages, DSO4 500 and J-18 
were selected to be tested on tumour cell lines because DSO4 500 showed the 
strongest blocking ability while J-18 represent a clinically approved alternative to 
DSO4 500. Cells were pre-treated with the blockers before being challenged with 
three different concentrations of Ferucarbotran.  
On all the tested cell lines, there was an increase in the intracellular iron content as 
the concentration of Ferucarbotran applied on cells increased. Interestingly, DSO4 
500 and J-18 were able to block the uptake of Ferucarbotran by cells at all the 
tested concentrations of Ferucarbotran (see Figure 3.12).  
 
Figure 3.12 Uptake and blocking of Ferucarbotran by different tumour cell lines  
All tested cell lines showed an increase in the uptake of Ferucarbotran by cells as the 
concentration of Ferucarbotran increased (blue bars). While both blockers tested: DSO4 500 
(red bars) and J-18 (green bars) decreased the amount of intracellular iron when cells were 
pre-treated with them. Bars represent the means of readings of 3 wells/treatment and error 
bars are for standard deviations. Due to the difference in the cell uptake the column graphs 
have different scaling on the y-axis. *p< 0.0001, **p<0.001, ***p≤0.01 and §p=0.07 as 
measured with Student’s unpaired t test compared to unblocked control.  
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3.2.5 Internalisation studies on glioma cell lines  
One of the most developed areas for the use of SPIONs in hyperthermia therapy 
has been for glioblastoma (see introduction section 1.8). Therefore, the 
internalisation of Ferucarbotran by the glioma cell lines was further investigated 
using CLSM and TEM. 
Similar to macrophages, confocal images of glioma cells showed the presence of 
Ferucarbotran aggregates in the cytoplasm with no nanoparticles detected in the 
nucleus (Figure 3.13). The images showed that U-87 MG cells tend to accumulate 
more Ferucarbotran compared to U-251 MG cells; these findings are consistent with 
the data obtained from the ferrozine assay. Orthogonal views of the confocal images 
showed the presence of Ferucarbotran inside the cells, nevertheless in U-87 MG 
some Ferucarbotran appeared to be around the cells either attached to cell debris or 
the glass slide (Figure 3.13 top right).    
 
Figure 3.13: CLSM of glioma cell lines 
U-87 MG and U-251 MG cells were incubated with Ferucarbotran chemically labelled with 
Alexa Fluor® 633-hydrazide (shown in green) for 4 hours. The cell membrane was then 
stained with CellMask® Orange (red) before the cells were fixed and the nuclei 
counterstained with Hoechst 33342 (blue). CLSM showed internalisation of Ferucarbotran by 
both cell lines with U-87 MG cells having more Ferucarbotran than U-251 MG. Scale bar 
=20µm. Orthogonal views (far right) of the Z-stacks showed the presence of Ferucarbotran 
inside the cells (white arrows) with some particles appearing outside the cells (arrow heads, 
U-87 MG). No unspecific background signal was detected in control cells treated with 
secondary antibodies only (not shown).  
 
U
-8
7 
M
G
 
U
-2
51
 M
G
 
Ferucarbotran Merge Cell membrane Orthogonal views 
  
106 
To further confirm the internalisation of Ferucarbotran by cells, TEM was used to 
visualise the electron dense nanoparticles inside the gliomas cells. Similar to CLSM, 
Ferucarbotran was internalised by both glioma cell lines (Figure 3.14 and Figure 
3.15). Ferucarbotran appeared as electron dense aggregates seen inside vesicles in 
the cytoplasm and not in the nucleus. These vesicles containing the aggregates 
were positive for iron when analysed with X-ray microanalysis, unlike other electron 
dense structures seen inside the cells.  
In summary, ferrozine assay, CLSM and TEM data all confirmed the uptake of 
Ferucarbotran by the glioma cells lines. 
 
Figure 3.14: TEM micrographs of U-251 MG cells 
U-251 MG cells treated with Ferucarbotran showed small black aggregates (black arrows 
and higher magnification (far right)) of particles inside the cells compared to untreated 
controls showing morphologically different electron dense vesicles (white arrows) which 
might be lipid or glycogen vesicles. 
 
Figure 3.15: TEM micrographs of U-87 MG cells 
U-87 MG cells showed a similar pattern to U-251 MG cells; however, Ferucarbotran uptake 
(black arrows) appears to be more in U-87 MG cells. In the untreated controls and 
Ferucarbotran treated cells electron dense structures were seen in the cytoplasm (white 
arrows), which might be ribosomes.       
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Figure 3.16: X-ray microanalysis of TEM sections of U-87 MG and U-251 MG cells 
Both glioma cell lines were tested for the elemental content of the electron dense 
aggregates, thought to be Ferucarbotran using X-ray microanalysis. The results shown (left) 
confirm the presence of iron (red arrows) in these aggregates (squares) indicating that these 
are indeed nanoparticles. Other electron dense areas in the TEM sections were also tested 
and are shown to be devoid of iron (squared regions right). These areas appear 
morphologically different from Ferucarbotran vesicles.  
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3.2.6 Neural stem cells (NSCs) 
After investigating the uptake and internalisation of Ferucarbotran by glioma cell 
lines, the uptake was further evaluated by other cells that might be present within 
proximity of the glioblastoma microenvironment; of great importance are the normal 
brain cells. A model that could mimic normal brain cells was achieved by using 
neural stem cells (NSCs) isolated from mouse brains (Regad et al, 2009) (discussed 
in more details in section 3.1.2). NSCs were differentiated following the protocol 
described in materials and methods section 2.2.5.1. Briefly, NSCs maintain their 
stemness and self-renewal properties when cultured in the presence of growth 
factors (EGF and FGF). To promote differentiation the cells were deprived of these 
growth factors leading to their transformation into neurons and glial cells. Glial cells 
then continue differentiation into astrocytes and oligodendrocytes (see Figure 3.17).  
To investigate the success of the differentiation protocol, the cells were investigated 
using CLSM and phase contrast microscopy. Once NSCs start to differentiate into a 
mixed culture of 3 cell types (neurons, astrocytes and oligodendrocytes); a clear 
change in their morphology was observed (Figure 3.18). The undifferentiated stem 
cells appear to have elongated and flattened cell bodies while differentiated cells 
have smaller nuclei and star-shaped ramifications. Each cell type was detected by 
immunofluorescence staining for differentiation markers (Olynik & Rastegar, 2012): 
neuronal βIII tubulin for early neurons; OLIG2 for cells derived from 
oligodendrocytes lineage and GFAP for astrocytes. As seen in Figure 3.18, both 
GFAP and neuronal βIII tubulin are structural cytoskeleton protein while OLIG2 is a 
nuclear protein. Undifferentiated stem cells tested negative for GFAP and βIII 
tubulin, which were then positive following differentiation to astrocytes and neurons, 
respectively. The undifferentiated stem cells tested positive for OLIG2 appearing in 
the elongated nuclei of all the stem cells while following differentiation, a clear 
change in the morphology of the cells’ nuclei could be seen (as they become 
rounder) with much fewer cells testing positive for the marker.  
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Figure 3.17: Differentiation protocol of NSCs 
NSCs maintain their stemness in culture media supplied with growth factors (EGF and FGF), 
once removed the cells differentiate into neurons, astrocytes and oligodendrocytes.  
 
Figure 3.18: Differentiation of Neural Stem cells (NSCs) 
After the differentiation protocol a change in the morphology of the cells was observed as 
seen from the phase contrast images on the far left. Cells were stained for different markers 
both before and after the differentiation protocol. Undifferentiated cells are positive for OLIG2 
only, which is positive in all the cells in the culture before differentiation. While the stem cells 
are negative for neural βIII tubulin and GFAP, unlike differentiated neuron and astrocytes 
respectively. Following differentiation, OLIG2 can only be seen in cells derived from the 
oligodendrocytes lineage. In phase contrast images the scale bar=100 µm, while CLSM 
images the scale bar=20 µm. In cells treated with secondary antibodies only, no unspecific 
background signal was detected (not shown).  
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Following the confirmation of differentiation, differentiated cells were treated with 
increasing concentrations of Ferucarbotran. Results of these experiments revealed 
that the differentiated NSCs had a similar pattern of uptake as previously tested 
cells (macrophages and tumour cell lines). As before there was an increase in the 
accumulation of intracellular iron as the concentration of Ferucarbotran increased 
(Figure 3.19 A). Prussian blue staining revealed the presence of blue aggregates 
inside the cells treated with Ferucarbotran (Figure 3.19 B).  
 
Figure 3.19: Uptake of Ferucarbotran by differentiated Neural Stem cells (NSCs) 
A: Ferrozine assay showed an increase in the intracellular iron content as the concentration 
of Ferucarbotran applied increased (p<0.0001 compared to untreated control). B: Prussian 
blue staining of differentiated NSCs. Cells treated with Ferucarbotran at 0.5 mgFe/ml 
showed the presence of blue aggregates compared to untreated controls.! Scale bar=100 
µm.   
To confirm the internalisation of Ferucarbotran by all the differentiated cells in the 
mixed culture, immunofluorescence staining was used. Cells were co-stained for 
Ferucarbotran using anti-dextran antibody and the 3 different neuronal markers 
(neuronal βIII tubulin, OLIG2 and GFAP). Results shown in Figure 3.20 revealed 
that Ferucarbotran was internalised by all the cells in the mixed culture (neurons, 
astrocytes and oligodendrocytes).  
It has been observed that once the cells starts differentiation some cell death occur 
and since the differentiation protocol entails maintaining the cells in the same culture 
media for 5 days; a lot of cell debris were seen. Extensive washing with PBS did not 
eliminate the debris suggesting that they either attach to the plastic plates or to live 
cells. In the CLSM images a lot of cell debris could be observed with Ferucarbotran 
attaching unspecifically to them (see arrow heads in Figure 3.20).  
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Figure 3.20: CLSM of differentiated NSCs treated with Ferucarbotran  
Cells were stained for Ferucarbotran (green) and different neural markers (red): anti-βIII 
tubulin for neurons, anti-GFAP for astrocytes and anti-OLIG2 for oligodendrocytes. Nuclei 
were counterstained with Hoechst 33342 (blue). All the neural cells in the mixed culture have 
internalised Ferucarbotran as shown from the orthogonal views of the Z-series stacks (white 
arrows). Ferucarbotran appear to attach unspecifically to cell debris as well (arrow heads). 
Scale bar=20 µm, no unspecific background signal was detected in control cells treated with 
secondary antibodies only (not shown). 
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Next, blockers tested on macrophages were also investigated for their ability to 
reduce the uptake of Ferucarbotran by NSCs. As shown in Figure 3.21, both DSO4 
500 and J-18 significantly reduced the intracellular iron levels of Ferucarbotran at all 
the tested concentrations as investigated with ferrozine assay and Prussian blue 
staining.    
 
Figure 3.21: Blocking the uptake of Ferucarbotran (FC) by differentiated NSCs  
Intracellular iron was detected with ferrozine assay (A) and Prussian blue staining (B). Blue 
bars represent unblocked cells, which show an increase in the intracellular iron as the 
concentration of Ferucarbotran increased. On the contrary cells pre-treated with DSO4 500 
(red bars) and J-18 (green bars) showed a marked reduction in Ferucarbotran uptake (at all 
tested concentrations) with DSO4 500 being a more efficient blocker. Bars represent the 
means of readings of 3 wells/treatment for 3 independent experiments and error bars are for 
standard deviations, *p<0.0001 compared to unblocked cells. B: Prussian blue staining 
showed similar findings with a marked reduction in the blue aggregates (Ferucarbotran) in 
the cells pre-treated with DSO4 500 and J-18. Cells were imaged with 20x phase contrast 
lens, scale bar=100 µm.  
3.2.7 PrestoBlue™ cell viability assay  
To investigate whether Ferucarbotran or the blockers (DSO4 500 and J-18) might 
induce cell death, PrestoBlue™ cell viability assay was used. Three cell lines (RAW 
264.7, U-87 MG and U-251 MG cells) were used as a preliminary platform to 
develop the assay.  
The assay was done to ensure that the concentrations of both Ferucarbotran and 
the blockers used were not toxic to cells. Concentrations tested started at 10 times 
higher than the ones used in the blocking experiments: Ferucarbotran (0.02 
mgFe/ml to 10 mgFe/ml), DSO4 500 (0.59 to 300 µg/ml) and J-18 (0.02 mg/ml to 10 
mg/ml). Incubations were done for four hours to mimic the uptake and blocking 
experiments. 
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Both DSO4 500 and J-18 did not affect the cell viability of the investigated cell lines 
at any of the concentrations tested when compared to PBS treated cells. Similarly 
Ferucarbotran treated tumour cells (U-251 MG and U-87 MG) showed no reduction 
in cell viability except with U-251 MG cells where a 20% reduction was observed at 
the highest tested Ferucarbotran concentration (10 mgFe/ml). RAW 264.7 cells also 
showed a 30% reduction in cell viability at Ferucarbotran concentrations of 5 and 10 
mgFe/ml.  
 
Figure 3.22: PrestoBlue™ cell viability assay 
Three cell lines (RAW 264.7, U-251 MG and U-87 MG cells) were incubated with 
Ferucarbotran (0.02 mgFe/ml to 10 mgFe/ml, red scale), DSO4 500 (0.59 to 300 µg/ml, 
purple scale) and J-18 (0.02 to 10 mg/m, blue scale) for 4 hours. No clear effect on the 
percentage cell viability was observed under the tested condition except with RAW 264.7 
cells (top) where a reduction of ~30% in cell viability was observed at 5 and 10 mgFe/ml. U-
251 MG cells also showed a reduction of ~20% in cell viability at 10 mgFe/ml. *p= 0.0005 
and **p < 0.000007. Each point represents the means of readings of 3 wells/treatment for 3 
independent experiments and error bars are for standard deviations. 
40 
60 
80 
100 
120 
140 
40 
60 
80 
100 
120 
140 
R
AW
 2
64
.7
 
U
-2
51
 M
G
 
U
-8
7 
M
G
 
%
 V
ia
bi
lit
y 
%
 V
ia
bi
lit
y 
%
 V
ia
bi
lit
y 
40 
60 
80 
100 
120 
140 
0.0
2
0.0
3
0.0
7
0.1
5
0.3
1
0.6
2
1.2
5) 2.5
) 5) 10
)
Ferucarbotran PBS DSO4 500 J-18 
0.0
20
 
0.0
39
 
0.0
78
 
0.1
56
 
0.3
13
 
0.6
25
 
1.2
5 2.5
 5 10
 
0.0
00
6 
0.0
01
2 
0.0
02
3 
0.0
04
7 
0.0
09
4 
0.0
19
 
0.0
38
 
0.0
75
 
0.1
5 0.3
 
Concentration mg/ml 
Ferucarbotran 
DSO4 500 
J-18 
**)*)
**)
  
114 
3.2.8 Fucoidan as a blocker  
Although DSO4 500 was shown to be a very efficient blocker, it has not been used 
clinically. Consequently a known ligand for scavenger receptors A and a food 
supplement, namely fucoidan, was introduced in the project. Fucoidan was 
investigated in preliminary proof-of-concept experiments on macrophages and a 
glioma cell line (U-251 MG).  
RAW 264.7 murine macrophages were pre-treated with fucoidan at 3 different 
concentrations: 30, 50 and 100 µg/ml followed by Ferucarbotran at 0.1, 0.5 and 1 
mgFe/ml. Cells pre-treated with fucoidan showed significant reduction in the uptake 
of Ferucarbotran at all tested conditions (Figure 3.23 Top). Furthermore, when 
fucoidan was compared to a similar concentration of DSO4 500 (30 µg/ml), fucoidan 
appears to have slightly less blocking ability; nevertheless, the uptake of 
Ferucarbotran by macrophages is significantly reduced with both blockers (Figure 
3.23 Bottom).  
Next, fucoidan was tested for its ability to block the unspecific uptake of 
Ferucarbotran by a glioma cell line (U-251 MG). Similar to the results discussed 
above; fucoidan decreased the uptake of Ferucarbotran by U-251 MG cells but to a 
lesser extent than DSO4 500 (Figure 3.24).     
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Figure 3.23: Blocking the uptake of Ferucarbotran by RAW 264.7 using fucoidan 
Top: Macrophages were pre-treated with three different concentrations of both fucoidan and 
Ferucarbotran and the intracellular iron was detected using ferrozine assay. Macrophages 
pre-treated with fucoidan showed a significantly (p<0.001 for all blocked compared to 
unblocked) lower uptake of Ferucarbotran at all the tested concentrations of the blocker and 
with different concentrations of Ferucarbotran. Bottom: Fucoidan and DSO4 500 were 
tested at equal concentrations of 30 µg/ml before the cells were challenged with 3 different 
concentrations of Ferucarbotran. Both blockers caused significant reduction in the uptake of 
Ferucarbotran by cells with DSO4 500 showing a slightly better blocking ability. Bars 
represent the means of readings of 3 wells/treatment and error bars are for standard 
deviations.    
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Figure 3.24: Effect of fucoidan on the uptake of Ferucarbotran by U-251 MG cells 
Cells were pre-treated with 3 different concentrations of Fucoidan and DSO4 500. Both 
blockers reduced the unspecific uptake of Ferucarbotran by cells at all tested concentrations 
of Ferucarbotran and the blockers. DSO4 500 appears to be more efficient than fucoidan. 
p<0.003 for all blocked compared to unblocked control. Bars represent the means of 
readings of 3 wells/treatment and error bars are for standard deviations.    
 
 
  
0 
10 
20 
30 
40 
50 
60 
0.1 mgFe/ml 0.5 mgFe/ml 1 mgFe/ml 
pg
Fe
/c
el
l 
U-251 MG 
Unblocked Ferucabotran 
Fucoidan 30 ug/ml 
Fucoidan 50 ug/ml 
Fucoidan 100 ug/ml 
DSO4 500 30 ug/ml 
DSO4 500 50 ug/ml 
DSO4 500 100 ug/ml 
  
117 
3.3 Discussion  
The work presented in this chapter investigated one of the central hypotheses of this 
thesis: the rapid clearance of SPIONs by the RES could be blocked using 
polysaccharide derivatives.  
RAW 264.7 murine macrophages were studied first and consistent with previous 
published reports (Hsiao et al, 2008; Yang et al, 2011), these cells showed 
concentration dependent uptake of Ferucarbotran. Internalisation was confirmed 
with TEM and CLSM where Ferucarbotran was observed in cytoplasmic endocytic 
vesicles with no localisation in the nucleus. In addition to published reports the work 
presented here utilised X-ray microanalysis to confirm that the observed electron 
dense aggregates in macrophages treated with Ferucarbotran were indeed iron 
oxide nanoparticles.   
Macrophages pre-treated with scavenger receptor A blockers, DSO4 500 and 
fucoidan, showed a significant decrease in the uptake of Ferucarbotran unlike the 
results observed with unsulfated dextrans (D-40 and D-70). These results are 
consistent with published literature reporting the blocking effect of DSO4 500 (Sonia 
et al, 2009) and fucoidan (Segers et al, 2013) and the lack of an inhibitory effect by 
unsulfated dextrans (Chao et al, 2012a) on the uptake of SPIONs by macrophages.    
Other investigated blockers in chapter 3 were low molecular weight dextran sulfates 
(DSO4 8, J-5 and J-18); these agents were not reported as RES blockers before. 
Results showed that DSO4 8 and J-18 blocked the uptake of Ferucarbotran by 
macrophages with J-5 showing a small blocking effect. Although the blocking effect 
was not as effective as DSO4 500 suggesting that the molecular weight affects the 
blocking ability of dextran sulfates.  
Tumour cell lines tested also showed an increase in the accumulation of 
Ferucarbotran proportional to the concentration applied in a similar pattern to that 
observed with macrophages and also consistent with published reports (Mailänder 
et al, 2008; Sun et al, 2005). Further internalisation studies using TEM and CLSM 
were performed on glioma cells confirming the presence of iron oxide vesicles in the 
cytoplasm. Furthermore, the effect of the polysaccharide blockers was evaluated on 
tumour cells. Despite the absence of reports recording the expression of scavenger 
receptor A on tumour cells, the blockers significantly reduced the uptake of 
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Ferucarbotran by cells. This effect has not been reported before which represents 
an interesting novel finding.    
The uptake of SPIONs by non-RES cells has been previously investigated in various 
cell tracking and homing studies. SPIONs can be used to magnetically label cells 
either in vitro or in vivo owing to their unique magnetic properties (Mailänder et al, 
2008; Wilhelm et al, 2003). MRI can then be used to image and track the homing of 
labelled cells in vivo (Mailänder et al, 2008). However, most of these studies utilised 
transfection agents and/or targeting agents or small peptides (e.g. protamine, PLL 
(poly-L-lysine) or HIV-Tat peptide) to increase the uptake of SPIONs by cells 
(Golovko et al, 2010; Lewin et al, 2000; Mailänder et al, 2008; Wilhelm et al, 2003). 
Nonetheless, these transfection agents are not suitable for use in humans and might 
have toxic effects on cells (Mailänder et al, 2008). The use of targeting strategies 
might also affect the biological function of cells (Sun et al, 2005) as well as affect the 
stability and overall charge of SPIONs altering their properties and behaviour. 
Therefore studying the uptake of unmodified SPIONs by non-RES cells becomes 
crucial, as it is a poorly investigated area.   
Similar to the findings presented in this chapter, Mailänder et al found that the 
uptake of formulated Ferucarbotran (Resovist®) is possible by cells without the need 
for a transfection agent. They investigated the uptake of Resovist® and Feridex® in 
mesenchymal stem cells (MSCs) and HeLa cells and found that Ferucarbotran was 
being readily taken up by both cell lines in a significantly higher dose dependent 
manner compared to Feridex® (Mailänder et al, 2008). They accounted the 
difference in uptake to the negatively charged carboxydextran coat of Resovist® 
unlike the neutral dextran coat of Feridex®. Similar findings were also reported by 
Sun et al, their work compared the uptake of SPIONs (Resovist®) to USPIO (SHU 
555C) by human fibroblasts, immortalized rat progenitor cells and HEP-G2 
hepatocellular carcinoma cells. They found that the cell lines tested had a higher 
capacity to accumulate SPIONs (Resovist®) more efficiently than USPIOs (Sun et al, 
2005). However, in both mentioned studies, they investigated the commercially 
formulated product (Resovist®) rather than the active ingredient (Ferucarbotran), the 
presence of excipients in Resovist® formulation (e.g. mannitol, lactic acid and 
sodium hydroxide (Schering, 2002)) might affect the way the cells interact with the 
nanoparticles, therefore, their data should be interpreted cautiously.  
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Similar to Resovist®, unformulated Ferucarbotran (studied in this chapter) is coated 
with carboxydextran; the presence of carboxylic groups on the surface of the 
particles renders them negatively charged (-25.7 mV) at physiological pH (Abdollah 
et al, 2014; Mailänder et al, 2008). The surface charge of SPIONs determines their 
behaviour and the way they interact with cells as previously discussed in the 
introduction section 1.4.1.2. The uptake of Ferucarbotran by tumour cell lines can 
therefore be accounted to its overall negative charge. It has been shown before that 
anionic SPIONs interact with the positively charged regions on the cell membrane 
and become internalised by fluid-phase endocytosis (Vigor et al, 2010; Wilhelm et 
al, 2003). Nevertheless, very little is understood regarding these processes (Jordan 
et al, 1999). In addition the blocking effects observed in this chapter with negatively 
charged sulfated polysaccharides (DSO4 500, J-18 and fucoidan) has not been 
reported before and could be due to the competition of the blockers with 
Ferucarbotran at the sites of internalisation leading to a decrease in the unspecific 
uptake of Ferucarbotran by cells. 
Next, the uptake of Ferucarbotran was evaluated on neurons, astrocytes and 
oligodendrocytes derived from differentiated NSCs. Ferrozine assay, Prussian blue 
staining and CLSM showed that Ferucarbotran is taken up and internalised by the 
differentiated neural cells, furthermore this was blocked using DSO4 500 and J-18. 
The cell uptake findings are similar to the work of Politi et al where Resovist® has 
been used to label neural stem/precursor cells (NPCs) in order to track their homing 
in vivo in mice using MRI (Politi et al, 2007); NPCs were labelled ex vivo with 
Endorem® (Feridex®) and Resovist®. Similar to finding by Mailänder et al discussed 
previously (Mailänder et al, 2008), Resovist® was able to label the cells without the 
need for a transfection agent while Endorem® conjugated to PLL showed a 
significantly higher uptake by cells (Politi et al, 2007). Nevertheless, the uptake of 
Ferucarbotran by the differentiated cells (neurons, astrocytes and oligodendrocytes) 
was not reported before.  
The expression of scavenger receptors in neural glial cells has been studied 
extensively due to their role in inflammatory responses associated with 
neurodegenerative diseases (e.g. Alzheimer’s disease) (Alarcón et al, 2005). Some 
reports have mentioned that scavenger receptor A is mainly expressed in microglial 
cells (brain macrophages) with astrocytes mainly expressing scavenger receptor 
class B (Alarcón et al, 2005). However, more recent studies have reported the 
expression of scavenger receptor A in astrocytes extracted from rat brains and are 
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believed to play a critical role during neuroinflammatory processes (Godoy et al, 
2012; Murgas et al, 2014). Therefore the uptake of Ferucarbotran by astrocytes 
might be mediated via these receptors. Furthermore, the blocking effect observed 
with DSO4 500 and J-18 could be accounted to competitive blockage of scavenger 
receptors on astrocytes. In contrasts, no data is available on the expression of 
scavenger receptor A on neurons and oligodendrocytes. Thus the uptake of 
Ferucarbotran might be accounted to unspecific uptake mechanisms similar to the 
results observed with tumour cells. 
3.4 Summary and conclusions   
The work presented in this chapter was investigating the hypothesis that 
polysaccharide derivatives could block the unwanted uptake of Ferucarbotran by 
cells. Four main research aims were proposed all of which were fulfilled: (i) 
quantitative and qualitative iron assays were developed to assess the intracellular 
iron uptake of Ferucarbotran; (ii) a number of cell lines were investigated 
(macrophages, tumour and non-tumour cell lines) for their ability to take up and 
internalise Ferucarbotran; (iii) seven different polysaccharides were investigated for 
their ability to block the uptake of Ferucarbotran by macrophages and finally (iv) a 
model mimicking normal brain cells was developed to investigate the interaction of 
Ferucarbotran with non-tumour cells.  All tested cell lines have successfully taken up 
Ferucarbotran and interestingly sulfated polysaccharides (e.g. DSO4 500, J-18 and 
fucoidan) were able to reduce the cellular internalisation of SPIONs regardless of 
the cell type, proving the hypothesis.   
In conclusion, the work presented here showed some novel and crucial findings 
regarding the cellular interactions of Ferucarbotran with macrophages and 
components of the tumour microenvironment. The use of pharmaceutical agents as 
blockers, if proved successful in vivo, will provide a safe approach to evade the RES 
and consequently a better prospective for clinical development. The anti-
hyperlipidemic drug (J-18), that has not been investigated before as a potential RES 
blocker, and the food supplement (fucoidan) showed a promising blocking effect in 
vitro. Furthermore the effect of the blockers on the uptake of SPIONs by tumour 
cells and NSCs have not been previously reported which might be a crucial finding 
that will affect the use of Ferucarbotran together with the blockers.  
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4.1  Introduction 
The work presented in chapter 3 with the RAW 264.7 cell model established that it is 
possible to reduce the uptake of Ferucarbotran by macrophages in vitro using 
polysaccharide derivatives. Work in the current chapter was designed to investigate   
if the blockers would perform to block Ferucarbotran uptake by the RES in the more 
complex in vivo environment. SPIONs are usually rapidly cleared by the RES 
leading to very short half-lives (see Figure 4.1 and sections 1.3.1.2 and 1.6.3). 
Therefore, a successful outcome of RES blocking would be to prolong the 
circulatory retention of SPIONs.   
 
 
Figure 4.1: Uptake of SPIONs by liver Kupffer cells 
A: Kupffer cells are specialised phagocytic cells lining the endothelium of liver sinusoids that 
have the ability to rapidly internalise SPIONs as they pass through the liver blood vessels. B: 
Prussian blue staining of a liver histology section of a mouse treated with 100 µmolFe/kg 
showing Ferucarbotran (blue aggregates, black arrows) internalised by Kupffer cells (white 
arrow).  
4.1.1 Experimental approach 
Approaches developed to measure circulatory retention of SPIONs are outlined 
below: first, methods were established to conjugate SPIONs to NIR dyes. Second, 
an experimental BALB/c mouse model (Figure 4.2) was developed for quantitative 
measurement of the SPIONs blood levels. Results from these experiments were 
used to select the lead in vivo blocker. Finally, for more comprehensive evaluation 
of the lead blocker, the SPIONs’ core was radiolabelled (De Rosales et al, 2009; de 
Rosales et al, 2011) allowing SPECT/CT imaging to measure the biodistribution of 
Ferucarbotran in different organs.   
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Figure 4.2: Experimental design of the in vivo 
blocking experiments 
(i) A blocker was injected intravenously. (ii) A 
blocking period was allowed ranging from 0 to 24 
hours depending on the blocker investigated. (iii) 
NIR dye-labelled SPIONs were injected 
intravenously. (iv) One hour following SPIONs 
injection, blood was collected from mice and 
measured on Odyssey® scanner. 
 
 
 
 
 
 
 
4.1.2 Research Aims and Objectives 
Aim: To develop a system to increase the circulatory retention of Ferucarbotran. 
Objectives: 
• To develop chemical conjugation strategies to link SPIONs to near infrared 
(NIR) dyes. 
• Evaluate the colloidal stability and characterize NIR-labelled SPIONs using 
visual inspection, DLS and TEM measurements. 
• Investigate the blocking effect of different polysaccharide derivatives in vivo 
as potential RES blockers. 
• Use SPECT/CT imaging to measure the effect of the lead RES blocker on 
the biodistribution of Ferucarbotran in vivo. 
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4.2 Results 
4.2.1 Conjugation of Nanomag-D-spio-NH2 (NM) to DyLight® 800 
First, a commercially available SPION was investigated. Nanomag®-D-spio-NH2 
(NM) are dextran coated amine functionalised SPIONs with hydrodynamic diameter 
in the range of 50-120 nm (Table 2.9). NIR labelled NM was used to establish the in 
vivo experimental conditions for SPIONs measurement in blood because the 
surface amine (NH2) groups are available for conjugation to NHS ester dyes 
(DyLight® 800 NHS ester) in a simple and efficient reaction (Figure 4.3).  
 
Figure 4.3: Schematic presentation of the chemical reaction between Nanomag-D-
spio-NH2 (NM) and DyLight® 800 NHS ester NIR dye. 
The NHS ester group available on the NIR dye attacks the amine groups on the dextran coat 
of NM. The reaction proceeded for 1 hour at RT in 50 mM sodium borate buffer.   
Following the conjugation reaction, serial dilutions of the conjugates were measured 
on the Odyssey® NIR scanner to check the success of the labelling. A linear 
increase in the signal intensity was observed as the iron concentration increased 
(Figure 4.4). Results showed that a high fluorescence signal could be detected for 
concentrations as low as 0.11 µgFe/ml indicating a very efficient conjugation 
reaction.  
The colloidal stability of the dye labelled SPIONs was investigated. Visual inspection 
revealed no apparent precipitations or changes in the physical appearance. DLS 
measurements were performed to further confirm the stability. Only minor changes 
in the Z-average hydrodynamic diameter and the polydispersity index (PDI) were 
observed before and after conjugation (Table 4.1). TEM was used to examine the 
iron oxide cores of SPIONs; no apparent changes were observed following the 
conjugation (Figure 4.5). NM SPIONs appeared highly crystalline with average core 
size of 6.019 (±1.82) nm in diameter ((Abdollah et al, 2014), Appendix 5). 
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Figure 4.4: Signal intensity of Nanomag-D-spio-NH2 labelled with DyLight 800 NIR dye 
A linear increase (R2=0.998) in the signal intensity of dye labelled Nanomag-D-spio-NH2 
(NM-DyLight 800) was observed as the iron concentration increased. Images of individual 
wells illustrating fluorescence intensity are shown on the right. 
Table 4.1: Characterisation data of Nanomag-D-spio (NM) 
Sample 
Hydrodynamic diameter 
Z-Average (nm) PDI 
NM 75.4 0.187 
NM-DyLight 800 74.3 0.208 
 
Figure 4.5: TEM micrograph of 
NIR labelled Nanomag-D-spio 
No clear changes were observed 
in the cores of the SPIONs 
following conjugation. High-
resolution TEM (HRTEM) images 
(lower panel) show lattice planes 
of iron oxide cores measuring 
6.019 (±1.82) nm in diameter.  
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Next, NM-DyLight 800 was tested in vivo with DSO4 500, an established RES 
blocker. Four DSO4 500 doses were tested: 3, 7.5, 15 and 30 mg/kg injected 24 
hours prior to NM-DyLight 800. Results showed that the NIR signal intensity of NM-
DyLight 800 was strongly enhanced in a dose dependent manner (Figure 4.6) 
(Abdollah et al, 2014). An improvement in the blood signal was seen even at the 
lowest tested concentration of DSO4 500 with approximately a 2-fold improvement 
observed as the doses doubled. 
 
Figure 4.6: Dot plot of mean signal intensity of mice treated with NM-DyLight 800 
The mean signal intensity (bar) (n=2) for mice treated with NM-DyLight 800 with and without 
24-hour pre-treatment with different doses of DSO4 500. A dose-dependent increase in the 
signal intensity was observed as the dose of DSO4 500 increased. Each mouse is 
represented by a square. Bottom: Images of individual wells illustrating fluorescence 
intensity are shown. M1= mouse 1, M2 = mouse 2. 
DSO4 500 was further tested at 30 mg/kg in four independent experiments (2-
mice/group each) with different batches of NM-DyLight 800. Mice pre-treated with 
the blockers showed a significant 15.6-fold improvement (p=0.0016, Tukey HSD 
test) in the median signal intensity compared to unblocked controls. The median 
signal intensity of the blocked group was 112 compared to 7.17 for unblocked mice 
(Figure 4.7) (Abdollah et al, 2014).  
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These results showed that DSO4 500 is an efficient RES blocker in vivo and that the 
developed animal model is suitable for tracing the blood levels of SPIONs. Next, 
Ferucarbotran was investigated.    
 
Figure 4.7: Box plot of compiled NM-DyLight 800 and DSO4 500 combined 
experiments 
Box plot of all NM-DyLight 800 experiments showing a statistically significant difference 
between the signal intensity of NM-DyLight 800 in mice pre-treated with DSO4 500 for 24 
hours prior to the administration of NM-DyLight 800 compared to unblocked control. Median 
signal intensity of blocked group was 112 compared to 7.17 for unblocked mice (p=0.016). 
4.2.2 Conjugation of Ferucarbotran to NIR dyes 
Having established the in vivo experimental conditions with NM-DyLight 800 and the 
known RES blocker DSO4 500, the next challenge was to develop a strategy to 
label Ferucarbotran.  
Ferucarbotran is coated with carboxydextran and therefore hydroxyl or carboxylic 
groups are available for conjugation (Figure 4.8). Three different strategies were 
investigated to functionalise these groups; two strategies utilised the hydroxyl 
groups while the third targeted carboxylic groups. Whilst conjugations to the 
hydroxyl groups tended to cause destabilisation of the SPIONs and/or a low 
labelling efficiency (Abdollah et al, 2014), conjugation to carboxylic groups proved 
successful as detailed below.  
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Figure 4.8: Structure of carboxydextran 
Ferucarbotran is coated with carboxydextran, which is a glucose polymer with a terminal 
carboxylic group. There are two functional groups available on its surface: hydroxyl (OH) and 
carboxylic groups (COOH) (red arrow).  
4.2.2.1 Conjugation of Ferucarbotran to IRDye 800 CW azide via carboxylic 
groups 
A 2-step approach was developed to conjugate a NIR dye to the carboxylic groups 
of Ferucarbotran using a bifunctional linker (dibenzocyclooctyne (DBCO)-amine). 
First, carboxylic groups were reacted with the amine moieties of the linker via the 
standard EDC/NHS chemistry. Second, the Ferucarbotran-DBCO was “clicked” with 
an IRDye® 800CW azide dye (Figure 4.9) (Abdollah et al, 2014).  
 
Figure 4.9: Schematic presentation of the 2-step reaction between Ferucarbotran and 
IRDye 800CW-Azide. 
This method combines the activation of the COOH groups present on the carboxydextran 
coat of Ferucarbotran using EDC/NHS to react with a DBCO-amine linker. The conjugate is 
then “clicked” with azide functionalised NIR dye (IRDye® 800CW-Azide). 
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Following the reaction, visual inspection of Ferucarbotran solution revealed no 
apparent changes (Figure 4.10). DLS measurements showed a 5.83 nm increase in 
the hydrodynamic diameter of FC-IRDye 800, which could be accounted to the 
presence of the dye. While PDI measurements confirmed the stability of the 
conjugates as only a slight difference was detected after conjugation (Table 4.2). To 
ensure the success of the conjugation, a serial dilution of the conjugate (FC-IRDye 
800) was measured on the Odyssey® NIR scanner. A linear increase in the 
fluorescence signal was observed as the iron concentration increased (Figure 4.11) 
(Abdollah et al, 2014). Similar to NM-DyLight 800, no changes were detected in the 
iron oxide cores following the conjugation as seen with TEM (Figure 4.12).  
 
 
Figure 4.10: Picture of Ferucarbotran solution before and after conjugation to IRDye 
800 
Visual inspection revealed no apparent difference between unconjugated Ferucarbotran (A) 
and FC-IRDye 800 (B). 
Table 4.2: Characterisation data of FC-IRDye 800 
Sample 
Hydrodynamic diameter 
Z-Average (nm) PDI 
FC  59 0.223 
FC-IRDye 800 64.83 0.237 
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Figure 4.11: Signal Intensity of FC-IRDye 800 
A linear relationship (R2=0.99) was observed between the iron concentration of FC-IRDye 
800 and the signal intensity as measured on Odyssey® scanner. Right: Images of individual 
wells illustrating fluorescence intensity are shown.  
 
Figure 4.12: TEM micrograph of FC and FC-IRDye 800 
No clear changes were observed in the iron oxide cores following conjugation. HRTEM 
showed core sizes of 3.75  (±0.834) nm. 
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4.2.2.2 Testing the labelled Ferucarbotran on RAW 264.7 cells 
FC-IRDye 800 was next evaluated for in vitro interactions with RES using the RAW 
264.7 cell line. The quantification by the NIR signal was compared to the 
quantification of iron using the ferrozine assay. Results (Figure 4.13) showed that 
both measurements revealed similar pattern of uptake and blocking where DSO4 
500 showed the highest reduction in the uptake of FC-IRDye 800 by cells while J-18 
led to ~ 2 fold reduction.  
 
 
Figure 4.13:  Blocking the uptake of FC-IRDye 800 on RAW 264.7 cells 
Macrophages were pre-treated with DSO4 500 or J-18 before adding FC-IRDye 800. Cells 
were incubated for 4 hours and then washed and the NIR signal (A and B) measured then 
the cells were lysed and the intracellular iron detected with ferrozine assay (C). Both 
methods showed that DSO4 500 caused a significant reduction in FC-IRDye 800 uptake 
while J-18 showed a small blocking effect. p<0.001 of all blocked groups compared to 
unblocked control in both assays as measured with Student’s unpaired t test. Values 
represent the means and error bars are for standard deviation for 3 measurements per 
treatment.    
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4.2.2.3 Testing FC-IRDye 800 in vivo with RES blockers  
FC-IRDye 800 was taken forward for in vivo testing, first with the established blocker 
DSO4 500 and subsequently with more translational polysaccharides: (i) the 
pharmaceutical agent J-18 and (ii) the food supplement fucoidan.  
DSO4 500 was investigated with four different batches of FC-IRDye 800; results 
were combined in a box plot shown in Figure 4.14. Mice were pre-treated with 
DSO4 500 24 hours before the administration of FC-IRDye 800. Results showed 
that a 5-fold improvement (p=0.0039, Tukey HSD test) in the blood signal was 
observed in mice pre-treated with the blocker compared to unblocked control. 
Median signal intensity of the blocked group was 14.13 compared to 2.76 in the 
unblocked control (Figure 4.14) (Abdollah et al, 2014).  
The in vivo blocking results presented so far have evaluated DSO4 500 when 
administered 24 hours before NIR labelled SPIONs. Next, the blocking effect of 
DSO4 500 was investigated when injected 0, 2 or 24 hours before FC-IRDye 800. 
DSO4 500 increased the blood levels at all the tested conditions with 24-hour 
blocking giving the highest blood signal of FC-IRDye 800 (Figure 4.15) (Abdollah et 
al, 2014). 
The results observed with DSO4 500 and FC-IRDye 800 confirmed the success of 
the conjugation reaction in vivo, and revealed similar trend of blocking to the one 
experienced with NM-DyLight 800. After establishing the system with colloidally 
stable dye labelled Ferucarbotran, J-18 and fucoidan were investigated in vivo.    
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Figure 4.14: Box plot of signal intensities of mice treated with FC-IRDye 800 with and 
without blocking 
Box plot of FC-IRDye 800 treated mice with and without 24-hour blocking with DSO4 500 
showing a significant increase in the signal of FC-IRDye 800 in the blood of blocked mice 
compared to unblocked control (p=0.0039). Median signal intensity of blocked group is 14.13 
compared to 2.76 in unblocked control. 
 
Figure 4.15: Signal of FC-IRDye 800 remaining in the blood of mice pre-treated with 
DSO4 500 at different blocking times 
Twelve mice were tested in total (3 mice per group). All blocking times tested (0, 2 and 24 
hours) showed an improvement in the blood concentration of FC-IRDye 800 with the highest 
observed with 24 hour blocking. *p=0.001 **p=0.01 compared to unblocked control, bars 
represent mean values (n=3) and error bars are for standard deviation. Right: Images of 
individual wells illustrating fluorescence intensity are shown. M1, M2 and M3 stand for 
mouse number. 
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The blocking effect of J-18 was tested in a small (2 mice/group) pilot experiment at 3 
different blocking times: 0, 30 and 120 minutes before administration of FC-IRDye 
800. A small improvement was observed in all the tested groups and more 
specifically when J-18 was given 30 minutes prior to Ferucarbotran injection (Figure 
4.16). Nonetheless, the blocking effect of J-18 was not as effective as DSO4 500.      
 
 
Figure 4.16: Signal of FC-IRDye 800 remaining in the blood of mice pre-treated with J-
18 at different blocking times 
Mice pre-treated with J-18 showed a small improvement in their blood signal compared to 
the unblocked group. The highest effect (2.7 times improvement) was seen in mice pre-
treated with J-18 for 30 minutes before FC-IRDye 800 injection. Each mouse is represented 
with a square and average with a bar. Fluorescence intensity of the blood samples are 
illustrated on the right, M1 = Mouse 1, M2 = Mouse 2.  
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The final blocker tested was fucoidan when administered 24 hours prior to FC-
IRDye 800; conditions already developed for DSO4 500. Results (Figure 4.17) 
showed no increase in the blood levels of Ferucarbotran in the fucoidan-treated 
group, unlike mice pre-treated with DSO4 500. When the experiment was repeated 
with the blockers administered directly before Ferucarbotran, results (Figure 4.18) 
revealed that mice pre-treated with fucoidan showed a 5.8 improvement in the blood 
signal of Ferucarbotran compared to 2.5 fold improvement seen with DSO4 500.  
 
Figure 4.17: Testing blocking effect of fucoidan when administered 24 hours prior to 
FC-IRDye 800 
Blockers were injected 24 hours prior to NIR labelled Ferucarbotran, mice pre-treated with 
DSO4 500 (n=3) showed an increase in the blood signal of Ferucarbotran compared to 
fucoidan blocked mice (n=3) and unblocked control (n=1). Each mouse is represented with a 
circle and average with a bar.  On the right fluorescence intensity of the blood samples are 
illustrated. M1 = Mouse 1, M2 = Mouse 2, M3 = Mouse 3.  
 
Figure 4.18: Fucoidan and DSO4 500 blockers tested when administered directly 
before FC-IRDye 800 
Fucoidan caused an increase in the signal of Ferucarbotran detected in the blood indicating 
effective blocking of RES. Under the tested conditions, fucoidan appears to be more efficient 
than DSO4 500. Each mouse is represented with a circle and average with a bar.  
Fluorescence intensity of the blood samples are illustrated on the right, M1 = Mouse 1 and 
M2 = Mouse 2.  
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4.2.3 Testing the blocking effect of fucoidan using SPECT/CT imaging 
Since Fucoidan was shown to be an efficient RES blocker as well as being readily 
available as a food supplement, it was tested with another system using 
radiolabelled Ferucarbotran. Ferucarbotran was labelled with Technetium-99m 
(99mTc) in order to trace its biodistribution with SPECT/CT imaging. Fucoidan was 
injected directly before 99mTc–Ferucarbotran then mice were scanned for 90 minutes 
(3 X 30 minutes slots) before being sacrificed and the organs harvested.  
A clear change in the pharmacokinetic behaviour of Ferucarbotran was observed in 
the fucoidan-blocked mice compared to unblocked control.  As seen in Figure 4.19, 
in the fucoidan treated mice, more 99mTc–Ferucarbotran was detected in the 
circulation (heart) up to 90 minutes post injection.  Furthermore, in the blocked mice 
a higher signal was detected in the spleen and the kidneys versus an almost 
exclusive signal in the liver of the unblocked mice. Biodistribution data revealed 
similar findings to the images as shown in Figure 4.20. The most striking difference 
is in the liver uptake as in unblocked mice the liver to blood ratio was 8.5 compared 
to only 0.5 in the blocked counterpart. While all other tissues showed similar tissue 
to blood ratios. 
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Figure 4.19: SPECT/CT images taken at 30 and 90 minutes post treatment of mice with 
99mTc-Ferucarbotran   
(A) Maximum intensity projection (MIP) SPECT/CT images after i.v. injection of radiolabelled 
99mTc-Ferucarbotran, (B) sagittal slice and (C) coronal slices of the MIP centered at the heart 
and (D) transverse slice also centered at the heart. Mice pre-treated with fucoidan (bottom 
panel) showed a clear change in the pharmacokinetics of Ferucarbotran. In the blocked mice 
a higher signal was detected in the heart (blood pool) even after 90 minutes following the 
injection, with more SPIONs detected in the spleen. While in the unblocked mice (top panel) 
the highest signal was detected in the liver and bladder with some still visible in the heart in 
the first 30 minutes, however by the end of the scan almost an exclusive signal is seen in the 
liver and the bladder. The bladder signal corresponds to the excreted metabolised 
radioisotope. 
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Figure 4.20: Biodistribution of 99mTc-Ferucarbotran in different tissues  
Top: Unblocked mice (blue bars) showed almost exclusive uptake of Ferucarbotran by the 
liver, while in blocked mice (red bars) SPIONs could be detected mainly in the blood and the 
spleen. In the tissue to blood ratios (bottom), the most striking difference was observed in 
the liver while the rest of the organs showed similar ratios between the two tested groups. 
***p<0.01, **p=0.05, *p=0.063 as tested with t test.  
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4.3 Discussion  
The work presented in this chapter supported the hypothesis that polysaccharide 
derivatives would prolong the circulatory retention of SPIONs. To test the hypothesis 
in vivo, two SPIONs (Ferucarbotran and Nanomag-D-spio-NH2) were conjugated to 
NIR dyes to measure their blood levels following administration of polysaccharide 
derivatives (DSO4 500, J-18 and fucoidan). Some of these new findings were 
published in ((Abdollah et al, 2014), Appendix 5) and are novel in two aspects: (i) 
methods for conjugation of NIR dyes to Ferucarbotran and (ii) the investigation of 
DSO4 500 and  pharmaceutical agents (J-18 and fucoidan) as blockers of the 
uptake of SPIONs by the RES. 
Tracing SPIONs in blood is confounded by the presence of haemoglobin, rendering 
iron quantification assays very difficult. Alternative methods have been used, for 
instance radioactive iron isotopes (e.g. 59Fe) were incorporated during the synthesis 
process (Majumdar et al, 1990), however this could be difficult for commercially 
available SPIONs. Other approaches used magnetic susceptibility measurements 
(MSM) via a magneto-susceptometer (Maurizi et al, 2014). The approach used in 
chapter 4 utilised NIR imaging which has been used extensively in vivo (Kondepati 
et al, 2008). Haemoglobin, oxyheamoglobin and water show low background 
interference as they exhibit low molar extinction coefficients at NIR wavelengths 
(Kim et al, 2005), this will facilitate measurement of NIR labelled SPIONs in whole 
blood. Whilst, labelling iron oxide nanoparticles with NIR dyes has been reported 
before (Hou et al, 2010; Tang et al, 2014); the mentioned studies fabricated their 
own nanoparticles and added the NIR labelling step during the manufacturing 
process. Meanwhile the work in chapter 4 labelled commercially available SPIONs. 
The initial in vivo experiments were performed with Nanomag-D-spio-NH2 labelled 
with an NHS ester dye. The conjugation reaction was gentle and maintained 
SPIONs colloidal stability. DSO4 500 was tested with NM-DyLight 800; different 
doses of the blocker were evaluated and 30 mg/kg appeared to show the highest 
blocking effect. DSO4 500 injected at doses as high as 50 mg/kg were reported to 
be tolerated by mice without significant lethality (Patel et al, 1983), however a safer 
30 mg/kg was chosen to minimize the side effects which might be induced by the 
toxic nature of DSO4 500. This dose was further evaluated in repeated experiments 
and results revealed a significant 15.6-fold improvement in the blood retention of 
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SPIONs in blocked mice. These results were very promising as well as consistent 
with previous findings in vitro (see chapter 3) and with DSO4 500 published data. 
Next, the main SPION of interest in this thesis was investigated. A conjugation 
strategy to label Ferucarbotran with NIR dyes was developed. The dextran coat 
maintains the stability of the nanoparticles in solution and solubilizes the cores 
(Shubayev et al, 2009), therefore, the coat is crucial in maintaining the colloidal 
stability of Ferucarbotran rendering functionalisation challenging. Most commercially 
available NIR dyes are usually functionalised with maleimide or NHS ester 
functional moieties to react with amines and sulfhydryl groups, respectively. These 
groups are readily available on biomolecules (e.g. proteins) but not on the 
carboxydextran coat of Ferucarbotran which contain either hydroxyl or carboxylic 
moieties.          
The most efficient labelling strategy was achieved via the carboxylic groups on 
Ferucarbotran carboxydextran coat by using a commercially available 
heterobifunctional linker (DBCO-amine). This employed using a combination of 
EDC/NHS and click chemistries under mild reaction conditions without breaking the 
hexose rings of dextran, thus maintaining the colloidal stability of Ferucarbotran. 
Visual inspection of Ferucarbotran solution following the reaction revealed no 
precipitations and only minor changes were recorded with DLS.  
Following the establishment of a conjugation strategy for Ferucarbotran, FC-IRDye 
800 was tested in vitro and in vivo. In vitro results were consistent with those 
observed with RAW 264.7 cell lines in chapter 3, DSO4 500 blocked the uptake of 
FC-IRDye 800 by cells more efficiently than J-18. In vivo, mice pretreated with 
DSO4 500 showed a significant 5-fold increase in the blood levels of Ferucarbotran. 
It appeared that DSO4 500 was more efficient in modifying the rapid clearance of 
NM-DyLight 800 than FC-IRDye 800, as a 15-fold improvement was observed with 
the former.  
In an attempt to optimise DSO4 500 blocking, the blocker was tested at different 
blocking times. Although a blocking effect was observed at all the tested conditions, 
the highest blood levels of Ferucarbotran was observed with 24 hours blocking 
consistent with the work done by Patel et al., which examined the effect of DSO4 
500 on the pharmacokinetic profile of liposomes. Similar to SPIONs, liposomes are 
also rapidly cleared from the circulation by liver Kupffer cells. Patel et al found that 
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liver blocking started as early as 2 hours post injection of DSO4 500 and peaked at 
12 hours. 70% of liver uptake of liposomes was blocked by 24 hours and recovery 
occurred 48 hours later with liver uptake resuming to normal (Patel et al, 1983).  
However a major drawback of using dextran sulfates is their potential toxicity. 
Dextran sulfate has been tested before as an anti-viral in HIV-1 positive patients and 
was poorly tolerated (Flexner et al, 1991). Although it should be taken into account 
that in this study dextran sulfate was used over a period of 2 weeks as a continuous 
i.v. infusion, which is different than if given as a single dose.  
Next, J-18 was tested with FC-IRDye 800; J-18 has smaller molecular weight than 
DSO4 500 (see Table 2.12) and therefore was tested with shorter blocking periods. 
A small improvement was seen with 30 minutes blocking. These results suggest that 
J-18 might need multiple i.v. dosing and/or intraperitoneal administration to achieve 
sustained release of the drug into the blood stream. This might enhance the small 
blocking effect seen in the preliminary experiments presented herein.  
Following the very promising results observed with fucoidan in vitro (see chapter 3), 
the blocker was investigated in vivo. Fucoidan was administered 24 hours prior to 
FC-IRDye 800, no enhancement in the signal was observed compared to DSO4 
500. Similar to J-18, this might be explained by the short half-life of fucoidan and its 
heterogeneity leading to its rapid clearance. Fucoidan tested in this thesis was 
obtained from Sigma Aldrich; it is a crude extract from Fucus vesiculosus with a 
wide size distribution (molecular weight between 20,000 – 200,000 Da (Sigma 
product information sheet)). This might affect its pharmacokinetic behaviour when 
given in vivo making it difficult to control. Nonetheless, when fucoidan was injected 
directly before FC-IRDye 800, a 5.8-fold improvement in the blood signal was 
observed compared to 2.4-fold improvement seen with DSO4 500 tested under the 
same conditions.  
To further evaluate the changes that occur in the biodistribution of Ferucarbotran 
following blocking with fucoidan, a new labelling strategy was applied. 
Ferucarbotran was radiolabelled with the gamma-emitting radioisotope 99mTc to 
trace its biodistribution using SPECT/CT imaging. The conjugation utilized the high 
affinity of a bifunctional bisphosphonate linker to the metal oxide core of 
Ferucarbotran; a technique developed by De Rosales et al (De Rosales et al, 2009) 
and have been used for SPECT detection of USPIO by Sandiford et al (Sandiford et 
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al, 2012). As expected, Ferucarbotran was mainly detected in the liver of the 
unblocked mice. On the contrary, pre-treatment with fucoidan dramatically changed 
the biodistribution of Ferucarbotran as more SPIONs were detected in the 
circulation, indicating efficient blocking of the liver. These findings are very exciting, 
as fucoidan might provide a safer alternative to DSO4 500 with fewer, if any, 
toxicities. Studies done with fucoidan has so far reported no toxic side effects both 
in vitro and in vivo (Kwak, 2014).  
There have been a number of approaches developed for evading the RES uptake of 
SPIONs. These include: (a) reducing their hydrodynamic diameter (i.e. using 
USPIO) to escape recognition by the RES and (b) modifying SPIONs coat with 
hydrophilic polymers (e.g. PEG, PVP, poloxamines and poloxamers) to reduce 
opsonisation (see introduction section 1.4.1.4).  
Many studies utilised the first approach; ultra-small long-circulating dextran coated 
iron oxide nanoparticles (LCDIO) of an average hydrodynamic diameter of 20 nm 
were developed (Moore et al, 2000; Shen et al, 1993). The long half-life of LCDIO 
extended their application beyond RES imaging, for instance they were used in 
vascular imaging (Frank et al, 1994), detection of lymph node metastasis 
(Weissleder et al, 1990) and labelling glioma tumours by passing the 
hyperpermeable tumour-brain interface (Moore et al, 2000; Zimmer et al, 1997). 
Apart from USPIO, PEGylation is still the main method used to create stealth 
nanoparticles (Fan et al, 2011; Gaur et al, 2000; Gupta & Gupta, 2005; Sandiford et 
al, 2012; Shubayev et al, 2009). However, some studies suggest that PEGylation 
might hinder the extravasation of nanoparticles to tumour cells (Li & Huang, 2010). 
Furthermore, the prolonged half-life caused by PEGylation might introduce 
unexpected toxicity or immunogenic responses. For instance stealth modified Doxil® 
significantly reduced the cardiotoxicity of doxorubicin but the prolonged half-life led 
to the emergence of new side effects  (e.g. mucositis and hand-foot syndrome) (Li & 
Huang, 2010; Lyass et al, 2000). In addition, the repeated administration of Doxil® in 
mice have resulted in the generation of anti-PEG IgM antibodies causing 
“accelerated blood clearance (ABC) phenomenon”. Binding of anti-PEG antibodies 
to the PEGylated liposomes led to their rapid clearance by the liver and spleen upon 
second administration (Li & Huang, 2010; Tagami et al, 2010).  
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Some studies combined both approaches of using USPIO and stealth coating. For 
instance Fan et al have coated their nanoparticles with o-carboxymethyl chitosans 
(OCMCS) and folic acid to evade the RES and target tumours expressing folate 
receptors, respectively. Their targeted/stealth nanoparticles were around 40 nm in 
diameter. In this study, the researchers concluded that the presence of OCMCS 
increased the hydrophilicity of SPIONs compared to uncoated ones; this enhanced 
their stability and reduced their recognition by macrophages. They also observed a 
27% reduction in the MRI signal intensity in mice bearing folate receptor positive 
tumours and receiving the targeted/stealth SPIONs (Fan et al, 2011).  
However, all the approaches discussed above would require manipulation of 
nanoparticles during the synthesis process, which is not possible for commercially 
available products with well-studied safety profiles (e.g. Ferucarbotran and 
Endorem®). Therefore, the work presented in this chapter provides a new 
perspective to prolong the half-life of SPIONs without the need to change their 
physicochemical characteristics.  
4.4 Summary and conclusions   
The work presented in this chapter tested one of the central hypotheses of this 
thesis: RES uptake of SPIONs could be blocked using polysaccharide derivatives. 
Results were consistent with the proposed hypothesis; DSO4 500 and fucoidan 
were shown to have the strongest effect on increasing the circulatory retention of 
SPIONs. To prove the hypothesis, a method to trace the blood levels of SPIONs 
was designed by chemically conjugating them to NIR dyes. Nanomag-D-spio-NH2 
was easily functionalised while Ferucarbotran proved to be very challenging. 
Nonetheless, both SPIONs were successfully labelled with NIR dyes while 
maintaining their colloidal stability as confirmed with visual inspection and DLS. 
Furthermore a new method to trace Ferucarbotran in vivo using SPECT/CT imaging 
was introduced. 
In conclusion, dye-labelled and radiolabelled SPIONs were readily traced in vivo 
and a method to modify their poor pharmacokinetics was established. The work 
presented in this chapter provides a step towards the clinical development of 
SPIONs by overcoming their rapid RES clearance.  
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5.1 Introduction 
The aim of the work described in this chapter was to address one of the main 
challenges of cancer nanomedicine: the need for functionalisation of nanoparticles 
with cancer targeting moieties. DARPins, small antibody-like proteins described in 
section 1.9.4, were chosen for use as targeting agents because they are small and 
stable proteins that are readily engineered to have a unique cysteine tag for site-
specific attachment to SPIONs.  
E69 (Boersma et al, 2011), a DARPin reactive with the epidermal growth factor 
receptor 1 (EGFR/HER1/ErbB1) tyrosine kinase transmembrane receptor was 
chosen as an exemplar DARPin for attachment. EGFR is overexpressed in many 
tumours for example glioblastoma (Chong & Jänne, 2013; Sanai et al, 2005), head 
and neck cancers, gastric, breast, cervical and non-small cell lung cancers 
(Mendelsohn & Baselga, 2006; Nicholson et al, 2001) and lined to poor prognosis 
(Boersma et al, 2011).   
The EGFR family comprises of four structurally related members: ErbB1 
(EGFR/HER1), ErbB2 (HER2/neu), ErbB3 (HER3) and ErbB4 (HER4) (Goffin & 
Zbuk, 2013; Mendelsohn & Baselga, 2006; Sheng & Liu, 2011). They consist of 
extracellular, transmembrane and cytoplasmic regions. Eleven ligands (e.g. EGF, 
TGF-α and neuregulin 1-4) are known to bind to these receptors, which result in 
their homodimerisation or heterodimerisation and subsequent conformational 
changes (with the exception of HER2, which can form stable dimers without ligand 
binding). Autophosphorylation of the cytoplasmic domain then occur triggering 
numerous downstream signalling pathways (Goffin & Zbuk, 2013; Sheng & Liu, 
2011).  
EGFR receptors play a critical role in normal tissue as well as in cancer. The 
deregulation of this family has been linked to malignant transformation and 
prognosis (Mendelsohn & Baselga, 2006). Several mechanisms were linked to 
abnormal receptor activation (e.g. gene amplification, overexpression of the 
receptors or their ligands, activating mutations and/or loss of negative regulatory 
mechanisms) (Mendelsohn & Baselga, 2006). The EGFR family has therefore been 
of great therapeutic interest especially in cancer and several therapies are being 
developed to target these receptors (Chong & Jänne, 2013; Mendelsohn & Baselga, 
2006). 
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Targeting SPIONs with E69 is advantageous because E69 is biologically inert 
(Boersma et al, 2011). The extracellular region of EGFR consists of four domains (I-
IV); EGF binds simultaneously to two sites on domain I and III leading to receptor 
dimerization and activation (Li et al, 2005). The antagonistic therapeutic antibody 
Cetuximab binds exclusively to domain III; the variable heavy chain (VH) of the 
bound antibody sterically inhibits the dimerization of the receptor and consequently 
the downstream signalling pathways (Bangham, 2005; Li et al, 2005). On the 
contrary to these biologically active binders, E69 binds to domain I away from the 
binding sites of both EGF and Cetuximab. 
Functionalised SPIONs able to specifically target the EGFR receptor could 
potentially facilitate the use of targeted magnetic hyperthermia therapy for cancers 
overexpressing this receptor (e.g. gliomas, colorectal carcinomas and lung cancers).  
5.1.1 Experimental approach 
Ferucarbotran was site-specifically conjugated to E69 and a control DARPin G3, 
reactive with HER2 (Goldstein et al, 2014; Zahnd et al, 2007). 
Assays were developed to investigate the presence of DARPins on the surface of 
SPIONs following the conjugation reaction; these include: western blots and DLS 
measurements. However, the presence of E69 on the coat of Ferucarbotran does 
not necessarily ensure that targeting could be achieved. Therefore, a series of 
immuno- and cellular assays were used to examine the specificity of Ferucarbotran-
E69 (FC-E69) conjugates to the target protein, EGFR.  
Immunoassays included the development of a suitable ELISA assay to examine the 
specificity of FC-E69. In order to develop cellular assays; EGFR expression on 
different cell lines was examined with western blotting and flow cytometry. Next, 
ferrozine assay was used to test the uptake of conjugates on the different cell 
models including cells expressing endogenous EGFR (e.g. U-251 MG cells) as well 
as cells retrovirally transduced with EGFR (SupT1 cells). 
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5.1.2 Research Aims and Objectives  
Aims: To develop a system to functionalise Ferucarbotran with cancer targeting 
agents. 
Objectives: 
• Conjugate Ferucarbotran to DARPins via site-specific attachment. 
• Evaluate the success of the conjugation chemistry via western blotting and 
DLS. 
• Develop various ELISA assays to evaluate the binding of FC-E69 to EGFR.  
•  Establish suitable cell assays for the investigation of the specificity of the 
conjugates. 
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5.2 Results  
5.2.1 Conjugation of Ferucarbotran to DARPins  
A 2-step approach was used to link the carboxylic groups present on the 
carboxydextran coat of Ferucarbotran to the cysteine tag of the DARPins. First, a 
standard EDC/NHS chemical conjugation was employed to link Ferucarbotran to the 
amine moiety of a bifunctional linker; BMPH. Second, the maleimide moieties of the 
linker, now attached to the nanoparticles, were reacted with the thiol groups present 
on the cysteine tags of the DARPins (Figure 5.1).   
 
Figure 5.1: Schematic presentation of the conjugation strategy between Ferucarbotran 
and DARPins (E69 and G3). 
A two-step approach was employed by using a bifunctional linker: BMPH. The amine part of 
the linker was first conjugated to the carboxylic groups available on the carboxydextran coat 
of Ferucarbotran followed by the reaction of the maleimide moieties of the linker to the 
cysteine tags of the DARPins.   
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5.2.2 Purification of Ferucarbotran-DARPins conjugates using Superdex 75 
Following the reactions, Ferucarbotran-DARPin conjugates were purified with size 
exclusion chromatography (SEC) on Superdex 75. First, a sample of E69 tested on 
Superdex 75 was eluted as a single peak and was shown on a Coomassie stained 
SDS-PAGE to have the right molecular weight (21.4 KDa) (Figure 5.2).   
Ferucarbotran conjugated to E69 (FC-E69) was eluted first in a single peak followed 
by a small peak of free E69 at the tail of the conjugate peak. Fractions 4 to 15 were 
pooled together and named “peak 1”, which corresponds to the conjugate FC-E69. 
Coomassie stained reducing gel confirmed the presence of E69 in peak 1 and 
fraction 24 (small peak for free E69). The presence of free E69 in peak 1 is due to 
the reducing conditions used in preparing the samples which leads to the 
dissociation of the bond between Ferucarbotran and E69 (Figure 5.3 top).       
The control anti-HER2 DARPin (G3) was conjugated to Ferucarbotran and then 
purified in a similar manner to FC-E69. Ferucarbotran-G3 (FC-G3) conjugate was 
eluted first followed by a smaller peak for G3. Fractions 5 to 17 were pooled 
together and named ‘peak 1’, which corresponds to the conjugate FC-G3. 
Coomassie stained gel confirmed the presence of G3 in fractions 40 and 47, which 
corresponds to free G3. While a faint band was seen in peak 1 due to the reducing 
conditions (Figure 5.3 bottom).      
The eluted samples were further tested with: 
• Western blotting: using polyclonal anti-DARPin mouse sera to detect the 
presence of DARPins on the conjugates. 
• Dynamic light scattering (DLS): to measure the change in the nanoparticle size 
following conjugation.   
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Figure 5.2: Elution of E69 on Superdex 75 packed column.  
(A) Chromatogram showing the elution of E69 as a single peak. (B) Coomassie stained gel 
showing fraction 10 (peak) to contain ~20 KDa protein consistent with E69 molecular weight. 
 
Figure 5.3: Purification of FC-E69 (Top) and FC-G3 (bottom) conjugates on Superdex 
75 column. 
A, C: Chromatogram showing the elution of FC-E69 or FC-G3 first as a single peak followed 
by the free E69 or G3, respectively. A picture of the column showing FC-E69 (brown) moving 
along the column as a single peak (top middle). B, D: Coomassie stained 16% gel 
confirming the presence of free E69 in fraction 24 and free G3 in fractions 40 and 47. 
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5.2.3 Characterisation of the conjugates  
5.2.3.1 Western blotting 
Western blotting was used for sensitive detection of DARPins on the conjugates. 
Samples were prepared either in reducing or non-reducing loading buffer. As shown 
from Figure 5.4 A, for FC-E69: peak 1 and fraction 24 tested positive for E69. Under 
non-reducing conditions, E69 could be detected at the top of the gel, as 
Ferucarbotran is too big to move through the gel, nevertheless some free E69 (at 
~22 KDa) was detected. Fraction 24, corresponding to excess unreacted E69, also 
tested positive. Under reducing conditions, no E69 was detected at the top of the gel 
due to the reduction of the bond. Two more peaks (fractions 45 and 62) were seen 
in the chromatogram, both tested negative for E69 and were not further analysed. 
As shown from Figure 5.4 B, similar findings were observed with FC-G3. The 
conjugate (FC-G3) was eluted first in a single peak named ‘peak 1’. Peak 1 was 
investigated at 150 and 300 µgFe/ml; both tested positive for G3 at the top of the gel 
(under non-reducing conditions). Fractions 40 and 47, corresponding to free G3, 
also tested positive. Fraction 65 appeared to be negative for G3 and was not further 
analysed. Under reducing conditions, G3 could be detected at ~ 14 KDa 
corresponding to monomer G3.     
5.2.3.2 DLS  
The conjugates were characterised using DLS to monitor the changes in their 
hydrodynamic diameter and PDI. A summary of the DLS characterisations is shown 
in Table 5.1. A 22.6 nm and 24.48 nm increase in the Z-average hydrodynamic 
diameter of FC-E69 and FC-G3, respectively, was observed with small changes in 
the PDI of the measured samples. DLS have also shown that the conjugate samples 
were uniform with no signs of destabilisation of the nanoparticles. Zeta potential 
measurement revealed a -4.6 mV and -2.7 mV increase in the charge of FC-E69 
and FC-G3, respectively, compared to unconjugated Ferucarbotran. The increased 
negative charge might be accounted to the negative charge of the DARPins on the 
surface of SPIONs.  
As shown in Figure 5.5, when size-distribution by intensity histograms were overlaid, 
a clear shift in the size distributions of both conjugates (FC-E69 and FC-G3) was 
observed in comparison to unconjugated Ferucarbotran. These results are 
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consistent with the presence of proteins on the surface of Ferucarbotran leading to 
an increase in the hydrodynamic diameter.   
 
Figure 5.4: Detection of DARPins on the conjugates with western blotting 
Samples were run on 16 % SDS-PAGE gel and DARPins detected with anti-E69 (A) or anti-
G3 (B) polyclonal mouse sera followed by anti-mouse HRP secondary antibody. A: Western 
blots to detect E69. Under non-reducing conditions; for FC-E69 the majority of E69 could be 
detected at the top of the gel where FC is expected to be found while under reducing 
conditions all E69 is found at ~ 22 KDa. B: Western blots to detect G3. Under non-reducing 
conditions the majority of G3 on FC-G3 could be detected at the top of the gel while under 
reducing conditions all G3 is found at ~ 14 KDa. Load samples are the unpurified conjugates 
prepared at either 1:1000 for FC-E69 or 1:500 for FC-G3. Control FC samples were 
prepared at 1 mgFe/ml. 
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Table 5.1: Characterisation of Ferucarbotran-DARPins conjugates 
Sample 
Hydrodynamic diameter Zeta Potential (mV) 
Z-Average (nm) PDI Mean (mV) Zeta Deviation (mV) 
FC  51.51 0.198 -28.3 17.2 
FC-E69 74.11 0.230 -32.9 13.7 
FC-G3 75.99 0.238 -31.0 8.32 
 
 
Figure 5.5: Size distribution by intensity of Ferucarbotran conjugates. 
DLS measurements showing the size distribution of unconjugated Ferucarbotran (red), FC-
E69 (green) and FC-G3 (blue). A clear shift in the size distribution could be seen following 
the conjugation due to the presence of proteins on the surface of the nanoparticles.    
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5.2.4 Development of ELISA assays 
The ELISA assays were developed with a fluorescently labelled secondary antibody 
rather than the more commonly used horseradish peroxidase (HRP) 3,3’-
diaminobenzidine (DAB) because the brown colour of Ferucarbotran interferes with 
the DAB signal giving a high background.  
5.2.4.1 Indirect ELISA 
 A schematic presentation of the ELISA layout is shown in Figure 5.6; first the plate 
was coated with the target protein then the samples were added. Suitable primary 
and secondary antibodies were then applied to detect the specific binding. Two 
primary antibodies were used: anti-E69 to detect the DARPins present on 
Ferucarbotran and anti-dextran to detect Ferucarbotran itself, an anti-mouse-IRDye 
800 CW was employed as a secondary antibody, except for Cetuximab treated wells 
which were detected with an anti-human DyLight 649 antibody and no primary 
antibody. The signal of the fluorophore labelled secondary antibodies was measured 
on Odyssey NIR scanner at 700 and 800 nm.  
Results are shown in Figure 5.7. In the anti-E69 treated samples, a positive signal 
was observed with FC-E69 and with the positive controls: E69 and Cetuximab. G3 
treated wells showed a small positive signal, this can be due to the cross reaction of 
anti-E69 with G3 DARPins. However, in the anti-dextran treated wells, all wells 
treated with Ferucarbotran (regardless of its functionalisation) gave a positive signal. 
This can be accounted to the unspecific binding of Ferucarbotran samples to the 
ELISA plate giving false positive results.      
 
Figure 5.6: Indirect 
EGFR ELISA layout 
ELISA plates were 
coated with EGFR 
followed by blocking then 
the addition of samples, 
primary antibodies and 
finally the fluorophore 
labelled secondary 
antibodies.  
Detect%with%mouse%an/0E69%serum%
or%an/0dextran%%%
Detect%with%an/0mouse%IRDye%
800%CW*%%
*For%Cetuximab:%detect%with%an/0human%DyLight%649%
EGFR% EGFR% EGFR% EGFR% Coat%with%EGFR%
Treat%with%conjugates,%
Ferucarbotran,%DARPins,%
Cetuximab*%or%PBS%
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Figure 5.7: Indirect EGFR ELISA results 
A: picture of the fluorescence signal obtained from the ELISA plate when measured at 800 
nm (green wells) and at 700 nm (for Cetuximab, red wells). B: table showing the samples 
corresponding to each well. C: column chart representing the average signal intensity of 
each sample and error bars are for the standard deviation. In the anti-E69 treated wells: FC-
E69, E69 and Cetuximab gave a positive signal. In the anti-dextran treated wells, it became 
apparent that Ferucarbotran was binding unspecifically to the ELISA plate regardless of the 
functionalisation. Signals of the PBS coated corresponding controls is subtracted from the 
signals intensities.  
5.2.4.2 Immobilizer plates ELISA 
The low hydrophilicity of Nunc™ Amino™ Immobilizer hydrophobic polysorp plates 
was thought to reduce the unspecific adsorption of the nanoparticles to the surface 
of the plate. Binding of biomolecules to the Immobilizer plate occurs via covalent 
linkage of amino or sulfhydryl groups (depending on pH) available on the 
biomolecules to reactive electrophilic groups tethered on a spacer arm on the 
surface of the plate (Thermo Fisher Scientific Inc., 2011). EGFR was immobilized on 
the surface of these plates via sulfhydryl (SH) groups then the samples were added, 
followed by anti-dextran to detect Ferucarbotran, anti-E69 or anti-G3 to detect E69 
and G3 treated wells, respectively. Then the binding was detected using an anti-
mouse IRDye 800 CW. For Cetuximab treated wells, an anti-human DyLight 649 
was used to detect the binding (Figure 5.8). 
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Results shown in Figure 5.9 revealed that Ferucarbotran bound non-specifically to 
the plate regardless of its functionalisation. Furthermore, although Cetuximab 
showed a positive signal, confirming the presence of EGFR on the plate, the signal 
observed for E69 was very low. One explanation could be accounted to the random 
covalent linkage between the plate and EGFR which might have affected the 
availability of E69 binding sites on EGFR’s domain I causing the low positive signal 
observed, but not the epitope of Cetuximab on domain III of EGFR’s extracellular 
region.    
Due to the difficulties in preventing Ferucarbotran from sticking unspecifically to the 
plastic microtiter plate, a different approach was investigated using sandwich ELISA.   
 
Figure 5.8: EGFR ELISA layout using Nunc™ Amino™ Immobilizer plates 
The plates have low hydrophilicity and are designed to have nucleophilic groups on a 
tethered arm attached to the plastic plate. At pH 7.5 these active sites react with the 
sulfhydryl groups present on EGFR to covalently link it to the plate. The samples are then 
added followed by primary and secondary antibodies.   
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Figure 5.9: EGFR ELISA results using Nunc™ Amino™ Immobilizer plates 
Ferucarbotran (FC) bound unspecifically to the plate regardless of conjugation. Cetuximab 
was able to bind to EGFR while E69 gave a small positive signal. Anti-dextran was used to 
detect FC and its conjugates, anti-E69 and anti-G3 used to detect E69 and G3. Anti-mouse 
IRDye 800 CW was used to detect them while Cetuximab was detected with anti-human 
DyLight 649. A: picture of the fluorescence signal obtained from the ELISA plate when 
measured at 800 nm (green wells) and at 700 nm (for Cetuximab, red wells). B: table 
showing the samples corresponding to each well. C: column chart representing the average 
signal intensity of each sample and error bars for the standard deviation. Signals of the PBS 
coated corresponding controls are subtracted from the signals intensities.  
5.2.4.3 Sandwich ELISA 
In this approach the target protein is “sandwiched” between the ligand and the 
detection antibodies as shown in Figure 5.10. It was hypothesised that this layout 
would provide a means to overcome non-specific binding of Ferucarbotran to plastic 
plates. It was made possible because E69 and Cetuximab bind to different epitopes 
on the EGFR receptor (Boersma et al, 2011). Thus the ELISA plate was coated with 
FC, FC-E69, FC-G3, E69, G3 or PBS. The samples were subsequently incubated 
with EGFR, which was detected with Cetuximab followed by anti-human DyLight 
649. The signal was measured at 700 nm on Odyssey NIR scanner.  
Results of the sandwich ELISA, shown in Figure 5.11, demonstrated that this 
approach is feasible and that E69 is in indeed successfully conjugated to 
Ferucarbotran in functional form; a positive signal was observed in FC-E69 and E69 
treated wells, as they were able to capture EGFR, unlike the rest of the samples. 
This layout might also give freedom to the EGFR protein to conformationally 
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orientate itself to bind to E69 immobilized on the surface of Ferucarbotran or on the 
plate.  
 
Figure 5.10: Sandwich EGFR ELISA layout 
ELISA plate was coated with the samples then the target protein (EGFR) was “sandwiched” 
between them and Cetuximab. Finally fluorophore labelled anti-human antibody was used to 
detect the specific binding.   
 
Figure 5.11: Sandwich EGFR ELISA results 
Both FC-E69 and E69 showed their ability to capture EGFR and tested positive, unlike the 
rest of the controls. Signal intensity was measured at 700 nm. A: picture of the fluorescence 
signal obtained from the ELISA plate when measured at 700 nm B: table showing the 
samples corresponding to each well. C: column chart representing the average signal 
intensity of each sample and error bars for the standard deviation. Signals of the PBS coated 
corresponding controls are subtracted from the signals intensities. 
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5.2.5 EGFR expression on U-251 MG cells  
Having established the binding of FC-E69 to EGFR in ELISA, the conjugates were 
then evaluated on cells.  
U-251 MG, human glioma cell line, was first investigated with the conjugates. U-251 
MG cells were previously reported to express intermediate levels of endogenous 
EGFR (Kang et al, 2006; Stea et al, 2003; Zhang et al, 2005). To further confirm 
EGFR expression on these cells, western blotting and flow cytometry were 
employed. 
Western blot (Figure 5.12) revealed that U-251 MG cells express moderate levels of 
endogenous EGFR similar to positive control cells (Hela53). Next, Binding of E69 to 
U-251 MG cells was confirmed with flow cytometry. Positive controls used were 
commercially available therapeutic antibodies: Cetuximab (anti-EGFR antibody) and 
Herceptin (anti-HER2). As shown in Figure 5.13, E69 and Cetuximab tested positive 
on the U-251 MG cells indicating the expression of EGFR on the cells while both 
anti-HER2 G3 and Herceptin tested negative.  
 
 
Figure 5.12: Western blot showing EGFR expression on U-251 MG cells 
Cell lysates were loaded into a 10% SDS-PAGE gel and EGFR expression was detected 
with a rabbit anti-EGFR antibody followed by an anti-rabbit HRP antibody. A mouse anti-β 
tubulin was used as a loading control followed by an anti-mouse HRP secondary antibody. 
U-251 MG glioma cells tested positive for EGFR similar to positive control (Hela53 cells) 
while A375 cells were negative for EGFR. 
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Figure 5.13: Flow cytometry analysis of EGFR expression on U-251 MG cells 
A: Gating was done using forward scatter area (FSC-A) and side scatters area (SSC-A) 
plots to identify intact cell population. Further gating was done to select for the singlet cell 
population using SSC area versus SSC height. B: Cells were treated with DARPins (E69 
and G3) and control antibodies (Cetuximab (anti-EGFR) and Herceptin (anti-HER2)) 
followed by Allophycocyanin (APC) labelled secondary antibodies. For DARPins: the 
detection antibody (anti-E69 or anti-G3) followed by anti-mouse-APC antibody was used as 
a negative control, while cells treated with anti-human APC antibody were used as negative 
control for Cetuximab and Herceptin. E69 and the positive control Cetuximab bound 
specifically to EGFR (left) with no detected binding for G3 or Herceptin on the cells. APC 
fluorescence signal is plotted on X-axis versus cell counts.  
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5.2.6 Uptake of conjugates on U-251 MG cells  
Next, the conjugates were tested on the glioma cells and iron content was 
measured with the ferrozine assay. As seen in Figure 5.14, there was a substantial 
increase in the uptake of FC-E69 by the cells compared to FC alone. However, the 
additional control of FC-G3 showed similar uptake to FC-E69, indicating that the 
apparent specific uptake of FC-E69 is due to an increase in non-antigen specific 
uptake of the nanoparticles following conjugation. Pre-treatment with DSO4 500 led 
to a decrease in the unspecific uptake, nonetheless, no increase in the uptake of 
FC-E69 was seen compared to FC-G3. 
The lack of specific binding might have been accounted to the presence of serum 
proteins in the cell culture media. Serum proteins could be adsorbed on the surface 
of Ferucarbotran forming a protein corona and masking E69 binding to EGFR. For 
this reason the binding was tested in the absence of serum. Results (Figure 5.14) 
revealed a generalised increase in the uptake of FC and its conjugates in the 
absence of serum. However, no clear difference was observed in the uptake of FC-
E69 compared to FC-G3. Blocking this unspecific uptake was achieved by pre-
treatment with DSO4 500, but similar to pervious results, no specific uptake of FC-
E69 was observed.  
Next, the conjugates were investigated on paired EGFR +/-  isogenic cell lines for 
more rigorous studies of non-antigen specific background cell uptake. 
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Figure 5.14: Uptake of Ferucarbotran-DARPins conjugates on U-251 MG cells detected 
with ferrozine assay 
Uptake of Ferucarbotran conjugates was investigated on U-251 MG cells in the presence 
(blue bars) and absence (red bars) of serum. Cells showed an increase in the uptake of FC-
E69 and FC-G3 compared to non-functionalised Ferucarbotran, which was further enhanced 
in the absence of serum. Cells pre-treated with DSO4 500 showed a reduction in the 
unspecific uptake of Ferucarbotran by the cells; nonetheless, no specific uptake was 
detected with FC-E69. Bars represent the means of readings of 3 wells/treatment and error 
bars are for standard deviations.    
5.2.7 Selection of isogenic cell models  
Retrovirally-transduced EGFR +/- cell lines (293T and SupT1 cells) were kindly 
provided by Dr Martin Pule’s lab (UCL Cancer Institute) and used to develop 
appropriate cell models to test the FC-E69 conjugates. EGFR and HER2 expression 
on these cell lines was investigated using western blotting while E69 binding was 
evaluated with flow cytometry.  
5.2.7.1 Western blotting 
Results showed that SupT1 and 293T cells tested negative for EGFR but their 
transduced counterparts were positive (Figure 5.15 A and B). SupT1 cells 
transduced with EGFR variant III (vIII), were also generated as a negative control 
because E69 does not bind to this variant. EGFR vIII had a lower molecular weight 
due to the truncation of part of domain I of the extracellular region of the receptor 
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(Klausz et al, 2011) (Figure 5.15 B). Hela53 cells were used as positive controls 
while RAW 264.7 and A375 cells were negative controls.  
HER2 expression results are shown in Figure 5.15 C. 293T cells expressed HER2 
similar to the positive controls (BT 474 cells), while SupT1 cells tested negative for 
the receptor similar to the negative control cells; MDA-MD 468. 
 
Figure 5.15: Western blots showing EGFR and HER2 expression in different cell lines 
Cell lysates were loaded into 7.5% SDS-PAGE gel. Blots were incubated with rabbit anti-
EGFR (A and B) or anti-HER2 antibody (C) or mouse anti-β tubulin antibody, as a loading 
control, before being treated with the corresponding HRP conjugated secondary antibodies. 
(A) and (B): non-transduced 293T and SupT1 cells tested negative for EGFR similar to 
negative controls (RAW 264.7 and A375 cells). EGFR transduced SupT1 and 293T cells 
tested positive similar to positive control cells (Hela53). Anti-EGFR antibody reacts with the 
truncated receptor EGFRvIII as shown in SupT1-EGFRvIII (B), which ran lower than EGFR. 
(C) 293T cells tested positive for HER2 similar to positive control BT 474, while SupT1 cells 
are negative for HER2. 
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5.2.7.2 Flow cytometry  
Binding of E69 to EGFR was investigated on the isogenic cell lines. The non-
transduced cells were used as a negative control to account for cells 
autofluorescence and detect any unspecific binding.  
E69 binding on 293T cells  
Cells were gated as shown in Figure 5.16. The gating was done on non-transduced 
and unstained 293T cells. Cells treated with secondary antibodies only showed no 
background above the unstained cells (Figure 5.17).  
Results showed that whilst both E69 and Cetuximab (positive control) bound 
strongly to EGFR-transduced 293T cells, both proteins also appeared to bind to 
non-transduced 293T cells (Figure 5.18), despite the lack of EGFR on these cells 
(as tested with western blotting, Figure 5.15). This could be due to the very low 
levels of endogenous EGFR present on 293T cells (Pao et al, 2004; Pennock & 
Wang, 2008). Therefore, although the binding appeared to be stronger in EGFR 
transduced cells than their non-transduced counterparts (Figure 5.18), the 293T 
model was considered unsuitable for specific testing of FC-E69 conjugates. 
Furthermore, 293T cells express HER2 rendering them unsuitable model for testing 
G3 conjugates (used as control).  
 
Figure 5.16: Gating for intact singlet cells using unstained and non-transduced 293T 
cell lines. 
Forward (FS) and side scatters (SS) were used to identify intact live cell population in the 
flow cytometry samples of 293T cells. Further gating was done to select for the singlet cell 
population using FS versus pulse width plots.  
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Figure 5.17: Histograms of 293T and 293T-EGFR cells treated with secondary 
antibodies only 
No background was detected when cells were treated with secondary antibodies only (anti-
mouse Alexa 488 and anti-human Alexa 488) compared to unstained cells.  
 
 
Figure 5.18: Overlay of Cetuximab and E69 binding on EGFR transduced and non- 
transduced 293T cells. 
Cells were treated with E69 and Cetuximab followed by Alexa Fluor 488 labelled secondary 
antibodies. Compared to untreated controls of both cell lines (blue: 293T and red: 293T-
EGFR), a shift in the fluorescence intensity can be seen in both cell lines when treated with 
Cetuximab and E69. However, a greater shift in the fluorescence can be seen in the EGFR 
transduced cell lines (orange) compared to non-transduced cells (green). Alex Fluor 488 
fluorescence is plotted on X-axis versus cell counts.  
Cetuximab E69 
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E69 binding on SupT1 cells  
Three different types of SupT1 cells were tested: the non-transduced cell line 
(SupT1-NT) was used as negative control; cells transduced with EGFR (SupT1-
EGFR) and control cells transduced with EGFRvIII (SupT1-EGFRvIII). Cetuximab 
and MR1.1 (anti-EGFR and anti-EGFRvIII antibodies, respectively (Klausz et al, 
2011)) were used as positive controls.  
Gating for intact cells in the samples was performed on the unstained SupT1-NT by 
plotting forward (FS) versus side scatters (SS) (Figure 5.19). 
 
Figure 5.19: Gating applied to select 
intact SupT1 cells 
Forward (FS) and side scatters (SS) were 
used to identify intact cell population 
using unstained and non-transduced 
SupT1 cells as a control.  
 
 
 
Results (Figure 5.20) showed that none of the tested proteins bound to SupT1-NT 
cells. While Figure 5.21 demonstrated that E69 bound specifically to SupT1-EGFR 
but not to SupT1-EGFRvIII. In contrast, Cetuximab, which is known to cross-react 
with EGFRvIII, bound to both cell types. G3 (anti-HER2) tested negative on all cell 
lines.  
The possibility that the serum proteins present in the cell culture media might 
interfere with E69 binding to EGFR was evaluated by flow cytometry. Binding was 
tested on SupT1-EGFR cells in the presence of different concentrations of foetal 
bovine serum (FBS) ranging from 0.1 up to 10% in cell culture media (RPMI). No 
reduction in the binding ability of E69 was detected in the presence of serum as 
shown in Figure 5.22.  
In summary results have shown that SupT1 cells do not express any endogenous 
EGFR or HER2 rendering them a potentially more suitable model than 293T for 
testing specific EGFR binding of the FC-E69 conjugates. 
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Figure 5.20: Binding of DARPins and 
control antibodies to SupT1-NT cells 
None of the tested antibodies or DARPins 
bound to the control non-transduced cell 
line (SupT1-NT). APC fluorescence signal 
is plotted on X-axis versus cell counts.    
 
 
 
 
Figure 5.21: Binding of E69 to transduced SupT1 cells (SupT1-EGFR and SupT1-
EGFRvIII) using flow cytometry.  
Cells were treated with DARPins (E69 and G3) and positive controls (Cetuximab and MR 
1.1) followed by APC labelled secondary antibodies. Only E69 bound specifically to EGFR 
(bottom left) with no detected binding on EGFRvIII cells. Cetuximab (top left) and MR 1.1 
(top right) cross-reacted with EGFRvIII and EGFR, respectively. Control anti-HER2 DARPin 
(G3, bottom right) did not bind to any of the tested cell lines. APC fluorescence signal is 
plotted on X-axis versus cell counts.   
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Figure 5.22: E69 binding to SupT1-EGFR 
cells in the presence of serum 
E69 binding to EGFR was challenged in the 
presence of FBS (0 to 10%) using flow 
cytometry. No effect on the binding was 
observed. APC fluorescence signal is plotted 
on X-axis versus cell counts. 
 
 
5.2.8 Uptake of conjugates by SupT1 cells 
Ferucarbotran and its conjugates were incubated with the different SupT1 cell lines 
and the intracellular iron uptake was evaluated by ferrozine assay.  Results showed 
that, in standard cell culture conditions, the uptake of FC conjugates was higher 
than non-functionalised FC, but no EGFR specificity was detected (Figure 5.23 A).  
This pattern was consistent with results observed with the previously investigated 
glioma cell line (U-251 MG) (Figure 5.14). 
The possibility that serum proteins formed a corona around Ferucarbotran, shielding 
the DARPins on its surface, was addressed by repeating the experiment in serum 
free media. Here, a similar pattern of uptake was observed (Figure 5.23 B) but with 
less differential uptake between the FC conjugates and the non-functionalised FC; 
in general higher pgFe/cell levels were observed in the absence of serum especially 
with SupT1-EGFRvIII cells (Figure 5.23 B Vs. Figure 5.23 A). Pre-treatment with 
DSO4 500 showed a decrease in the unspecific uptake, nevertheless, no increase 
in the uptake of FC-E69 was seen compared to FC-G3 in SupT1-EGFR cells. 
Interestingly, it appears that DSO4 500 was less efficient in the presence of serum. 
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Figure 5.23: Uptake of FC and its conjugates by SupT1 cells 
SupT1 cells (NT, EGFR and EGFRvIII) were incubated with SPIONs (FC, FC-E69 or FC-G3) 
for 4 hours in cell culture media, (A) containing serum or (B) serum free, with or without pre-
treatment with DSO4 500, before being washed, lysed and the iron content measured by the 
ferrozine assay. No evidence of specific uptake of FC-E69 by SupT1-EGFR cells was 
detected under the tested conditions. It also appears that DSO4 500 is less efficient in 
blocking SPIONs uptake by cells in the presence of serum. Results represent average of 3 
wells/treatment and error bars are for standard deviation.     
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5.3 Discussion  
The work presented in this chapter describes the development of methods for site-
specific attachment of anti-EGFR DARPin to Ferucarbotran and the evaluation of 
the cancer targeting potential of the conjugates. 
Many studies have functionalised SPIONs with proteins (Bouras et al, 2015; 
Kaluzova et al, 2015) and most functionalisation strategies utilise random 
associations to functional groups present on the surface of the targeting protein to 
link it to the nanoparticles. This is usually achieved via the amino, sulfhydryl or 
carboxylic groups present on lysine, cysteine or glutamic acid residues, respectively, 
of the proteins. Nevertheless, the random associations to these amino acids might 
interfere with the protein’s binding site to the target ligand. To overcome this 
problem, the work presented in this thesis employed a site-specific conjugation 
strategy to link DARPins to Ferucarbotran. The conjugation was achieved via 
heterobifunctional linker (BMPH) to a unique C-terminal cysteine tag on the 
DARPins away from its binding domains, thus maintaining DARPin functionality. The 
results were particularly encouraging as all other Ferucarbotran conjugation 
methods investigated in this project were not successful. Furthermore, there is very 
little published data on Ferucarbotran labelling techniques. Aurich et al reported 
covalently labelling Ferucarbotran with fluorescent markers via reductive amination 
of the hydroxyl groups (Aurich et al, 2012). While another study by Jeon et al 
conjugated Ferucarbotran to doxorubicin via ionic rather than covalent linkage; the 
positively charged chemotherapeutic drug was loaded on the negatively charged 
carboxydextran coat of Ferucarbotran (Jeon et al, 2014). However, to the best of my 
knowledge, there have been no published reports on successful attachments of 
proteins to Ferucarbotran.   
Following the conjugation reaction, methods were established to: (i) purify the 
conjugates and (ii) confirm the success of the conjugation reaction by developing 
assays to test the presence of DARPins on the surface of the SPIONs. For this 
purpose Superdex 75, a SEC matrix, was used for purification, furthermore, western 
blotting and DLS measurements showed the presence of DARPins on the surface of 
the conjugates. After this analysis, the conjugates were tested for their ability to bind 
to the target antigen. Developing ELISA assays to confirm the specificity of FC-E69 
to EGFR proved to be difficult. Two different microtiter plates were investigated, the 
hydrophilic Nunc™ MaxiSorp and the hydrophobic Nunc™ Amino™ Immobilizer 
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plates, where Ferucarbotran bound unspecifically to both plates causing high 
background signal. To overcome these difficulties, a sandwich ELISA assay was 
developed in which the strong interaction between Ferucarbotran and the microtiter 
plate was exploited. Both E69 and FC-E69 tested positive while Ferucarbotran 
controls (FC and FC-G3) tested negative suggesting specific binding of EGFR to 
FC-E69.  
Despite the promising ELISA results, the specificity of FC-E69 conjugate was lost on 
cells. These findings direct us back to the challenging cellular interactions of 
SPIONs, which are still to be fully understood. Prior to functionalisation, the uptake 
of Ferucarbotran by a wide range of tumour and non-tumour cell lines was 
investigated in chapter 3. The negatively charged Ferucarbotran was unspecifically 
internalised by all the tested cells (macrophages, tumour cell lines and NSCs). 
Thus, it was expected that the same pattern would persist upon functionalisation 
with DARPins since the conjugates exhibit higher negative charge and bigger 
hydrodynamic diameters when compared to Ferucarbotran (Table 5.1). However, 
the conjugates were internalised by the cells more efficiently than the non-
functionalised Ferucarbotran. Furthermore, pre-treatment with the blocker DSO4 
500, which was previously shown to reduce the unspecific uptake of Ferucarbotran 
by cells, further highlighted that the increased uptake was not mediated via EGFR 
as both FC-E69 and FC-G3 uptake by cells was reduced. 
The formed protein coronas around nanoparticles upon exposure to serum were 
reported to occur rapidly and were shown to be extremely complex (Tenzer et al, 
2013). For instance the study done by Tenzer et al, on silica and polystyrene 
nanoparticles with various sizes and surface charges, revealed a corona of about 
300 different proteins formed within seconds of exposure of nanoparticles to human 
plasma (Tenzer et al, 2013). Furthermore, it has been reported that the formed 
corona around targeted protein-functionalised nanoparticles could shield the binding 
sites of the protein leading to loss of target specificity (Salvati et al, 2013). 
Therefore, the cell uptake experiments in chapter 5 were repeated in serum free 
media. Results of these experiments revealed a generalised increase in the uptake 
of Ferucarbotran by cells regardless of the functionalisation. This increase might be 
explained by the effect of cell starvation. Smith et al have reported a 20-fold 
increase in the uptake of carboxylated polystyrene nanoparticles by HeLa cells in 
the absence of serum (Smith et al, 2012). Similar findings were also postulated by 
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Lesniak et al in studies done on silica nanoparticles; a higher internalisation 
efficiency was reported in serum-free media (Lesniak et al, 2012). 
The concept of targeting nanoparticles to cancer cells has been widely exploited 
(see introduction sections 1.3 and 1.9). In general the size, charge and surface 
coatings of the targeted nanoparticles greatly affected their interactions with target 
cells (Albanese et al, 2012; Sun et al, 2005; Thorek & Tsourkas, 2008; Vigor et al, 
2010). Several attempts to target nanoparticles to cancer cells via the EGFR 
receptor have been reported, either for therapeutic or diagnostic applications (Bazak 
et al, 2014). Targeting nanoparticles to EGFR has been achieved by functionalising 
them with whole monoclonal antibodies (e.g. Cetuximab) (Bouras et al, 2015; 
Kaluzova et al, 2015; Liu et al, 2011; Suwa et al, 1998), small antibody fragments 
(e.g. anti-EGFR scFv) (Yang et al, 2009) or EGFR ligands (e.g. EGF) (Shevtsov et 
al, 2014). These studies all appeared to show EGFR-specific cellular uptake of 
nanoparticles, although none of them employed Ferucarbotran, which might explain 
the discrepancy with the work presented in this thesis. Some postulated reasons for 
the lack of FC-E69 specificity on cells are: 
Firstly, the anionic surface charge of Ferucarbotran greatly affects its interaction 
with cells as demonstrated here and in chapter 3, leading to high background signal. 
This property was further enhanced when functionalised with proteins. Successful 
targeting examples found in literature utilised SPIONs coated with neutral dextran 
(Shevtsov et al, 2014; Vigor et al, 2010), which exhibit low background uptake in 
cells. For instance, the study done by Shevtsov et al, 33 nm dextran coated SPIONs 
were functionalised with EGF and showed specific uptake by EGFR expressing C6 
glioma cell line (Shevtsov et al, 2014).  
Secondly, direct comparison between EGFR targeted Ferucarbotran and published 
material is difficult, because cellular interactions of nanoparticles are governed by 
their individual physicochemical properties (Albanese et al, 2012; Sun et al, 2005; 
Thorek & Tsourkas, 2008; Vigor et al, 2010). For instance, in the study done by 
Kaluzova et al and Bouras et al, PEG (MW 2000) coated iron oxide nanoparticles 
(IONPs) were functionalised with Cetuximab, an anti-EGFRvIII antibody and a 
control human IgG antibody. The negatively charged nanoparticles were internalised 
by the cells before functionalisation, similar to the findings presented here. 
Nevertheless, the study reported that specific uptake of Cetuximab-IONPs could be 
detected above the background signal of IONPs in EGFR expressing cell lines 
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leading to enhanced cytotoxicity (Bouras et al, 2015; Kaluzova et al, 2015). When 
compared to Ferucarbotran, the investigated PEG nanoparticles were relatively 
small (11 and 20 nm for IONPs and IONPs-Cetuximab, respectively), which are 
around 4 to 5 times smaller than Ferucarbotran (51 nm) and its DARPins conjugates 
(~75 nm), making direct comparison difficult. In contrast with their findings, 
specificity of anti-CEA scFv functionalised SPIONs to CEA was lost when charged 
PEGylated-dextran coated SPIONs were used compared to neutral dextran coated 
ones (Vigor et al, 2010). These contradicting findings emphasize that a case-by-
case examination of targeted nanoparticles is crucial.     
Thirdly, DARPins are inherently different in structure and size compared to whole 
antibody (Cetuximab) investigated in most studies (e.g. (Bouras et al, 2015; 
Kaluzova et al, 2015)); E69 is 21 KDa compared to 150 KDa for whole antibody. 
Although both E69 and Cetuximab, when compared in the same experiment, 
showed high affinity and specificity to EGFR, the presence of the protein on the 
surface of the nanoparticles makes the interaction more complex. The DARPins 
might be buried within the dextran coat of Ferucarbotran making them less available 
for binding. 
Finally, a critical look at some published studies has revealed some concerns in cell 
assays studying targeting SPIONs to cancer cells. Most studies investigate the 
uptake of functionalised SPIONs in two different types of cancer cells lines: one 
expressing the target protein and the other showing no detected expression (e.g. 
(Fan et al, 2011; Vigor et al, 2010)). The work presented in chapter 3 has revealed 
that this could be problematic; as it appears that cancer cells internalise SPIONs 
with different capacities, with some able to accumulate high pgFe/cell 
concentrations, while in others barely detectable levels were observed. Therefore 
the use of isogenic +/- cell lines might provide a better-controlled system. 
Furthermore, some studies compare the functionalised SPIONs to the non-
functionalised counterparts (e.g. (Fan et al, 2011; Shevtsov et al, 2014)), flagging 
another concern. If FC-E69 was compared to Ferucarbotran only, one might have 
concluded specific false positive results if the control FC-G3 was not added.  
Therefore, to better interpret experimental results, SPIONs should be functionalised 
with a null-binder targeting moiety with similar size and/or structure to the targeting 
protein. The lack of binding of FC-E69 conjugates in the established well-controlled 
cellular models has highlighted these concerns.  
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5.4 Summary and conclusions  
A method to site specifically conjugate Ferucarbotran to a cancer-targeting agent 
was developed. Conjugates were purified using SEC and the success of the 
conjugation was confirmed with western blotting and DLS measurements. The 
specific uptake of FC-E69 conjugates by EGFR was evaluated with ELISA and 
cellular assays. FC-E69 specifically bound to EGFR in ELISA, nevertheless, no 
specific binding was detected on cells.  
In conclusion, the work presented here has revealed crucial findings; Ferucarbotran 
can be functionalised with cancer-targeting agents but this does not necessarily lead 
to cell-specific uptake. SPIONs interact differently with cells when functionalised 
with a protein on their surface. This altered behaviour might be mistaken as false 
positive results and therefore it is of utmost importance to add the relevant 
experimental controls to correctly interpret the results.   
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6.1 Introduction 
Ferucarbotran has been shown to have good heating potential both in vitro and in 
vivo (see section 1.7). This, together with the established safety profile of Resovist® 
makes it an excellent candidate to develop for localised hyperthermia in the clinic.  
However, Ferucarbotran is composed of a mixture of SPIONs with different 
hydrodynamic diameters ranging from 45-65 nm (product information sheet). This 
heterogeneity is a draw back for hyperthermia applications because the SPION size 
is related to its heating potential at a given frequency (Gonzales-Weimuller et al, 
2009). Such heterogeneity can result in an ill-defined mixture of therapeutic agents, 
with possibly some particles being ineffective. Therefore, it becomes crucial to 
optimise nanoparticle preparations to reduce polydispersity (Kowalczyk et al, 2011) 
and achieve improved magnetic heating characteristics (Jordan et al, 2003). It was 
hypothesised that this could be achieved by fractionating SPIONs and selecting 
fractions with the best magnetic heating properties. It is proposed that more defined 
Ferucarbotran, with greater heating potential, would have new application in the 
emerging field of magnetic hyperthermia as anti-cancer treatment (see sections 
1.6.4, 1.7 and 1.8).  
Fractionation of nanoparticles has been achieved via centrifugation, filtration or 
chromatographic techniques which are dependent on the particle size and shape 
(Kowalczyk et al, 2011). For magnetic nanoparticles the two main methods used 
are: SEC (Nunes & Yu, 1989; Rheinländer et al, 2000a; Rheinländer et al, 2000b) 
and magnetic separation (Ishihara et al, 2013; Jordan et al, 2003; Rheinländer et al, 
2000a).  
Magnetic separation separates nanoparticles based on their magnetic moments as 
they pass through a column packed with magnetic spheres in the presence of 
magnetic field gradients. Magnetic size separation has been correlated with the 
nanoparticles core diameter which affects their magnetic moments (Aurich et al, 
2012; Rheinländer et al, 2000b).  
SEC is the separation of molecules based on their sizes as they pass through a 
column packed with a gel filtration matrix (Barth et al, 1996; GE-Healthcare, 2014; 
Rheinländer et al, 2000b). The matrix consists of porous beads; as the sample 
passes through the matrix, large molecules are eluted first while smaller ones get 
trapped in the matrix pores and thus are eluted later (GE-Healthcare, 2014) (see 
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Figure 6.1). As shown in the theoretical chromatogram in Figure 6.1 C, high 
molecular weight components are eluted first either in the column void volume or as 
the first peaks depending on the column’s cut off, followed by the intermediate then 
the small molecular weight components. Therefore SEC relies on the hydrodynamic 
diameter of nanoparticles, which include both the nanoparticles’ core and coat. 
Nevertheless, Rheinländer et al showed that the core diameter usually correlates 
with the overall hydrodynamic diameter of the nanoparticles (Rheinländer et al, 
2000a). Therefore one can conclude that although the two separation methods rely 
on completely two different characteristics of magnetic nanoparticle they render 
similar results (Rheinländer et al, 2000a).  
6.1.1 Experimental approach 
The work presented in chapter 6 investigated both methods of fractionation with a 
special emphasis on SEC, a much gentler method usually employed for separation 
of proteins (Barth et al, 1996). Three different SEC matrices were investigated for 
their ability to fractionate Ferucarbotran: Sephadex G-100, Superdex Prep Grade 
(75 and 200) and Superose Prep Grade (6 and 12). The properties of the different 
media investigated are shown in Table 6.1. 
Fractionated Ferucarbotran was characterised with DLS and tested for heating 
potential. The most commonly used measurements for magnetic heating ability of 
SPIONs are either the specific absorption rate (SAR) or the intrinsic loss power 
(ILP) (Wildeboer et al, 2014). SAR is an extrinsic parameter defined as the heating 
power generated per unit mass of magnetic nanoparticles (Wildeboer et al, 2014) 
and is represented in Equation 6.1. While, the intrinsic loss power is an intrinsic 
system independent parameter, which relies on the heating capacity of the magnetic 
nanoparticle (Kallumadil et al, 2009; Wildeboer et al, 2014) and is represented in 
Equation 6.2. ILP is generally considered more reliable and therefore was used in 
this chapter as a measure of the heating ability of fractionated Ferucarbotran.   
             Equation 6.1 
              Equation 6.2 
SAR = ΔT
Δt
C
mFe
ILP = SAR H2 f  
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Where SAR (Wg-1) is specific absorption rate; ΔT is the change in temperature; Δt change of 
time; C (Jg-1 K-1) is the heat capacity per unit mass of fluid; mFe  (g) is the iron mass in the 
fluid per unit mass of fluid, ILP (Hm2 g-1) is the intrinsic loss power, H is the strength of the 
alternating magnetic field (AMF) and f (Hz) is the frequency of AMF.  
6.1.2 Research Aims and Objectives  
Aim: To fractionate Ferucarbotran into more uniform solution with improved heating 
potential.  
Objectives:  
• Evaluate different SEC matrices for their ability to fractionate Ferucarbotran 
into different sizes. 
• Analyse Ferucarbotran fractions with DLS and magnetic hyperthermia 
heating ability.    
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Figure 6.1: Principles of size exclusion chromatography 
A: Schematic presentation of a SEC column packed with gel filtration matrix as a sample 
containing molecules of different sizes pass through it. B: Zoomed in schematic presentation 
of a single bead. A gel filtration matrix is made of porous beads with different pore sizes; 
large molecular weight molecules (red circles, B) are the quickest to pass through the 
column (red arrow, A), as they are not trapped within the pores and therefore are eluted first, 
unlike intermediate (green) and small (blue) molecules that are eluted in later fractions. C: 
Theoretical chromatogram of a typical elution profile. Void volume (V0): the volume 
equivalent to ~30% of total column volume and is the volume external to the column pores. 
Large molecules are expected to elute in or just after the void volume depending on the 
column cut off. Total volume (Vt): is the total volume of the column from sample injection to 
the last eluted peak. Column volume (CV) is the volume between V0 and Vt. 
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Table 6.1: General properties of gel filtration media investigated in this chapter 
Information from (GE-Healthcare, 2014). 
Medium Bead size (µm) Compositions 
Fractionation 
range for 
dextran 
Fractionation range 
for globular proteins 
Sephadex G-
100 
100-310 
(wet) 
Cross-linked 
dextran 1-100 KDa 4-150 KDa 
Superdex 75 
Prep grade 24-44 Composite of 
cross-linked 
agarose and 
dextran 
0.5-30 KDa 3-70 KDa 
Superdex 
200 Prep 
grade 
24-44 1-100 KDa 10-600 KDa 
Superose 6 
Prep grade 30-40 
Highly cross-
linked agarose 
n/a 5-5000 KDa 
Superose 12 
Prep grade 30-40 n/a 1-300 KDa 
KDa: Kilo Daltons, n/a: not available  
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6.2 Results  
6.2.1 Magnetic separation of Ferucarbotran using MACS® LS column 
Magnetic separation of Ferucarbotran was performed on commercially available 
MACS LS columns used with QuadroMACS™ Separator.  
Magnetic separation protocol was adapted from the guidelines provided by the 
manufacturer. Initially 50 µg of Ferucarbotran was applied on the column and the 
amount of iron recovered at each stage was calculated; 21.34% of the sample was 
lost in the first wash while only 35.6% was eluted from the column and 34.8% 
appears to have irreversibly bound to the column. This was considered as poor 
recovery of the sample and might be due to insufficient binding of Ferucarbotran to 
the magnetic column. Therefore a lower amount of 20 µg iron was tested in an 
attempt to improve recovery. A small improvement was observed as 40.1% of the 
sample was successfully eluted from the column while 23.4% was irreversibly bound 
to the column. These results were disappointing and this method was thought not to 
be suitable for the separation of Ferucarbotran.   
Table 6.2: Results of purification of Ferucarbotran using MACS columns 
 50 µgFe loaded 20 µgFe loaded 
 µg of iron % of sample µg of iron % of sample 
Flow through 1.17 2.34 0.67 3.36 
Wash 1 10.67 21.34 4.66 23.30 
Wash 2 1.49 2.97 1.09 5.47 
Wash 3 1.44 2.87 0.88 4.39 
Eluted 17.81 35.62 8.02 40.10 
Total  65.13%  76.6% 
Irreversibly bound  34.8%  23.4% 
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6.2.2 Size exclusion chromatography (SEC) 
Next, a number of SEC media were investigated for their ability to fractionate 
Ferucarbotran. Despite the information available by GE-Healthcare (SEC media 
manufacturer) regarding the fractionation range of each SEC media (see Table 5.1), 
the interaction of Ferucarbotran with SEC beads is unpredictable. Furthermore, the 
exact molecular weight of Ferucarbotran is unknown and therefore 5 different media 
were investigated.  
6.2.2.1 Sephadex G-100 and Superdex 75 Prep Grade 
Sephadex G-100 
The first matrix investigated was Sephadex, a media prepared by cross-linking 
dextran with epichlorohydrin. Sephadex G-25 (MW cut off = 5 KDa) had been 
previously used to purify Ferucarbotran from NIR dyes (used in chapter 4). 
Encouragingly, these experiments showed that Ferucarbotran did not bind 
irreversibly to Sephadex. However, Ferucarbotran was eluted unfractionated in the 
void volume i.e. too large to enter the column matrix, indicating that Sephadex with 
higher MW fractionation range would be more suitable leading to the investigation of 
Sephadex G-100. However, results for Sephadex G-100 showed that Ferucarbotran 
still eluted in a single peak in the column’s void volume (Figure 6.2), making the 
matrix unsuitable for size fractionation of Ferucarbotran. In addition, due to the 
compressible nature of the matrix it was necessary to perform the purification 
process at very low flow rates, rendering the process time consuming. Therefore a 
number of other non-compressible hard matrices were evaluated for applicability 
(e.g. Superdex). Superdex matrix provides a combination of the high-resolution 
capacity of cross-linked dextran (e.g. Sephadex) as well as the rigidity and the 
stability of highly cross-linked agarose (e.g. Superose) (GE-Healthcare, 2014). 
Superdex 75 
As previously shown in chapter 5, Superdex 75 eluted Ferucarbotran-DARPins 
conjugates unfractionated in the column’s void volume (Figure 5.3). Nonetheless, 
the conjugates were shown to be 22-24 nm bigger in size when compared to 
unconjugated Ferucarbotran (see Table 5.1). In addition, the presence of a protein 
on the surface of the SPIONs might interfere with their interaction with the 
chromatography media. Therefore a sample of unconjugated Ferucarbotran was 
loaded into the column and as previously described was eluted as a single peak in 
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the column’s void volume (Figure 6.2). This indicates that Superdex 75, as with 
Sephadex G-100, is unsuitable for size fractionation of Ferucarbotran. 
 
Figure 6.2: Chromatogram of Ferucarbotran elution on Sephadex G-100 and Superdex 
75 packed columns 
Ferucarbotran (brown) is eluted as a single peak in the column void volume as shown in 
both the chromatograms and the pictures.  
6.2.2.2 Superdex 200 
SEC matrices with higher fractionation ranges were explored. First Superdex 200 
was investigated. It has a wide fractionation range and was found to fractionate 
Ferucarbotran into 2 distinct peaks (Figure 6.3). The 2 peaks of Ferucarbotran were 
investigated with DLS and results revealed that peak 1 (fractions 2-12) had a Z-
average hydrodynamic diameter of 70.88 nm while peak 2 (fractions 14-41) was 
27.2 nm in diameter. The heating potential of both peaks was subsequently 
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FC eluted 
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evaluated by measuring the temperature profile of the fractionated samples during 
exposure to the alternating magnetic field. Results revealed that the larger 
nanoparticles were effective generators of heat with an intrinsic loss of power (ILP) 
of 3.65 versus 1.07 for the smaller ones (Figure 6.4). 
 
Figure 6.3: Elution profile of Ferucarbotran on Superdex 200 
A: Chromatogram of Ferucarbotran loaded on a column packed with Superdex 200, 
Ferucarbotran was eluted in 2 peaks, peak 1: fractions 2-12 and peak 2: fractions 14-41. B 
and C: pictures of the column showing the 2 peaks of Ferucarbotran (brown). 
 
Figure 6.4:  Characterisation results of fractionated Ferucarbotran on Superdex 200 
Ferucarbotran peaks were pooled into fractions 2-12 which when measured on DLS had a Z-
average hydrodynamic diameter of 70.88 nm and ILP of 3.65 (black curve, C) while fractions 
14-41 were 27.2 nm in diameter with an ILP of 1.07 (red curve, C).     
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6.2.2.3 Superose 
Superose 6 and Superose 12 were also investigated for their ability to fractionate 
Ferucarbotran. Superose medium is composed of highly cross-linked porous 
agarose particles with broad fractionation range.  
Superose 12 Prep Grade 
Results showed that, on the Superose 12 packed column, Ferucarbotran was 
separated in a single peak with a shoulder indicating poor and incomplete 
separation of the different sized particles (Figure 6.5). Superose 12 Ferucarbotran 
fractions 3-10 were pooled as peak 1 and the shoulder fractions (11-24) were 
pooled and named “shoulder”. DLS revealed that peak 1 had a uniform size 
distribution with a Z-average hydrodynamic diameter of 59.88 nm and a PDI of 
0.203. The shoulder had a Z-average hydrodynamic diameter of 36.30 nm and PDI 
of 0.680 (Figure 6.6). The ILP of both peaks was measured revealing that peak 1 
had a higher heating potential with an ILP of 2.59 while the shoulder has a very low 
ILP of 0.59 (as shown in Figure 6.7).        
 
Figure 6.5: Separation of Ferucarbotran on Superose 12 packed column. 
A: Ferucarbotran was eluted from the column in a peak (1) and a small shoulder (2), as also 
seen in the image of the column. 
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Figure 6.6: Characterisation of the different peaks of Ferucarbotran eluted on 
Superose 12 packed column using DLS. 
Peak 1 (fractions 3-10) appears to have a uniform size distribution with a Z-average 
hydrodynamic diameter of 59.88 nm compared to the shoulder (fractions 11-24), which 
appear to be non-uniform.  
 
Figure 6.7: Heating profile of fractionated Ferucarbotran 
Peak 1 (black) appears to have superior heating properties when compared to the shoulder  
(red). Although the samples were tested at different concentrations, the ILP is a 
concentration-independent value. Peak 1 had an ILP of 2.59 compared to 0.59 for the 
shoulder fraction.   
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Superose 6 Prep Grade 
Ferucarbotran was also tested on Superose 6; this media has the widest 
fractionation range (Table 6.1). On this matrix, Ferucarbotran was separated into 3 
pools of fractionated samples (Figure 6.8).  Fractions 4-10 contained a distinct peak 
(peak 1), fractions 11-27 formed an indistinct peak where the trace did not return to 
baseline and fractions 28-47 formed a second distinct peak (peak 3). DLS 
measurements revealed that the peaks had a Z-average hydrodynamic diameter of 
79.34 nm, 42.06 nm and 24.25 nm for peak 1, 2 and 3 respectively (Figure 6.9).       
ILP measurements of the 3 peaks revealed that peak 1 had the best heating 
potential (ILP=3.8), being superior to the other 2 peaks and the unfractionated 
starting material (ILP=1.4) (Figure 6.10). 
Visual inspection of the fractions running through the Superose 6 packed column 
(Figure 6.8) revealed that most of the SPIONs within Ferucarbotran are eluted in the 
later fraction (peak 3) meaning that they are the small nanoparticles with poor 
heating properties (ILP= 0.04). 
 
Figure 6.8: Chromatogram of fractionation of Ferucarbotran on Superose 6 
(A) Chromatogram showing Ferucarbotran separated into 2 distinct peaks that did not return 
to baseline and were subsequently shown to be 3 overlapping peaks. (B) Picture of the 
column showing the three distinct populations of Ferucarbotran (brown). 
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Figure 6.9: Characterisation of the eluted fractions of Ferucarbotran on Superose 6 
using DLS 
The 3 fractions appear to have a uniform size distribution with peak 1 having a Z-average 
hydrodynamic diameter of 79.34 nm while peak 2 and peak 3 were 42.06 nm and 24.25 nm, 
respectively.  
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Figure 6.10: Heating profile of fractionated Ferucarbotran on Superose 6 
Peak 1 (blue) had the highest ILP, showing superior heating potential. While peak 2 (green 
curve) and peak 3 (red curve) had ILP values of 1.7 and 0.04, respectively. The 
unfractionated Ferucarbotran had an ILP of 1.4, which shows the improved heating potential 
of fractionated Ferucarbotran. Despite the samples being prepared at different 
concentrations, the ILP is a concentration-independent value.   
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6.3 Discussion 
The work presented in this chapter investigates the third central hypothesis of this 
thesis: Ferucarbotran heterogeneity could be overcome by physical separation 
using SEC.  
The results of this chapter revealed that fractionation of Ferucarbotran could be 
successfully achieved by SEC. Three different types of matrices were investigated 
for their ability to fractionate Ferucarbotran. Only Superdex 200, Superose 6 and 
Superose 12 were able to fractionate Ferucarbotran due to their large fractionation 
ranges. The most efficient separation was achieved with Superose 6, a finding that 
has not been previously reported. Fractionated Ferucarbotran on Superose 6 
contained different sizes of nanoparticles with the majority of SPIONs exhibiting 
small diameters. These results are consistent with published data by others that 
suggests that Ferucarbotran (Resovist®) exhibits bimodal size distribution; mainly 
consisting of small nanoparticles which can form stable multi-core aggregates with 
better magnetic properties (Eberbeck et al, 2011; Löwa et al, 2014; Thünemann et 
al, 2008). Those larger particles (core size ~25 nm) were estimated to constitute 
only 3% of Resovist® solution and were accounted for the superior magnetic particle 
imaging (MPI) potential of the SPIONs (Eberbeck et al, 2011). 
Similar to other SPIONs, fractionation of Ferucarbotran has been investigated 
before, with most published reports utilising magnetic fractionation (Aurich et al, 
2012; Ishihara et al, 2013; Nohara et al, 2013; Romanus et al, 2007; Yoshida et al, 
2013) and no available published studies reporting the use of SEC. Generally, SEC 
is considered easier than magnetic fractionation because the latter usually includes 
bespoke manufacture of electromagnets with high magnetic field gradients. These 
magnets are usually manufactured by the researchers themselves (Löwa et al, 
2014; Rheinländer et al, 2000a; Yoshida et al, 2013) or extensive tuning of 
commercially available electromagnets is required (Aurich et al, 2012; Löwa et al, 
2014). This renders magnetic fractionation unstandardised, difficult to replicate and 
scale up to a bigger production environment required for the clinical development of 
SPIONs and their transition to the clinic. Therefore, the results discussed in this 
chapter propose a new technique to fractionate Ferucarbotran to optimise its 
magnetic properties using a simple and a reproducible method.   
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Examples of studies attempting the magnetic fractionation of Ferucarbotran are 
discussed below. For example Nohara et al used magnetic fractionation methods to 
separate Ferucarbotran in to 3 different fractions of 57 nm, 59 nm and 60 nm in 
diameter and exhibiting different T2 relaxivities (Nohara et al, 2013). While Ishihara 
et al explored centrifugal separation, gel filtration and magnetic separation to 
prepare Ferucarbotran samples with improved magnetizing properties and improved 
imaging capabilities (Ishihara et al, 2013). Nonetheless, efforts presented in this 
chapter using commercially available MACS LS magnetic columns with the 
QuadroMACS™ separator were not optimal and resulted in poor recovery of 
Ferucarbotran. This suggests that for effective magnetic separation of 
Ferucarbotran, strong electromagnetic field gradients are required. This conclusion 
was also confirmed by the work of Aurich et al. In their study magnetic fractionation 
of Ferucarbotran was done using MACS LS columns placed in a tuneable 
electromagnetic field. Fractions of mean hydrodynamic diameters of 92.3 nm, 64.7 
nm, 45.5 nm and 26.9 nm were obtained (Aurich et al, 2012). Löwa et al have also 
used the MACS LS columns with a different electromagnet and were able to 
fractionate Ferucarbotran into 10 nm and 64 nm fractions (Löwa et al, 2014). The 
study by Löwa et al also used another technique called asymmetric flow field-flow 
fractionation, similar to SEC, separates particles based on their hydrodynamic 
diameter (Löwa et al, 2014). Asymmetric flow field-flow fractionation resulted in 8 
fractions between 12 and 83 nm (Löwa et al, 2014). Romanus et al fractionated 
Ferucarbotran using MACS XS columns with an electromagnet that can be tuned 
with variable magnetic field strengths, this method yielded fractions with core sizes 
varying between 21 and 5.2 nm (Romanus et al, 2007). Since Ferucarbotran was 
mainly developed as an MRI contrast agent, most of the mentioned studies tested 
the magnetic particle imaging (MPI) potential of the fractions (Aurich et al, 2012; 
Ishihara et al, 2013; Löwa et al, 2014; Nohara et al, 2013; Yoshida et al, 2013). 
Meanwhile, the work presented in this chapter evaluated the heating profile of the 
fractions, which is an important parameter for the clinical development of 
Ferucarbotran for magnetic hyperthermia therapy of cancer.  
6.4 Summary and conclusions  
Ferucarbotran has been successfully fractionated to obtain a more homogeneous 
sub-population. This was done using SEC, which is an easy, fast and a reproducible 
method that could be scaled up. Furthermore the fractionation of Ferucarbotran 
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using SEC has not been reported before which highlights the importance of the work 
presented here.   
In conclusion, the fractionated Ferucarbotran obtained here exhibited superior 
heating capabilities that might improve Ferucarbotran’s prospective as an anti-
cancer hyperthermia therapy.  
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The work presented in this thesis combined nanotechnology, cell biology, 
chromatography and chemistry techniques to provide some advances towards the 
development of SPIONs as cancer nanomedicines.  
The site-specific delivery of therapies has been a difficult to achieve aim for the 
treatment of most illness and most specifically cancer. Due to the toxic nature of 
anti-cancer therapies, the need for targeted therapeutic effect is more urgent. In 
order for nanomedicines to fulfil their theranostic potential and achieve this goal, a 
number of biological barriers have to be overcome (Blanco et al, 2015). These 
barriers include: opsonisation and removal by the RES; nonspecific biodistribution; 
cellular internalisation; degradation by endosomal and lysosomal compartments and 
drug efflux pumps (Blanco et al, 2015; Ferrari, 2010).  
The first and main culprit in the lack of efficacy of nanomedicines is the RES, which 
sequesters nanoparticles away from the intended site of delivery into the liver and 
spleen. Approaches developed for RES avoidance has been long sought after; of 
these PEGylation is the most widely used. Nonetheless newer approaches include 
developing bio-nano hybrid systems by using biomimetic coatings, coating with self 
peptide or loading into mesenchymal stem cells (Blanco et al, 2015; Gao et al, 
2013). Nanoparticles have been functionalised with CD47, a “marker of self” peptide 
that gives a “don’t eat me” signal to macrophages leading to longer circulation times 
and better tumour localisation (Rodriguez et al, 2013). While the work of Parodi et al 
camouflaged silicon nanoparticles with leukocyte membrane (Parodi et al, 2013) 
and that of Hu et al clocked nanoparticles by coating them with the cell membrane 
of platelets (Hu et al, 2015) or red blood cells (RBCs) (Hu et al, 2011). In general, 
biomimetic coating of nanoparticles have led to prolong circulation times and/or 
localisation to the intended therapeutic sites (Blanco et al, 2015). Other approaches 
used cell carriers, specifically mesenchymal stem cells (MSCs). MSCs are 
therapeutically advantageous as vehicles for drug delivery owing to their low 
immunogenic properties and thus tend to “hide” nanoparticles from clearance by the 
host immune system (Auffinger et al, 2013; Gao et al, 2013). Furthermore, MSCs 
possess the ability to home to tumours and distant metastases (Hall et al, 2007; 
Kidd et al, 2009; Loebinger et al, 2009a; Loebinger et al, 2009c; Nakamizo et al, 
2005; Studeny et al, 2004). For instance Loebinger et al showed that intravenously 
injected MSCs loaded with SPIONs were detectable with MRI in lung metastases 
(Loebinger et al, 2009c) while Riegler et al delivered SPIONs-loaded MSCs to the 
intended therapeutic region via magnetic targeting (Riegler et al, 2013).  
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The work presented in this thesis used a different stagey by using RES blockers, 
these blockers were able to not only block the liver uptake of SPIONs but also 
prolong their circulatory retention. Furthermore, the investigated polysaccharides 
proved effective in vitro, in vivo and with 2 different types of SPIONs. Although 
Nanomag-D-spio-NH2 has different surface chemistry, charge and size from 
Ferucarbotran, it appears that both SPIONs exhibited similar pharmacokinetic profile 
of rapid liver elimination and had prolonged circulatory retention in mice pre-treated 
with the blockers. These observations could potentially extend the work presented in 
this thesis to other SPIONs or indeed other classes of nanoparticles that might differ 
from Ferucarbotran yet are rapidly eliminated by the liver. The use of clinically safe 
RES blockers, particularly fucoidan, is advantageous as it might accelerate its 
progression to the clinic as a combination therapy with SPIONs.   
Specific internalisation of nanoparticles by cancer cells is another barrier that needs 
to be addressed. The seminal review by Hanahan and Weinberg discussing the 
hallmarks of cancer in 2000, with an updated review published in 2011, revealed the 
unique properties of cancer cells that differentiate them from normal cells (Hanahan 
& Weinberg, 2000; Hanahan & Weinberg, 2011). These properties were greatly 
exploited to design targeted therapies; nanomedicines particularly exploited 
angiogenesis via the EPR effect (see section 1.3.1.1). The other hallmark widely 
used for targeting is the autonomy of cancer cells for growth factors, for this purpose 
the deregulation of cell surface receptors that convey growth-stimulatory signals are 
most commonly overexpressed in cancer cells (Hanahan & Weinberg, 2000), 
making them of particular interest for cancer-selective drug delivery. Examples of 
receptors targeted by nanomedicines include: the EGFR family, transferrin, folate, 
integrin and G protein-coupled receptors, among others (full list reviewed in (Akhtar 
et al, 2014)).  
In this thesis EGFR, a known overexpressed receptor in a wide range of cancers 
(Mendelsohn & Baselga, 2006; Nicholson et al, 2001), was chosen for targeting 
using unique antibody-like proteins (DARPins). The use of DARPins to target 
nanoparticles to cancer cells has not been reported before, thus the findings 
presented herein are novel. Although EGFR targeting could not be achieved under 
the tested conditions, the complexity of the intertwined physicochemical properties 
of Ferucarbotran and the biological barriers of cancer cells was highlighted in my 
work. Therefore a number of critical insights were presented: (a) whilst 
Ferucarbotran internalisation by tumour cells could be beneficial for cancer cell 
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labelling, its internalisation by normal brain cells (as discussed in chapter 3) could 
lead to morbid side effects; (b) the presence of a protein on the surface of SPIONs 
changes their cellular interactions and should be carefully accounted for in 
experimental design and finally (c) although this was not shown in the work 
presented here, combining blocking of the unspecific uptake of SPIONs by cells with 
targeting might achieve the desired specificity of functionalised SPIONs by cancer 
cells. 
Finally, the well-studied safety profile of MRI contrast SPIONs (e.g. Resovist® and 
Feridex®) in patients (Etheridge et al, 2013) should have facilitated their transition 
from diagnostic to therapeutic cancer nanomedicines. Nonetheless, the redirection 
of SPIONs from imaging agents to hyperthermia therapy requires reinvestigating 
their physicochemical properties, addressing the challenges that arise and thinking 
of novel approaches to optimise them for the new intended use. The work in this 
thesis showed that Ferucarbotran could have improved heating properties using a 
simple, fast and reproducible SEC-based fractionation method. Due to the ease of 
this process and its suitability for good manufacturing practice (GMP) standards, the 
inclusion of a final SEC fractionation step could be added during the manufacturing 
process of SPIONs to render a more homogenous population with improved heating 
properties. Furthermore, long-term stability studies and quality control checks done 
by the manufacturer on the fractionated samples could be employed; the presence 
of large nanoparticles in close proximity might lead to flocculation or irreversible 
aggregations. 
Future directions 
The work presented in this thesis has opened a wide range of exciting avenues on 
the path to develop SPIONs as cancer nanomedicines. Future work could be 
directed towards better understanding the mechanism of cellular interactions of 
SPIONs especially by non-RES cell lines. Fractionated Ferucarbotran by SEC could 
interact differently with cells, therefore, uptake experiments using the different 
fractions on different cell lines would provide useful insights on the effect of size on 
the cellular interactions of SPIONs.  
The established chemical conjugation strategies to link SPIONs to NIR dyes 
(Abdollah et al, 2014) could be used to the trace their biodistribution in vivo. A 
mouse pod attached to the LI-COR Odyssey scanner can be used to trace and 
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quantify dye labelled conjugates in vivo (Kovar et al, 2007a; Kovar et al, 2009; 
Kovar et al, 2007b; Sampath et al, 2007). The NIR imaging system could also help 
characterise the change in SPIONs PK when blockers are administered via different 
routes. Future studies done to improve the PK behaviour of SPIONs could also 
exploit the preliminary results discussed with 99mTc-Ferucarbotran SPECT imaging 
system which showed the feasibility of this technique to trace the biodistribution of 
SPIONs in vivo. The live imaging of mice via SPECT at different time points 
following the administration of the blockers was beneficial but could be extended to 
include more time points or multiple injections of the blockers to completely block 
the RES. 
Future work could include the optimisation of the RES blocking effect of the 
investigated polysaccharide derivatives. For instance fucoidan, a food supplement, 
could be administered orally or via intraperitoneal injection to enhance its blocking 
effect. Fucoidan has been extracted from different species of seaweed (Li et al, 
2008); studying the blocking behaviour of the different fucoidans is another 
possibility. Fucoidan examined here, extracted from Fucus vesiculosus, exhibited 
wide size distribution and therefore its fractionation with SEC could provide a more 
uniform product with improved/prolonged RES blocking effect.  
The lack of binding observed with FC-E69 to EGFR on cells might be accounted to 
the burial of E69 within the dextran coat of Ferucarbotran. Therefore, the use of 
variable length PEG linkers might solve this problem. In the study done by Salvati et 
al, they concluded that a certain length of PEG is required to achieve the targeting 
of their nanoparticles to transferrin receptor (Salvati et al, 2013); suggesting that a 
specific PEG length would achieve the desired exposure of the targeting moiety to 
the receptors present on the surface of the cancer cell. To take this work forward, 
intense characterisation of the Ferucarbotran-DARPin conjugates should be 
performed, this include the calculations of the number of DARPin moieties per 
nanoparticle and whether the achieved ratio is enough to enhance specific binding 
of the SPIONs to cancer cells. The use of G3 DARPin as a control is not optimal as 
it is smaller than E69, 14 KDa versus 21 KDa. Therefore, the use of a null binder 
DARPin with similar molecular weight to E69 would provide a better control. Finally, 
to achieve efficient targeting, another approach would be to conjugate neutral 
SPIONs to DARPins as this might overcome the unspecific uptake of negatively 
charged Ferucarbotran by cells. Once specificity is confirmed in vitro, in vivo studies 
using tumour xenografts could be done. The RES blocking, already established 
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(Abdollah et al, 2014), could help the targeted SPIONs localise better to the tumour 
xenografts and aid in the development of a targeted hyperthermia therapy for 
cancer.     
In conclusion, my work showed that unwanted cellular uptake of SPIONs could be 
blocked with polysaccharide derivatives. The improved circulatory retention of 
SPIONs by RES blocking is achievable and obtaining more uniform SPIONs with 
improved magnetic properties is possible. The project also highlighted the 
complexity of the SPIONs’ cellular interactions as well as the difficulties lying ahead. 
Despite the similarities between the size, charge, coating and core of a certain class 
of nanoparticles, each appear to behave in a unique way when in contact with 
biological systems like cells, blood, or organs. This complexity is further enhanced 
when they are coated with proteins. Therefore, the individuality of SPIONs makes 
their clinical development more difficult, but as our understanding increase this will 
help us develop more efficient, safer and targeted cancer nanomedicines.  
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Indirect ELISA 
White: EGFR coated  grey: PBS coated  red: measured at 700 nm channel 
 
1 2 3 4 5 6 7 8 9 10 11 12 
A 13.69 13.4 12.59 3.72 3.68 4.13 0.34 0.35 0.35 0.32 0.3 0.37 
B 0.9 0.53 0.51 5 5.64 5.28 0.3 0.3 0.29 0.34 0.28 0.3 
C 0.57 0.4 0.37 16.38 16.42 15.84 0.37 0.32 0.3 5.45 5.43 5.56 
D 0.43 0.39 0.33 0.28 0.33 0.33 0.55 0.29 0.3 0.3 0.3 0.28 
E 6.02 5.53 5.32 4.78 5 5.04 0.65 0.73 0.86 0.59 0.79 1.05 
F 4.95 4.81 5 0.64 0.7 0.59 1.02 0.95 1.05 0.35 0.36 0.49 
G 0.39 0.77 0.48 5.36 5.35 5.23 0.32 0.35 0.29 5.02 5.13 5.16 
H 0.43 0.49 0.71 0.32 0.29 0.34 0.34 0.31 0.32 0.31 0.3 0.39 
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B FC FC FC E69 E69 E69 FC FC FC E69 E69 E69 
C G3 G3 G3 Cetuximab Cetuximab Cetuximab G3 G3 G3 Cetuximab Cetuximab Cetuximab 
D PBS PBS PBS    PBS PBS PBS    
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G G3 G3 G3 Cetuximab Cetuximab Cetuximab G3 G3 G3 Cetuximab Cetuximab Cetuximab 
H PBS PBS PBS    PBS PBS PBS    
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Immobilizer ELISA 
 
 White: EGFR coated; Grey: PBS coated; Primary antibodies were added according to colour code (e.g. FC-E69 was detected with anti-
dextran). Underlined wells were treated with sample and then anti-human DyLight 649 (i.e. no 1ry antibody).   
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B E69 E69 E69 PBS PBS PBS G3 G3 G3 PBS PBS PBS 
C Cetuximab Cetuximab Cetuximab PBS PBS PBS       
+ 
S
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e D FC-E69 FC-E69 FC-E69 FC-G3 FC-G3 FC-G3 FC FC FC PBS PBS PBS 
E E69 E69 E69 PBS PBS PBS G3 G3 G3 PBS PBS PBS 
G Cetuximab Cetuximab Cetuximab PBS PBS PBS       
 1 2 3 4 5 6 7 8 9 10 11 12 
A 4.23 3.12 3.36 3.28 3.67 3.57 4.01 4.04 3.88 0.59 0.26 0.26 
B 0.59 0.6 0.63 0.25 0.24 0.24 0.32 0.33 0.35 0.26 0.26 0.25 
C 7.97 8.2 7.32 5.47 5.58 5.57 0.24 0.24 0.25 0.24 0.25 0.25 
D 0.23 0.23 0.25 0.24 0.25 0.24 0.22 0.26 0.28 0.27 0.28 0.27 
E 0.29 0.46 0.39 0.58 0.28 0.3 0.38 0.39 0.42 0.24 0.24 0.25 
F 0.26 0.27 0.26 0.23 0.24 0.24 0.25 0.25 0.25 0.23 0.24 0.25 
G 6.19 6.73 6.12 6.34 6.54 6.39 0.26 0.24 0.23 0.23 0.26 0.25 
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Sandwich ELISA 
 
 
 
 
 
 
 
      White: EGFR treated  Grey: PBS treated  
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1 2 3 4 5 6 7 8 9 10 11 12 
A 14.83 14.13 14.53 5.93 5.82 5.99 5.15 5.18 5.22 5.01 5.17 5.31 
B 5.88 5.75 5.52 10.76 10.89 13.48 5.01 5.18 5.15 4.96 5.1 5.21 
C 5.26 5.29 5.17 5.57 5.48 5.46 5.11 5.11 5.1 5.22 5.3 5.29 
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Elution profile of gel filtration standard on SEC columns 
Components of the gel filtration standard obtained from Bio-Rad. 
 
 
 
 
 
Chromatogram of gel filtration standard run on Sephadex G-100 packed 
column: Proteins that are larger than the cut off (150 KDa), i.e. thyroglobin and γ-
globulin, came out in the column’s void volume followed by 3 peaks representing 
ovalbumin, myoglobin and vitamin B12 with molecular weights of 44,17 and 1.3 KDa 
respectively.  
Void 
44 KDa 
17 KDa 
1.3 KDa 
Component Molecular Weight (KDa) 
Thyroglobulin (bovine) 670 
γ-Globulin (bovine) 158 
Ovalbumin (Chicken) 44 
Myoglobin (horse) 17 
Vitamin B12 1.35 
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Elution profile of the gel filtration marker run through an XK 16/50 column 
packed with Superdex 75: Both high molecular weight proteins (thyroglobin 670 
KDa and γ-globulin 158 KDa) were eluted as a double-headed peak in the column’s 
void volume followed by the lower molecular weight proteins.  
 
Elution profile of gel filtration standard on Superdex 200 packed column: All 
proteins in the molecular weight marker were separated into 5 distinct peaks 
conductivity trace is shown in red. 
Void 
44 KDa 
17 KDa 1.3 KDa 
670 KDa 
158 KDa 
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Elution profile of the gel filtration standard run on a column packed with 
Superose 12: Superose 12 has a fractionation range of 1-300 KDa so the biggest 
protein (thyroglobulin, 670 KDa) was eluted first in the column void volume followed 
by 4 different peaks of the other proteins.  
 
Elution profile of gel filtration standard run on column packed with Superose 
6: All proteins in the molecular weight marker were separated into 5 distinct peaks 
as shown in the chromatogram. Nevertheless the fractionation efficiency appears to 
be less for the higher molecular weight proteins as the peaks overlap.  
 
  
Void 
670 KDa 
44 KDa 
17 KDa 
1.3 KDa 
158 KDa 
44"KDa"
17"KDa"
1.3"KDa"
158"KDa"
670"KDa"
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Prolonging the circulatory retention of SPIONs using dextran sulfate: in vivo 
tracking achieved by functionalisation with near-infrared dyes. Maha R. A. 
Abdollah, Tammy Kalber, Berend Tolner, Paul Southern, Joseph C. Bear, Mathew 
Robson, R. Barbara Pedley, Ivan P. Parkin, Quentin A. Pankhurst, Paul Mulholland 
and Kerry Chester (2014). Faraday Discussions 175 (0): 41-58, 
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presented in the Preclinical Nuclear Imaging (PNI) Symposium, London, UK, 
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Paolo Salomoni, Shane Minogue, Paul Mulholland, Quentin Pankhurst, and Kerry 
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